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Introduction: SDF-1α is a chemoattractant cytokine that can deliver both acute 
and chronic cardioprotective benefits to the heart. Although CXCR4 has been 
viewed as a main receptor for SDF-1α, a secondary receptor, CXCR7, has 
emerged as an important mediator of SDF-1α signalling. Interestingly, 
endothelial CXCR7 has been found to promote regeneration and ameliorate 
fibrosis in various tissues and organs; however, its exact role in ischaemic 
disease has yet to be determined. Therefore, we sought to examine the 
expression and function of CXCR7 in cardiovascular tissues, focusing on its 
potential as a novel cardioprotective strategy. 
Methods: RNAscope in situ hybridization, western blotting and flow cytometry 
were used to investigate expression and function of CXCR7 on endothelial cell 
lines, isolated mouse endothelial cells, and in the whole mouse heart. We 
examined CXCR7 downstream signalling pathways in presence and absence of 
CXCR7 agonists TC14012 and VUF11207 fumarate, as well as the effects of the 
CXCR7 agonists on endothelial cell migration and acute ischaemia-reperfusion 
injury. 
Results: CXCR7 is expressed in the adult mouse heart and in the endothelial 
cell lines MCEC and HUVEC. Most CXCR7 protein in the endothelial cells was 
observed to be intracellular under basal conditions. In line with this expression 
profile, exposure to CXCR7 agonists failed to activate cardioprotective protein 
kinases ERK1/2 and PI3K/Akt. Moreover, VUF11207 did not ameliorate acute 
ischaemia-reperfusion injury, whereas the role of both CXCR7 agonists in 
migration and angiogenesis is less clear. 
Conclusions: CXCR7 is expressed in the mouse vascular endothelium, but its 
role in activating cardioprotective signalling pathways, as well as its overall 
contribution to cardioprotection is unclear. Activation of the CXCR7 receptor 




Acute myocardial infarction (MI) affects over 180,000 people per year in the UK 
alone. Despite advances in emergency medicine, which significantly reduced the 
morbidity and mortality of cardiovascular diseases in the last 60 years, there is 
still scope to limit the damage levered by MI, via novel cardioprotective or pro-
regenerative interventions. 
This work presents the results of an investigation into the role of CXCR7 
receptor in MI and whether its modulation can afford cardioprotection or 
stimulate angiogenesis in ex vivo and in vitro models. It suggests a pro-
angiogenic role of endothelial CXCR7, specifically pertaining to cell migration, 
which could affect future approaches to either limit or initiate angiogenesis in a 
physiological or a pathological setting. There was no direct cardioprotective 
effect of CXCR7 observed in our experiments and further work is needed to 
elucidate its role in cardioprotection after MI. The results presented in this thesis 
will mostly benefit the research community within academia who could draw on 
its work to design experiments to further test the hypotheses set in this thesis. 
Furthermore, this work could also benefit research organizations outside 
academia to build upon the data presented in this work and to design pro- or 
anti-angiogenic therapies based on CXCR7 receptor modulation.  
Most of all, the work in this thesis contributes to a body of research on a 
relatively novel CXCR7 receptor and its role in cardioprotection and cell 
migration aspect of angiogenesis. Combined with research that will be 
performed over the following years or decades this thesis could help to bring 
advances in cardioprotective and pro-regenerative therapies, which could 
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The term cardiovascular disease encompasses a multitude of conditions, where 
narrowing or blockage of blood vessels leads to detrimental effects on the heart. 
One of the most prevalent causes of morbidity and mortality in the western world 
is a group of conditions that belong under an umbrella term of coronary artery 
disease (CAD). Characterized by formation of an atherosclerotic plaque that 
forms inside one or more coronary arteries, via the process known as 
atherosclerosis; CAD is an inflammatory and fibrotic process that occurs in stages 
2. It begins with an accumulation of white blood cells and fatty lipids inside the 
coronary arteries, followed by formation of one or more lipid cores that can be 
surrounded by a fibrous cap 3,4. There is progressive stenosis and a gradual 
stiffening of the vessels, which impedes coronary blood flow. Due to decreased 
lumen and haemodynamic changes present in the vessels, the thin fibrous cap 
overlying the plaque can rupture or erode, which causes accumulation of red 
blood cells and formation of a blood clot that can either fully occlude the artery in 
question or form a thrombus 3, 5. Subsequently, if the narrowing of the vessel is 
severe enough, the lack of oxygen flowing to the heart will cause myocardial 
ischemia and can even lead to myocardial infarction. The formation of an 
atherosclerotic plaque is not an immediate process and it can take decades for 
the vessel to be occluded enough to become clinically significant. Patients with 
atherosclerosis are often not aware of the severity of their condition. That is, until 
they experience an ischaemic episode, characterized by a transient chest pain, 
known as angina 6.  
Hyperlipidaemia, diabetes, hypertension, as well as unhealthy lifestyle choices, 
including obesity, poor diet and smoking can severely affect the rate of 
atherosclerosis, and lead to coronary artery disease development 7, 8. 
Due to high prevalence of CAD and atherosclerosis in the increasingly aging 
population it is important to promote prevention, especially regarding the risk 
factors and lifestyle choices, which can play an important role in the development 
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of coronary artery disease 9, 10. Overall, cardiovascular disease is a widespread 
problem with approximately 7 million people affected by it in the UK alone (BHF 
statistic, 2016). Thus, it is important to develop strategies and promote new 
research to tackle the growing problem of cardiovascular disease not only in the 
UK, but globally.  
1.1 Myocardial infarction 
Although the rate of deaths attributable to cardiovascular disease has declined by 
more than three quarters since 1961, there are still a high proportion of patients 
with CAD that will go on and suffer a myocardial infarction (BHF statistic 2016). 
Acute myocardial infarction (MI) affects around 188,000 people in the UK every 
year and despite constant advances in emergency medicine it is still responsible 
for significant morbidity and mortality (BHF statistics, 2016) 11. In terms of  
pathophysiology, acute myocardial infarction can be defined as a loss of 
cardiomyocytes as a consequence of an ischaemic insult 12. However, myocardial 
infarction is a complex process with many metabolic and structural changes 
providing additional detrimental effects to the heart. During MI the coronary 
arteries become blocked, cutting off oxygen supply to the heart and generating 
an ischaemic environment that results in necrosis of the affected part of the heart 
muscle 13. There are several recognized clinical interventions, such as 
intravenous thrombolytic therapy and primary percutaneous coronary intervention 
(PCI) that aim to re-establish blood flow. However, these treatments focus 
primarily on early reperfusion, which, although beneficial overall, is known to 
cause additional reperfusion-related injury 14. Further to the more common 
mechanical interventions, there are also pharmacological interventions capable 
of affording cardioprotection and salvaging the still-viable myocardium. Kubler 
and Haass defined the term cardioprotection (also known as acute 
cardioprotection) as any intervention, either mechanical or pharmacological, that 
is capable of preserving the integrity of the heart by reducing or preventing 
myocardial damage 15.  
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The field of cardioprotection has come a long way since then, with several 
interventions emerging as potentially suitable clinical therapies.  For example, a 
member of the β-blocker family metoprolol and glucagon-like peptide-1 drug 
exenatide, which have shown promise in clinical trials, are currently undergoing 
further evaluations as to their cardioprotective potential 16-18. 
Nevertheless, the extent of damage suffered by the myocardium is still dependent 
on timely reperfusion; therefore, research into minimizing reperfusion injury and 
promoting regeneration of damaged myocardium is one of the most important 
areas of cardiovascular research 19. 
The damage seen after MI occurs in two stages, first during ischaemia and then 
again during reperfusion. As the blood vessel is blocked and the blood supply to 
the myocardium is affected, a series of biochemical and metabolic changes take 
place in the now ischaemic heart muscle 20, 21. After MI, reperfusion is crucial to 
begin myocardial salvage, while itself being a detrimental phenomenon 14. The 
reestablishment of coronary blood flow during reperfusion can cause further 
cardiomyocyte necrosis, myocardial stunning and microvascular dysfunction, 
where the damage to the endothelium prevents normal blood flow and causes a 
potentially deadly no-reflow phenomenon 20, 22. Therefore, when devising 
approaches to protect the viability of heart muscle, either ischemic injury, 
reperfusion injury, or both can be targeted. To describe these actions, the term 
cardioprotection is commonly used.  
 Ischaemic injury  
Myocardial ischaemia occurs as a result of a mismatch between the supply and 
the demand of oxygen, with the extent of the damage to the myocardium 
dependent on the duration and magnitude of tissue ischaemia 23. Consequentially, 
timely reperfusion strategy remains a foremost priority when it comes to MI 
interventions. During ischaemia, there is a series of metabolic changes that 
underpin the diminished oxygen supply to the heart muscle.  
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Obstruction or blockage of a coronary blood vessel impedes blood flow and 
causes a reduction in available glucose in myocardial tissues. This leads to 
reduced availability of ATP, and with it a switch to anaerobic metabolism, namely 
anaerobic glycolysis 12.  However, the myocardium is not equipped with sufficient 
anaerobic metabolic pathways to supply the high provisions of ATP needed for 
normal function, and available ATP is quickly used up 24, 25.  
Therefore, when exposed to ischemia, there is a dilatation of coronary vessels to 
try and increase the blood flow and keep the myocardium sufficiently supplied with 
oxygen and glucose to satisfy the metabolic needs. Despite these efforts, ATP is 
quickly depleted, leaving the heart vulnerable to the effects of ischaemia. 
Meanwhile, the switch from aerobic to anaerobic metabolism lowers the pH, and 
activates a buffering mechanism 12. Hydrogen ions are excreted via the Na+/H+ 
exchanger followed by a large influx of sodium ions to balance the loss of 
intracellular hydrogen  26. Furthermore, activation of various ATPases brought on 
by a lowered pH causes an efflux of potassium ions accompanied by an 
accumulation of cytosolic calcium, which provides an arrhythmogenic 
environment  27,12. The metabolic changes outlined above also trigger the release 
of intracellular proteases, such as the calcium-dependent protease calpain 28. 
Calpain then exerts a disruptive effect on the cell structure, and its activation leads 
to hypercontractility and subsequent activation of apoptotic pathways. It also 
paves the way for the opening of the mitochondrial permeability transition pore 
(MPTP) during reperfusion 26, 28.  
 Reperfusion injury 
The existence of lethal reperfusion injury separate from the ischaemic damage 
has been something of a controversy over the past couple of decades, with its 
existence having sometimes being called into question 29-31. Some authors have 
contested the evidence in favour of reperfusion injury, citing the lack of available 
human data and failure to translate the beneficial effects of ameliorating 
reperfusion injury from bench to bedside. However, since then, lethal reperfusion 
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injury has garnered support and has become generally accepted as an insult to 
the myocardium that occurs separate from the ischaemic damage 14. As with 
ischaemic injury, reperfusion injury is also associated with damage and death of 
cardiomyocytes, although via different pathologies than those outlined above.  
Microvascular dysfunction in the form of activated leukocytes and platelets, 
generation of reactive oxygen species (ROS), increased extravasation of fluid and 
proteins all converge to deal a harmful blow to the endothelium 22, 32. A detrimental 
process known as the no-reflow phenomenon can also occur during reperfusion 
period of myocardial infarction 33.  The term refers to damage sustained by the 
endothelium by all major pathogenic mechanisms, namely injury due to 
ischaemia/reperfusion (IR), thrombus formation and increased endothelial 
susceptibility to injury 34. It is also associated with adverse post-infarct 
complications, as well as a higher mortality rate and can occur in as many as a 
third of cases of MI 35, 36.  A less harmful process that can occur during reperfusion 
is myocardial stunning, which unlike the no-reflow phenomenon is deemed less 
injurious and is usually followed by a complete functional recovery 37. It can arise 
after as little as 15 minutes of ischaemic injury and is largely facilitated by release 
of free radicals and excessive calcium 38. Even though the myocytes are injured 
in this process, they ultimately recover their function without a prolonged 
detriment to the heart muscle 19. Altogether, reperfusion injury prompts a second 
wave of cardiomyocyte death, however, if it is established early enough (between 





1.2 The role of endothelial cells and angiogenesis in MI 
 Endothelial cell development  
The term endothelium refers to the innermost layer of vessels found in the 
cardiovascular and lymphatic system. Therefore, it is broadly divided into vascular 
and lymphatic endothelium. This thesis primarily focuses on the vascular 
endothelium, which is further divided into arterial and venous endothelium, and 
comprised of specialized cells called endothelial cells. In mice, as well as humans, 
endothelial cells develop from hemangioblasts derived from the mesoderm, which 
give rise to both, multipotent haematopoietic stem cells (HSC) and angioblasts 39. 
To generate both cell types, hemangioblasts form clusters, also called blood 
islets, and positioning of the cells within those clusters provides the distinction 
between the two cell types 40. Cells, which will become haematopoietic cells 
become clustered in the middle, while the angioblasts arrange themselves along 
the periphery 39, 41. Angioblasts give rise to endothelial cells, which further 
differentiate into either arterial or venous endothelial cells. The entire process of 
endothelial cell development is highly regulated and involves a multitude of 
transcription and growth factors in order to achieve formation of vascular plexuses 
present in the adult organism 42.  
Pinto et al. suggest that 55% of all nuclei in the murine heart belong to the 
endothelial cells, 32% to cardiomyocytes and 13% to fibroblasts 43. Moreover, 
endothelial cells are reported to make up only 3.2 – 5.3% of the volume fraction 
of the rat heart 44. Disparities in numerical representation of different cell types 
that appear in the published literature can be partially attributed to different 
research methods employed to investigate the cellular composition of the heart, 
with results obtained by Pinto et al. considered to be the most reliable 45. However, 
the percentages of cells that comprise the heart are also proposed to vary 
between species and regions of the heart 46. Furthermore, despite the endothelial 
cells not comprising a large proportion of the heart volume, they play an important 
role in cardiac physiology and pathology. For example they play a pivotal role in 
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maintaining vasomotor tone, modulating cardiac growth and development, and 
are known to modulate cardiac rhythmicity 47. Additionally, endothelial dysfunction 
contributes to the development of congestive heart failure through impaired 
systemic perfusion and diminished exercise capacity 48. 
Along with the aforementioned cell types, there is another type of cell postulated 
as capable of differentiating into mature endothelial cells. Endothelial progenitor 
cells (EPC) are bone marrow-derived cells, first identified by Asahara et al. in 1997 
49.They were described by Urbich and Dimmeler as non-endothelial progenitor 
cells, which possess clonal ability to multiply and are capable of differentiating into 
mature endothelial cells 50. The existence of EPC has been widely debated, as it 
is unclear how exactly they develop and give rise to mature endothelial cells 51, 52. 
Furthermore, to investigate EPC researchers have employed numerous different 
methods of cell isolation and characterization, which makes it difficult to surmise 
if the investigated populations of cells were comparable across different studies 
53. Additionally, there is a lack of in vivo evidence of EPC existence and only a 
few studies so far have attempted to examine the clinical relevance of these cells 
51. So far, research points towards EPC being comprised of HSC in various stages 
of differentiation, and which display certain pro-angiogenic functions (e.g. 
vascular repair), but with little evidence of potential for vascular differentiation 54, 
55. Due to the increasing presence of EPC in the literature, research regarding 
these cells cannot be ignored, but the use of term “EPC” should be further defined 
to include a specific type of cell and its precise function so their contribution to 
vascular processes in health and disease can be properly characterized 56.  
 Angiogenesis 
Angiogenesis is an important physiological process, whereby new vessels 
develop from pre-existing vessels through migration, growth and differentiation 




This requires cooperation of a range of cell types and signalling pathways, as well 
as numerous pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and others 58, 59. As in other crucial 
physiological processes angiogenesis is tightly regulated; however, it becomes 
dysregulated during many pathological conditions, such as inflammation, cancer 
and ischaemic heart disease 59, 60. One of the mechanisms through which 
angiogenesis occurs is sprouting, which proceeds in several key stages: i.) 
endothelial cell activation by various growth factors (e.g.:VEGF, bFGF) and 
subsequent degradation of extracellular matrix (ECM) components by  MMPs and 
(MMP1 and MMP2) ii.) migration of endothelial cells into ECM and towards a pro-
angiogenic stimulus (e.g. hypoxia) forming new endothelial sprouts as they 
proceed, iv.) after which the sprouts extend towards the pro-angiogenic stimulus, 
creating a vessel lumen and ultimately forming a new blood vessel 61. This thesis 
will focus on one aspect of angiogenesis, namely endothelial cell migration. It 
consists of three distinct processes: i.) directional migration of cells toward a 
gradient set by soluble chemoattractants (e.g. VEGF) - chemotaxis, ii.) directional 
migration produced by mechanical forces (e.g. fluid shear stress) - mechanotaxis 
and iii.) directional migration, which is generated by a gradient of immobilized 
ligands (e.g. integrins) - haptotaxis 62-67.  
The role of angiogenesis in many pathological conditions, including 
cardiovascular diseases, has been well documented. Current therapies aimed at 
treating myocardial infarction mainly deal with restoration of blood flow to the 
ischaemic area, be it mechanical or pharmacological. This brings with it its own 
problems and its efficacy is largely dependent on the time of initiation of the 
treatment 68. As the understanding of neovascularization after myocardial 
infarction has grown, so has the notion to harness angiogenesis as a potential 




One of the strongest stimuli for the induction of angiogenesis is hypoxia, whilst 
also being a defining feature of ischaemic heart disease. VEGF represents a 
crucial element in the angiogenic process, since it can stimulate quiescent 
endothelial cells and activate them to commence the process of new vessel 
growth. During a period of hypoxia, there is activation of hypoxia inducible factor 
1 (HIF-1), a heterodimeric transcription factor that induces VEGF gene expression 
and subsequently secretion of VEGF, leading to new sprout formation  (Fig. 1-1) 
70.  
Hypoxia is also one of the main characteristics of MI. As described in section 1.1.1 
the blockage of coronary vessels leads to impaired oxygen delivery to the area of 
infarcted myocardium, resulting in localized tissue ischaemia 12. This causes 
oxygen sensing mechanisms in the heart to detect low levels of oxygen in the 
tissue and initiate the pro-angiogenic response, which forms a part of the tissue 
regeneration process in infarcted myocardium 71. Early reperfusion of the infarcted 




Figure 1-1: Hypoxia acts as a powerful angiogenesis stimulus. Hypoxia activated HIF-1α, 
which couples to ubiquitously expressed HIF-1β subunit to form initiate gene expression of several 
hypoxia-induced genes, such as VEGF. Pro-angiogenic properties of VEGF then stimulate 
activation, migration and differentiation of endothelial cells into new blood vessels. Image adapted 




The idea to use angiogenesis to aid heart regeneration after MI is not new, and 
such treatments are defined as pro-regenerative.  PCI, thrombolysis and other 
pharmacological interventions are already being used to minimize damage seen 
from MI and can be very effective when applied quickly. However, these 
procedures will not benefit all patients equally. Patients presenting with 
microvascular dysfunction, who lack a well-developed collateral circulation exhibit 
prolonged ischaemia, and perfusion of the ischaemic myocardium via PCI does 
little to improve the clinical outcome 73. In such cases, stimulating angiogenesis 
and restoring microvascular integrity can be an effective way to overcome the 
hurdle posed by dysfunctional microvasculature and aid in successfully 
reperfusing the ischaemic myocardium. Similarly, use of pro-angiogenic growth 
factors has been hypothesized to have beneficial effects on the ischaemic 
myocardium, although this area of research is still in its infancy and needs to be 
explored further 74.  
1.3 The role of ligand SDF-1α and chemokine receptors CXCR4 and 
CXCR7 in cardiovascular health 
 SDF-1α 
SDF-1 (stromal derived factor 1); also termed CXCL12 is an 8 kDa peptide 
belonging to a group of peptides known as chemokines. Chemokines are made 
of four conserved cysteines with two disulphide bonds and function primarily as 
chemoattractants 75. They are involved in various cell processes, including cell 
trafficking, activation, and differentiation. In order to achieve this, they bind to G-
protein coupled receptors (GPCRs) that signal via G-proteins or less commonly, 
through β-arrestins 76, 77. SDF-1 is a ligand for two such G-protein coupled 
receptors, CXCR4 and CXCR7, where CXCR4 signals through G-proteins and 
CXCR7 through the β-arrestin pathway (Fig 1-2)78. There are multiple splice 
variants of SDF-1, with SDF-1α, which is made up of three exons being the most 
common 75.  
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The remaining splice variants all contain the same three exons as SDF-1α, with 
an additional fourth exon that is unique to each of the alternative splice variants 
75. Due to SDF-1α being expressed in most body tissues and organs, its 
degradation is an important and well-regulated process and consists of N-
terminus proteolysis and C-terminus degradation. The latter is mediated by 
carboxypeptidase N and is specific to SDF-1α, which is the most widespread and 
arguably most crucial variant 75, 79, 80. Other SDF-1 isoforms include SDF-1β that 
exhibits functions relating to the embryonic development and the vascular system, 
and SDF-1γ, which is a predominant variant of SDF-1 expressed in the rat adult 
brain, whilst also being expressed in the hearts of humans and mice 80-83. Little is 
known about the rest of the SDF-1 splice variants, namely the δ, ε and φ isoforms 
75. Considering they have only recently been identified in human tissues, their 





Figure 1-2: Signalling crosstalk between CXCR4 and CXCR7. Binding of SDF-1α to CXCR4, 
CXCR7 or the CXCR4/CXCR7 heterodimer activates several downstream signalling pathways 
and induces phosphorylation of various kinases, including, MAPK, PKA and PI3K. Image from 
Wuerth et al.84. 
 CXCR4 
SDF-1α/CXCR4 axis is important in numerous physiological processes, including 
cell migration, homing, survival, organogenesis and angiogenesis 1, 85. CXCR4 
receptor belongs to the C-X-C family of chemokine receptors, where two N-
terminal cysteine (C) residues are separated by a different amino acid (X) 86. 
Originally identified as a human immunodeficiency virus co-receptor, CXCR4 is 
expressed in a variety of cells including cells of the immune and central nervous 
system, endothelial cells, cardiomyocytes, and fibroblasts 87-91. Due to the wide 
range of actions it encompasses it can be exploited for clinical applications, such 
as mobilization of hematopoietic stem cells in certain types of cancer, via blockage 
of the CXCR4 receptor 92, 93. It therefore comes as no surprise that this axis has 
been widely studied in the context of cancer and autoimmune diseases, as well 
as being identified as a possible cardioprotective effector 76, 94, 95.   
Deregulation of the SDF-1α/CXCR4 axis is crucial to many pathological states 
and has also been found to be an important player in myocardial infarction and 
other hypoxic conditions, such as ischaemic cardiomyopathy 96, 97. Exploiting its 
cell homing properties, SDF-1α/CXCR4 axis has also been used to home cells to 
the ischaemic myocardium to increase myocardial salvage and improve left 
ventricular (LV) function 98-100. Supporting the role of SDF-1α/CXCR4 in 
cardiovascular disease are also numerous genome-wide association studies 
(GWAS) that link it with increased risk for myocardial infarction and death, but 
leave us in the dark as to the exact nature of this link 101-103.  Despite the fact that 
there is still much to be discovered about the CXCR4 receptor, it is the lesser 




While the SDF-1α/CXCR4 axis might be well studied, CXCR4 receptor is not the 
only receptor capable of binding SDF-1α. CXCR7, also known by its alternative 
names, ACKR3 (atypical chemokine receptor 3) and RDC1 (receptor dog cDNA 
1) is an atypical chemokine receptor that binds two known ligands, I-TAC 
(Interferon-inducible T-cell alpha chemo-attractant or CXCL11) and SDF-1α. 
Interestingly, recent studies have shown that CXCR7 can bind SDF-1α with 
approximately ten to twenty times greater affinity than CXCR4 78, 104. CXCR7 was 
first cloned from the canine cDNA library in 1990 by Libert et al., and attracted 
interest due to greater than 90% similarity between its dog and human homologs 
105. It was initially thought to be a VIP (vasoactive intestinal peptide) or calcitonin-
gene related receptor; however, this notion was later dismissed due to lack of 
evidence 106-108. Thus, it was not until 2005, when its now-confirmed ligands I-TAC 
and SDF-1α were identified, that the interest in the CXCR7 receptor began to 
grow 78, 106, 109.  
Expression and signalling  
CXCR7 is expressed in a variety of mammalian cells and tissues, including in  the 
heart, lung, liver, brain and the immune system, however, its exact expression 
profile, as well as its function remain disputed 109. Recent studies have shown 
CXCR7 expression by several different types of endothelial cells, including 
endothelial progenitor cells, human pulmonary microvascular endothelial cells, 
human umbilical vein endothelial cells (HUVEC), and human lymphatic 
endothelial cells 110-113. Meanwhile the expression profile of CXCR7 in the cardiac 
endothelial cells has not yet been thoroughly examined, with most CXCR7 
expression data postulated from effects seen in transgenic mice with endothelial-
specific inducible CXCR7 deletion 114, 115. Cardiac origin of endothelial cells might 
be an important factor when investigating the role of endothelial CXCR7 in the 
heart, due to high degree of heterogeneity and a different transcriptional profile 
that can be attributed to endothelial cells in a tissue-specific manner 116, 117. 
35 
 




CXCR7 has been shown to induce SDF-1α ligand internalization and degradation, 
along with providing cells with a growth and survival advantage and increased 
adhesion properties 113, 118. Upon further examination it was discovered that the 
DRYLAIV motif (Asp-Arg-Tyr-Leu-Ala-Ile-Val)  present in the majority of 
chemokine receptors is replaced by the DRYLSIT (Asp-Arg-Tyr-Leu-Ser-Ile-Thr) 
motif in CXCR7  (Figure 1-3) 109. Since, DRYLAIV motif is considered vital for G 
protein coupling and calcium signalling, it is proposed that CXCR7 cannot signal 
through G-proteins, as it is common with GPCRs, and is also insensitive to 
pertussis toxin in most tissues 113, 119, 120.  
 
Figure 1-3: Comparison of DRYLAIV and DRYLSIT motifs in CXCR4 and CXCR7. Classical 
chemokine receptors, such as CXCR4 exhibit a DRYLAIV motif that is necessary for G protein 
signalling. On the other hand, atypical chemokine receptors (e.g. CXCR7) possess a DRYLSIT 
motif that replaces the DRYLAIV motif (differences between motifs are underlined in red) and 
allows them to preferentially bind and signal through β-arrestins. Substituted amino acids are 




Calcium  plays an important role in many cellular processes, such as cell survival, 
cell death, as well as setting the cellular membrane potential 121. Since Ca2+ 
signalling typically occurs through G protein signalling, CXCR7 signalling on its 
own cannot elicit Ca2+ mobilization. In order to initiate the rise in intracellular 
calcium, phospholipase C (PLC) cleaves phosphatidylinositol bisphosphate 
(PIP2) into secondary messengers inositol trisphosphate (IP3) and diacylglycerol 
(DAG). IP3 then goes on to stimulate the opening of the IP3-mediated Ca2+ 
channels and subsequently triggers a rise in intracellular calcium, as seen in 
Figure 1-6 76, 122.  
Since CXCR4 and CXCR7 both possess the same ligand, SDF-1α, it can be a 
challenge determining precisely which receptor is responsible for the observed 
actions. One of the hallmarks of CXCR7 signalling is its inability to signal through 
G proteins and its reliance, instead, on signalling via β-arrestins 123. β-arrestins 
are scaffolding proteins more commonly associated with receptor desensitization 
and were long believed to lack meaningful signalling capacity, acting instead as 
cellular response dampeners 124. Rather than signal through a G-protein signalling 
pathway, CXCR7 recruits β-arrestin in a ligand-dependent fashion 123. Cells 
featuring transfected CXCR7 were shown to recruit β-arrestin to the plasma 
membrane following the incubation with either, SDF-1α or I-TAC ligand 125, 126. 
One of the most prominent differences of β-arrestins and G-protein signalling is 
the inability of β-arrestins to induce calcium mobilization, a hallmark of GPCR 
signalling 113, 120. However, active signalling of the SDF-1α/CXCR7 axis that is 
capable of activating effectors downstream of β-arrestins, has since been shown 
in various cell types, such as haematopoietic stem cells 127, 128. 
One exception where CXCR7 seems to utilize G proteins for signalling is in 
astrocytes, where there is evidence of a G-protein dependent mechanism 
resulting from SDF-1α binding to CXCR7 129-132. However, due to its inability to 
signal thorough G proteins in other tissues, CXCR7 was initially thought incapable 
of independent signalling and viewed solely as a decoy receptor for SDF-1α 119. 
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It is true that upon binding of SDF-1α or I-TAC, CXCR7 aids in internalizing and 
degrading the ligand, functioning as a scavenger receptor 133, 134. However, recent 
evidence points to it also being capable of independent signalling through β-
arrestins. This appears to be the case with CXCR7, where evidence points to 
activation of mitogen activated protein kinases (MAPK), PI3K and AKT after 
binding by SDF-1α and I-TAC 84, 123, 127, 135, 136.  
CXCR7 receptor also heterodimerizes with its fellow chemokine receptor CXCR4, 
in response to binding of the SDF-1α ligand. Before the discovery of CXCR7, 
CXCR4 was considered a unique receptor for SDF-1α and this ligand –receptor 
couple was widely studied due to its importance in a variety of cellular processes 
137. CXCR4/CXCR7 heterodimers form quickly and efficiently and can signal 
through G proteins and β-arrestins, with the argument being made for preferential 
activation of the latter 120, 135. Formation of CXCR4/CXCR7 heterodimers also 
modifies some of the properties of CXCR4 when not bonded in a dimer, namely 
calcium signalling 120. Interestingly, CXCR7/CXCR4 heterodimers on the other 
hand are able to elicit a greater Ca2+ response than CXCR4 receptor signalling 
on its own 135, 138. Furthermore, SDF-1α is also capable of forming homodimers 
under physiological conditions, but CXCR7 receptor preferentially binds the 
monomeric form 109, 139, 140. Despite abundant evidence of heterodimerization in 
vitro, in recent years questions were posed whether CXCR4/CXCR7 can form 
heterodimers in vivo, since there is not a lot of evidence to support this claim 109, 
133, 141, 142.  
It has been previously reported that CXCR7 is scarcely expressed on the surface 
of most cells, including endothelial cells, with a substantial intracellular pool of the 
receptor present in the cytosol of various types of cells 143, 144. SDF-1α-
CXCR4/CXCXR7 ligand-receptor pair is internalized following SDF-1α binding, 
which might explain the intracellular reservoir of the receptor 141. It is also a 
possibility that internally located CXCR7 recycles back to the cell membrane, 
where it regains functional activity 78, 109.  
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Hartmann et al. showed that in T-cells a portion of intracellular CXCR7 is located 
in endosomes, as evidenced by the co-staining of CXCR7 with endosomal 
markers 144.  Therefore, they propose that only a small fraction of CXCR7 that 
constantly shuttles between the intracellular stores and the surface membrane is 
available under a steady-state level. As such, CXCR7 is capable of scavenging 
and internalizing its chemokine ligands, which are then degraded to prevent their 
release  back into the circulation 134. Nevertheless, in the presence of increasing 
evidence the prospect of CXCR7 possessing a signalling role independent of its 
scavenging function cannot be ignored. 
CXCR7 in cardiac development and transgenic knockout models 
CXCR7 is also important in embryogenesis and early cardiac development as 
evidenced by cardiovascular defects present in transgenic mice with germline 
deletion of the receptor. In the heart, CXCR7 expression has been detected at 
embryonic day (E) 10.5, followed by a change in the expression pattern at E14.5. 
Thereby, it is postulated that CXCR7 is abundantly expressed during periods of 
critical cardiac growth and vascularization 109. This is supported by the fact that 
CXCR7 expression also corresponds to the period of coronary vascular 
development, including vascular plexus formation and vascular remodelling 
between E11.5 and E16.5, after which the receptor expression steadily decreases 
145. Interestingly, just as the expression of CXCR7 decreases, there is a rise in 
CXCR4 receptor expression, which also coincides with the period of development 
when CXCR4 and SDF-1α germline knockout mice die 88, 109, 113, 146, 147.  
There have been several papers published on the effects of CXCR7 germline 
deletion.  Gerrits et al. reported that mice with a germline  CXCR7-/- genotype 
exhibited a 30% survival rate 1 week after birth, with adult mice of the same 
genotype displaying signs of myocardial degeneration and fibrosis 148. They also 
noted that some CXCR7-/- mice presented with an enlarged heart, as well as 
hyperplasia of the ventricles and the septum 148.  
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Yu et al. published observations of semilunar valve thickening and ventricular 
septal defects, while Sierro et al. observed thickening of the pulmonary valve, the 
aorta and the bicuspid arterial valves; a phenotype, which was also reiterated in 
mice with endothelial-specific deletion of CXCR7 114, 119. There are slight but 
noticeable differences in phenotypes of CXCR7-/- mice produced by different 
groups, which can be attributed to distinct genetic manipulations used to generate 
these mice. Some of these characteristics are shared with the CXCR4-/- mice, but 
most are unique to the CXCR7 -/- mice 149. 
CXCR4 and CXCR7 receptor agonists 
 
As the interest in CXCR7 increased, so did the demand for a highly selective 
CXCR7 agonist, which does not activate CXCR4. There are currently three 
agonists of CXCR7 available for commercial use, the small molecule agonists 
VUF11207 and VUF11403, and the peptidomimetic TC14012 agonist. TC14012 
started out as TC140, a CXCR4 inverse agonist, derived from the horseshoe crab 
peptide polyphemusin 150. It was later modified to TC14012, a serum-stable 
CXCR4 compound. Introduction of C-terminal amidation on TC14012 removed 
conformational constrains present on T140, which allowed it to bind to CXCR7 
and recruit β-arrestins, with a binding strength comparable to the natural ligand 
SDF-1α 151, 152.  VUF11207 was among 24 derivates that were synthesized by 
Wijtmans et al. from a styrene-amide scaffold and pharmacologically evaluated to 
determine their structure-activity relationship and functional activity. Structural-
activity relationship was determined by competition binding experiments and 
assessed the impact of different chemical groups “attached” to the styrene-amide 
scaffold on CXCR7 affinity. The compounds that displayed favourable affinity to 
CXCR7 were then subjected to further functional evaluation. VUF11207 along 
with another compounds VUF11403 emerged as the compounds that performed 




The β-arrestin2 recruitment assay on CXCR7-expressing HEK293 cells revealed 
VUF11403 as a high-affinity ligand of CXCR7 with an EC50 of 1.0 nM and 
VUF11207 with an EC50 of 1.6 nM, surpassing the affinity displayed by SDF-1α in 
this assay (EC50= 2.6 nM) 153. Additionally, both compounds also performed well 
in an ELISA internalization assay, with both reducing CXCR7 surface availability, 
although VUF11207 (EC50 = 14.1 nM) displayed higher efficacy than VUF11403 
(EC50 = 23.7 nM). Based on these results, VUF11207 was selected as the best 
CXCR7 agonist to use in the study. Moreover, VUF11207 is also one of the few 
commercially available CXCR7 agonists and antagonists with a fully disclosed 
chemical structure (Figure 1-4) 153. 
 




1.4 Cardioprotective and pro-regenerative interventions 
 Current cardioprotective interventions 
Cardioprotective agents – ischaemic injury 
There are a considerable number of cardioprotective strategies that have been 
shown to be effective in experimental models, with most of them focusing on 
reperfusion, but there are some, such as β-blocker drugs, that are aimed solely 
at ameliorating ischaemic injury. β-blockers are believed to be able to reduce the 
progression of ischaemic damage and therefore reduce the final infarct size 154. 
However, clinical trials have failed to conclusively demonstrate this effect when 
administered to the patients 155-158. As such, they might not be the universal 
cardioprotective agents they were once believed to be.  
Nevertheless, β-blockers are still considered an important part of post-myocardial 
infarction management, and represent one of the most prescribed cardiovascular 
drug groups 154. Another approach in targeting ischaemia associated with 
myocardial infarction makes use of hypothermia (30 - 35°C), which is thought to 
arrest the progression of ischaemic damage and improve outcomes after MI 159, 
160. Still, this therapeutic approach is not without its limitations. There is a lack of 
safe cooling techniques available, and since target temperature should be 
reached well before the reperfusion stage to ensure maximum benefit, it might not 
be very advantageous for patients suffering with out-of-hospital MI. However, It 
could bring additional benefits to  patients if administered as an adjunct therapy 
together with PCI 161. Moreover, sodium-hydrogen exchange inhibitors (e.g. 
Cariporide), capable of ameliorating the rise in intracellular calcium have been 
shown to afford cardioprotection when administered prior to the index ischaemia 
162, 163. However, that makes them useful agents in circumstances such as 
coronary artery bypass surgery (CABG) where ischaemic insult is expected, and 
less so in acute myocardial infarction where the onset of ischaemia cannot be 
predicted. Furthermore, sodium-hydrogen inhibitors exhibit adverse off-target 
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effects, increasing mortality and the rate of cardiovascular events, which further 
limits their prospective use as safe and effective cardioprotective agents 164, 165 
Cardioprotective agents – reperfusion injury 
As opposed to dealing with ischaemic injury, the bulk of interventions and drugs 
show a cardioprotective effect on the heart by exhibiting their effects at the 
reperfusion stage of the I/R injury. To date, rapid restoration of blood flow to the 
affected area of the heart muscle remains the most effective cardioprotective 
strategy. This is mostly achieved via primary percutaneous coronary intervention 
(PCI) or thrombolytic therapy (e.g. tissue plasminogen activator, streptokinase) 
that breaks down the obstructing blood clot 166-168.  
In recent years, a lot of effort has been put into shortening the time between the 
onset of symptoms and the start of reperfusion 169. However, it is not always 
possible to bring the patients to the cardiology unit in sufficient time to allow for 
maximum benefit that can be gained from mechanical reperfusion 166. Therefore, 
pharmacological therapies that have shown promise in protecting the heart 
against the onslaught of damage seen after myocardial infarction could help 
provide additional benefit in situations where timely PCI cannot be achieved.  
Volatile anaesthetic agents have been shown to exert beneficial effects during 
CABG surgery, where transient ischemia due to surgery is known to occur. There 
is also evidence of a more direct cardioprotective involvement of volatile 
anaesthetics, such as isoflurane and other fluranes, in various in vitro and in vivo 
models of I/R injury 170-173. Exenatide, an antidiabetic drug is another agent that 
has been shown to reduce the final infarct size when administered as a continued 
infusion, just before the start of PCI. Exenatide is an analogue of hormone 
glucagon-like peptide 1 (GLP-1), linked with activation of pro-survival kinase 
pathways when administered prior to reperfusion 174, 175. Despite these actions, it 
is not yet known if its effects lead to improved clinical outcomes, with more clinical 
trials needed to assess its cardioprotective ability 17, 176.  
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In contrast, Cyclosporine-A displays its cardioprotective capacity by preventing 
the opening of the MPTP at reperfusion stage, which reduced the final infarct size 
in experimental studies 177. Therefore, it comes as a surprise that a recent large 
randomized clinical trial Cyclosporine and Prognosis in Acute Myocardial 
Infarction Patients (CIRCUS), which included patients with ST-segment elevation 
myocardial infarction (STEMI), did not show a beneficial effect for Cyclosporine-
A with all-cause mortality as primary endpoint of the trial 176, 178 . This goes to 
show how hard it is to achieve a successful translation of a cardioprotective 
approach from experimental models in vitro and in vivo to the efficacious therapy 
that can be used in the clinic. 
Pre-conditioning 
One of the most promising non-pharmacological cardioprotective interventions is 
ischaemic pre-conditioning.  A technique, that delays cell death by subjecting the 
myocardium to brief episodes of ischaemia before a sustained episode of 
infarction has been first described by Murry et al. who showed that it reduces 
infarct size in dogs 179.  
Pre-conditioning is not dependent on the existence of collateral coronary 
circulation or the size of the animal model and the beneficial effects afforded by 
pre-conditioning have been since observed in many different species, including 
humans  180-183. Despite the breakthrough pre-conditioning provided, it was hard 
to apply it to the clinical setting, since the pre-conditioning treatment would have 
to be applied in the patient before the MI has even occurred. It was not until the 
discovery of ischaemic post-conditioning by Zhao et al.  that the clinical application 
became a possibility  184. Post-conditioning works on a similar basis to pre-
conditioning with the only exception being that the brief ischaemic cycles are 
applied prior to reperfusion instead of prior to ischaemia. The discovery of post-
conditioning also cemented the case for lethal reperfusion injury, since the 




To test how well the treatments that were so successful in animal models 
performed in humans, STEMI patients were subjected to post-conditioning cycles 
of ischaemia shortly after initiating reflow in the proof of concept trial by Staat et 
al. 186. The clinical trial was a success and showed a reduced creatine kinase 
(surrogate marker for infarct size) in the pre-conditioned group of patients. 
However, many clinical trials that came thereafter showed only a small benefit of 
pre- and post-conditioning or failed to replicate this feat entirely 187, 188. This might 
be due to the latter trials making use of a less regulated patient environment, with 
a more real-life scenario where potential confounders and variables cannot be 
controlled for accurately.  
Overall, pre-conditioning technique and its variations (remote ischaemic 
conditioning, post-conditioning) are seen as beneficial for the heart, however 
finding the right setting for their utilization, so they can exert the most impact, has 
proven challenging.  
 The role of CXCR4 and CXCR7 
RISK cardioprotective pathway 
The Reperfusion Injury Salvage Kinase (RISK) signalling pathway was first 
described by Yellon’s group in 2002 to define the cardioprotective effects of 
urocortin 189. It consists of two parallel signalling cascades PI3K/AKT and 
MEK1/ERK1/2, which underlie the cardioprotective effects of several known 
interventions (e.g. preconditioning, adenosine) 190-192. In order for the pro-survival 
kinases of the RISK pathway to be able to afford cardioprotection, they must be 
activated at the time of early reperfusion 190. For example, IPC-mediated 
cardioprotection through the RISK pathway occurs in two phases: i.) the trigger 
phase, which occurs during the preconditioning cycles and ii.) the early 
reperfusion phase, when activation of pro-survival kinases is postulated to prevent 
the opening of the mPTP and consequently mitigates the I/R injury 193, 194.  
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However, the cardioprotective effects exhibited by RISK pathway activation are 
not limited to IPC and can also be observed with administration of 
pharmacological agents, such as adenosine, insulin, opioids and others 190, 194-196. 
Thus, the current consensus is that the RISK signalling pathway is shared by most 
cardioprotective therapies 191.  
The RISK pathway is activated by G protein signalling, which phosphorylates 
Phosphoinositide-3-kinase (PI3K) and MEK1/2, triggering a signalling cascade 
involving phosphorylation of AKT also known as protein kinase B and ERK1/2 
also known as mitogen protein kinase (MAPK3/1), respectively. It is important to 
note that PI3K/AKT and ERK1/2 are not restricted to the RISK pathway. In fact 
they are involved in many pathological and physiological signalling pathways and 
represent some of the most ubiquitous signalling molecules present in nearly 
every cell in the human and murine organism 197, 198. However, in the context of 
cardioprotection, where AKT and/or ERK1/2 signalling is posited to culminate in 
beneficial effects on the myocardium, the term RISK signalling pathway is used 
to describe their involvement. Similarly, the so-called Survivor Activating Factor 
Enhancement (SAFE) pathway, which signals through JAK-STAT has also been 
shown to confer cardioprotection, independently of the RISK pathway 199. Both, 
RISK and SAFE signalling pathway activation was shown to reduce final infarct 
size at reperfusion, with the pathways often described as a molecular basis of 
cardioprotection 200-202. Additionally, Huang et al. suggested that the SDF-
1α/CXCR4 axis affords cardioprotection directly by working through STAT3, which 
forms a part of the SAFE signalling pathway 203. The cardioprotective stimulus is 
thought to work twofold, indirectly through the ability of CXCR4 to mobilize stem 
cells and directly via activation of the RISK and SAFE pathways (Fig. 1-5) 203, 204.  






Figure 1-5: Signalling through RISK and SAFE cardioprotective pathways. 
RISK pathway signalling involves activation of a GPCR, which in turn phosphorylates either MAPK 
or PI3K, leading to ERK1/2 and AKT activation, respectively. This in turn blocks the mPTP opening 
and prevents cell death from reperfusion injury. On the other hand, SAFE cardioprotective 
pathways signals through TNF-α binding to a TNF receptor, which induces activation of the 
JAK/STAT complex. This again leads to blockage of the mPTP and cell survival.  Image adapted 




The role of CXCR4 in cardioprotection 
Due to known effects of SDF-1α on stem cell homing, retention, repair, as well as 
ventricular remodelling it comes as no surprise that investigation of 
cardioprotective properties of SDF-1α/CXCR4 axis has garnered a lot of interest 
100, 205, 206. The sustained release of engineered SDF-1α analogue from a hydrogel 
injected into the myocardium peri-MI, has proven an effective cardioprotective 
measure in a rat model of myocardial infarction 207. The procedure was performed 
in vivo with permanent ligation of the LAD and analysis of rat hearts 4 weeks post-
MI showed reduction of LV fibrosis in hearts injected with a hydrogel containing 
the engineered SDF-1α analogue versus hearts injected with hydrogel alone. The 
administration of SDF-1α has also proven cardioprotective when delivered directly 
via an intracardiac injection post-MI in an in vivo permanent ligation model. Mice 
injected with SDF-1α displayed significantly better cardiac function than the 
controls, immediately post infarction and in the longer term, along with decreased 
scar formation, which was observed several weeks after the initial ischaemic insult 
100. Furthermore, pre-conditioning increases the levels of SDF-1α, and it is 
hypothesized that the cardioprotective effects exhibited by this intervention are 
due to SDF-1α/CXCR4 signalling through RISK cardioprotective pathway (Figure 
1-6) 91, 190.  
Additionally, injection of skeletal myoblasts overexpressing SDF-1α post-MI in an 
in vivo rat model of MI with permanent LAD ligation, improved LV contractile 
function and promoted myocardial regeneration in the long term  208. Interestingly, 
administration of skeletal myoblasts overexpressing SDF-1α into the peri-infarct 
zone 8 weeks post-MI still managed to improve contractility of the LV 8 weeks 
post-treatment, specifically fractional shortening, compared to the LV contractility 
observed prior to cell therapy. Meanwhile, administration of skeletal myoblasts 
without SDF-1α overexpression, did not afford such cardioprotection 209.  
Furthermore, SDF-1α administration prior to MI improved myocardial functional 
recovery immediately post-MI in a mouse Langendorff I/R model.  
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These beneficial effects have largely been attributed to the SDF-1α/CXCR4 







Figure 1-6: SDF-1α/CXCR4 signalling through the RISK cardioprotective pathway. RISK 
pathway signalling involves activation of a GPCR, which in turn phosphorylates either MAPK or 
PI3K arm of the signalling pathway, leading to ERK1/2 and AKT activation, respectively. This in 
turn blocks the opening of the mPTP and prevents cell death. At the same time SDF-1α/CXCR4 
signalling also triggers Ca2+ mobilization, involved in many cellular processes, through PIP2/IP3 
signalling. 
On the other hand, there is also evidence that CXCR4 can act in a detrimental 
fashion, worsening the outcome after MI. In a study by Liehn et al. CXCR4 
heterozygous knockout mice exhibited reduced infarct size when measured 4 
weeks after myocardial infarction 210. This could be due to CXCR4-dependent 
alteration of adverse remodelling and involvement of reparative pathways, 
however there were no additional effects on cardiovascular function 210. 
Transgenic rats, in which CXCR4 overexpression in the heart has been achieved 
with administration of an adenoviral vector, showed an increase in infarct size and 
worsening cardiac function, when compared to wild type rats. CXCR4 
overexpression was also associated with increased inflammatory cell infiltration 
and cardiomyocyte apoptosis in the ischaemic heart 211.  
Similarly, induced overexpression of SDF-1α in rat cardiomyocytes led to worse 
outcomes when rats were subjected to I/R injury compared to controls. Although, 
supra-physiological levels of the ligand could be responsible for part of the effect 
211, 212. The case remains that there is evidence for both, protective and 
detrimental effects of CXCR4 receptor in the cardiovascular setting.  
Previous studies also suggested that the timescale of CXCR4 increase in the 
heart after MI does not correspond to the peak of SDF-1α activity 213. It looks as 
though the way SDF-1α/CXCR4 axis behaves, depends at least partially upon the 
temporal alignment and/or the timing of SDF-1α and CXCR4 expression, which 
then dictates whether the subsequent downstream signalling events prove to the 




The role of CXCR7 in cardioprotection 
Compared to CXCR4, less is known about the signalling through CXCR7 in 
cardioprotection, be it through the RISK pathway, or other signalling pathways. 
There is mounting evidence of RISK and SAFE pathway involvement through 
ERK1/2, AKT, JAK/STAT and MAPK pro-survival signalling downstream of 
CXCR7 receptor in tumour progression and metastasis, but less is known about 
CXCR7 signalling in cardiovascular cell types 214-218. One of the hallmarks of RISK 
pathway activation is phosphorylation of ERK1/2 and AKT, which can be easily 
determined in an experimental setting, for example via western blotting. Past 
research shows that CXCR7 activation, using either SDF-1α or TC14012, can 
induce ERK1/2 and/or AKT phosphorylation on various cell types, including 
cardiac stem cells, HUVEC, and T cells of the immune system 115, 219, 220. CXCR7 
has been shown to signal via recruitment of β-arrestins to the plasma membrane, 
as described in section 1.3. However, less is known about signalling downstream 
of CXCR7, and what further signalling pathways this might activate. Current 
knowledge of SDF-1α/CXCR7 signalling via RISK pathway in different cell types 
is summarized in Figure 1-7.  
Chen et al. showed by western blotting that SDF-1α induced phosphorylation of 
AKT on c-kit+  rat cardiac stem cells 15 min after administration 219. On the other 
hand, the administration of CXCR7 small interfering RNA (siRNA), in the presence 
of SDF-1α, inhibited AKT phosphorylation and restricted cell migration in 
response to SDF-1α 219. Kumar et al. showed that pre-treatment of Jurkat T cells 
with CXCR4-blocking antibody and subsequent administration of SDF-1α, 
induced maximal phosphorylation of AKT 15 min after administration 220. This was 




Figure 1-7: SDF-1α/CXCR7 signalling through the RISK cardioprotective pathway. The 
binding of SDF-1α to CXCR7 triggers β-arrestin recruitment, which in turn activates either the 
MAPK (ERK1/2) or the AKT arm of the RISK signalling pathway, leading to cell proliferation and 
chemotaxis or cell survival, respectively. 
Phosphorylation of AKT was abrogated in the presence of wortmannin, an 
irreversible PI3K inhibitor. Pre-treatment of Jurkat T cells with wortmannin before 
stimulation with SDF-1α also inhibited cell survival, suggesting the importance of 
CXCR7-AKT signalling pathway for T cell survival 220.  
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Similarly, SDF-1α incubation in the presence of CXCR4-blocking antibody elicited 
maximal phosphorylation of ERK1/2 10 min post-administration, and was found 
to play an important role in the chemotactic response of Jurkat T cells 220. 
Moreover, Rajagopal et al. showed that HEK293 cells transfected with CXCR7 
have the ability to recruit β-arrestins after stimulation with SDF-1α, leading to 
sustained ERK1/2 activation 135. Moreover, phosphorylation of AKT and ERK1/2 
as a result of CXCR7 stimulation has been reported in rat cardiac stem cells 219. 
Similarly, Zhao et al. showed that SDF-1β signalling through CXCR7 protects from 
palmitate-induced apoptosis via AMPK and p38 MAPK in H9C2 (rat cardiac 
myoblast) cells 221.  Thus, various evidence suggests that CXCR7 activation is 
able to couple to PI3K/AKT and ERK1/2 kinases.  
Only a few papers focus specifically on CXCR7 in endothelial cells. Zhang et al. 
showed that activation of CXCR7 via administration of TC14012 in HUVEC 
induces phosphorylation of PI3K, which stimulates endothelial tube formation. 
This change in phosphorylation status was abrogated by administration of PI3K 
inhibitor, LY294002, which  also inhibited tube formation 222. Further information 
about the importance of AKT and ERK1/2 activation in endothelial cells comes 
also from experiments performed on isolated mouse aorta endothelial cells by 
Hao et al. 115. In this study, pre-treatment of cells with IL-1β induced cell 
proliferation, while the administration of CXCR7 antagonist or CXCR7 siRNA, 
decreased phosphorylation of AKT and ERK1/2 and consequently reduced cell 
proliferation.  Therefore, it seems that in endothelial cells CXCR7-dependent 
activation of ERK1/2 and/or AKT plays a role in angiogenesis and cell 
proliferation, processes through which CXCR7 could exert its cardioprotective 
effects. Nevertheless, the exact signalling components downstream of SDF-
1α/CXCR7 have not yet been elucidated, and they might differ in various cell types 




Hao et al. have shown that intraperitoneal administration of CXCR7 agonist, 
TC14012 (10 mg/kg), immediately post-MI and then every 6 days for 24 days, in 
an in vivo mouse model of MI with permanent ligation, significantly decreased final 
infarct size 4 weeks post-MI. However, the role of CXCR7 and its agonists in an 
acute myocardial infarction setting has not yet been defined 115. Hao et al. 
reported that mice with inducible, endothelial-specific CXCR7 deletion exhibit 
increased neointima formation after endothelial denudation injury in the femoral 
artery 115. Furthermore, Hao’s group also showed that endothelial deletion of 
CXCR7 in mice impaired cardiac function, reduced survival rate and increased 
infarction size after permanent ligation myocardial infarction. Therefore, evidence 
exists of endothelial CXCR7 being important for not only cardiac development, 
but also cardiac function and warrants further investigation in terms of its 
cardioprotective capacity. 
The study by Hao et al. has been published during my PhD, and unfortunately 
explored many of the same ideas that I was also interested in, especially the role 
of CXCR7 agonists on long-term cardioprotection and the role of CXCR7 in 
myocardial infarction in CXCR7 knockout mice 115. That prompted me to focus 
more on the acute side of cardioprotection, as well as the pro-angiogenic aspects 
of CXCR7 so as to explore more novel concepts, rather than just repeat what has 




The role of CXCR4 and CXCR7 in myocardial regeneration 
 
As already discussed in section 1.4.1 there are a variety of clinical interventions, 
either mechanical of pharmacological, that can be utilized in the setting of 
myocardial infarction. Most of those interventions are based on re-establishing 
blood flow, providing so-called reperfusion therapy. However, not all patients will 
benefit from reperfusion therapy equally; for example those with microvascular 
dysfunction will experience less benefit from reperfusion therapy than those 
without 223. For those patients, increasing the rate of vessel regeneration in the 
infarcted myocardium can offer an alternative, long-term approach to  
cardioprotection afforded by timely reperfusion.  Most current therapies focus on 
acute cardioprotective interventions, usually administered during or immediately 
after MI. However, many MI patients then go on to develop heart failure and 
designing therapies aimed at long-term pro-regenerative solutions that go past 
the scope of acute cardioprotection, could also improve patient prognosis and 
decrease the rate of heart failure occurrence. Native pro-angiogenic response 
after MI is present in the adult heart to some extent although the mechanism of 
vessel regeneration in the ischaemic heart in general is not well understood 224, 
225 . Furthermore, this response is likely insufficient to cope with the damage 
caused by coronary vessel occlusion 225, 226.  
 
Pro-angiogenic therapies administered after MI have shown therapeutic potential 
in preclinical studies in the past. Most pro-angiogenic therapies investigated so 
far have focused on delivery of angiogenic growth factors or stem and progenitor 
cells that are believed to have pro-angiogenic potential, with limited success 63, 
227, 228. However, there are many different stages involved in the mechanism of 
angiogenesis, offering numerous therapeutic targets that researchers can 




SDF-1α is a major contributor to the process of angiogenesis. It plays a crucial 
role in endothelial cell migration, retention, proliferation, as well as recruitment 
and survival of EPCs to sites of ischaemia-induced injury 229,112, 230. Therefore, 
SDF-1α/CXCR4 signalling in the infarcted myocardium is thought to promote 
recruitment and survival of adipose-derived regenerative cells, c-kit+ endogenous 
cardiac stem cells and bone marrow stem cells 96, 98, 206. Stem cells that have been 
externally delivered to the ischaemic heart (e.g. intramyocardial, intracoronary 
injection) have been shown to improve cardiac function and limit damage to the 
left ventricle, despite poor retention and engraftment at the site of injection 99, 100. 
The beneficial effects of injected stem cells are hypothesized to be a result of 
paracrine effects of stem cells on their surrounding cells, such as release of 
cytokine growth factors and stimulation of angiogenesis and are largely believed 
to  rely on SDF-1α/CXCR4 signalling. Preliminary animal studies on rodents 
showed good regeneration of cardiac function after injection of stem cells into 
ischaemic myocardium 231. However, despite several clinical trials showing 
improvement in clinical outcomes after stem cell administration in patients with 
ischaemic heart disease, no study has yet shown myocardial regeneration on a 
scale of that seen in animal studies 232, 233. This further highlights the widening 
chasm between bench and bedside and is emblematic of what is occurring in the 
areas of myocardial regeneration, cardioprotection and beyond. 
The role of CXCR7, however, is even less understood. There is a lack of 
knowledge regarding the role of CXCR7 in cardiac injury and subsequent 
revascularization and regeneration efforts that take place in the damaged tissues. 
Most of the data so far comes from groups studying CXCR7 in regeneration and 
fibrosis of various tissues, with little research focusing specifically on the heart 234, 
235.  A great deal of studies on CXCR7 have focused on its role in angiogenesis 
in the context of cancer biology, but less so in other processes 236, 237. Increased 
levels of CXCR7 have been shown in tumour vasculature, where CXCR7 plays 




Research conducted by Yan et al. suggests that CXCR7 is not involved in EPC 
migration and proliferation, whereas EPC survival depends solely on CXCR7 112.  
Formation of SDF-1α-induced EPC tube formation on the other hand, is heavily 
dependent on both receptors working in unison to guarantee a maximum  
response 112. This highlights a complementary rather than redundant role of both 
receptors regarding the EPC, which could also extend to other cell types (e.g. 
differentiated endothelial cells). CXCR7 was also found to mediate matrix 
metalloprotease- 2 (MMP-2) release, which could represent another mechanism 
responsible for CXCR7-triggered revascularization after ischaemic injury 112, 118. 
Additionally, Hao et al. showed that inhibition of CXCR7 negatively affects 
angiogenesis, while Zhang et al. showed that SDF-1α promotes tube formation, 
proliferation and migration of HUVEC, although they do not distinguish whether 
these actions are mediated through CXCR4 or CXCR7 receptors 115, 222.  
Furthermore, Ding et al. reported that CXCR7-Id1 signalling mediates liver 
regeneration and limits fibrosis, while CXCR4-FGFR1 signalling in the same 
setting promoted fibrogenesis 234. CXCR7 was also found   to promote lung 
alveolar repair and to abrogate fibrosis after acute lung injury, by signalling 
through the Wnt signalling pathway 240. Additionally, SDF-1α/CXCR7 signalling 
after pneumonectomy prompted AKT-dependent MMP-14 release from activated 
platelets, which stimulated alveolar regeneration 235.  
All in all, there is mounting evidence of CXCR7 involvement in angiogenesis and 
through that a potential to help re-establish sufficient vascular supply to the 
myocardial tissue damaged by ischaemia/reperfusion (I/R) injury. This pro-
angiogenic approach through CXCR7 could potentially provide long term benefits 




1.5 Hypothesis and Aims 
 Original hypothesis 
The original hypotheses to be investigated in this thesis are: 
1. CXCR7 is expressed on cardiovascular cell types. 
 
2. Activation of endothelial CXCR7 stimulates components of 
cardioprotective and regenerative signalling pathways.  
 
3. Activation of CXCR7 induces acute cardioprotection after myocardial 
infarction  
 
4. Activation of CXCR7 promotes long-term regeneration by stimulating 
angiogenesis  
 Aims 
The specific aims and objectives of the study are to: 
1. Investigate expression of CXCR7 in cardiovascular cell types.  
- Confirm expression of CXCR7 in mouse cardiovascular tissues. 
- Confirm expression of CXCR7 in endothelial cells of cardiac origin. 
- Investigate localization of CXCR7 and CXCR4 receptors in endothelial 
cells and identify an appropriate cell line for use in in vitro experiments. 
2. Investigate whether CXCR7 agonist VUF11207 exhibits cardioprotective 
effects in a rat ex vivo perfusion model. 
- Investigate if the administration of VUF11207 prior to reperfusion has an 
effect on the final infarct size in MI. 
- Investigate if the administration of VUF11207 prior to reperfusion has an 
effect on the LDH release during MI. 
58 
 
- Examine whether the administration of VUF11207 prior to reperfusion has 
an effect on the functional parameters of the heart. 
3. Investigate whether administration of CXCR7 agonists is able to induce AKT 
and/or ERK1/2 phosphorylation, in order to examine RISK pathway signalling. 
- Examine the effect of VUF11207 and SDF-1α on AKT, ERK1/2 
phosphorylation status in HUVEC. 
- Examine the effect of TC14012 and SDF-1α on AKT, ERK1/2 
phosphorylation status in HUVEC. 
4. Generate mice with inducible, endothelial-specific CXCR7 deletion. 
- Characterize the mouse model by investigating endothelial CXCR7 RNA 
and protein content. 
- Examine whether the mice exhibit the loss of endothelial CXCR7 protein. 
5. Investigate the effects of CXCR7 agonists on HUVEC migration. 
- Examine the effects of CXCR7 agonists, VUF11207 and TC14012 on 





2 Materials and methods 
This chapter describes the general methods and materials used throughout this 
thesis. All reagents used were from Sigma-Aldrich (Dorset, UK), unless stated 
otherwise. All perfusion solutions were made using water from a MiliQ dispenser 
with a resistance of >18.0 MΩ and filtered (1 μm pore size) before use. 
2.1 Experimental use of animals 
All animals were housed in individually ventilated cages with 12h light/dark cycles 
under pathogen-free conditions. Standard chow and water for the animals was 
provided ad libitum, with the temperature of the housing unit maintained at 21°C. 
Animals were regularly inspected for signs of ill health (reduced weight gain, 
piloerection, hunching etc.) and routine care was administered by the University 
College London (UCL, UK) Biological Services Unit (BSU). Experiments were 
performed in line with best practice as described by the Home Office License 
Training Course Modules 1-4. All animal work was carried out in accordance with 
the Guidelines on the operation of Animals (Scientific Procedures) Act, as 
published by the UK home office in 1986 and Amendment Regulations 2012. All 
procedures contained within the application have been reviewed by the 
institutional veterinary surgeon Olga Woolmer (2017). The experiments are 
conducted within the terms of the Animals (Scientific Procedures) Act 1986, under 
Project License number PPL 70/8556, (“Protection of the Ischaemic and 
Reperfused Myocardium”) issued to Prof. Derek Yellon in 2015. 
2.2 Transgenic mouse lines 
 Generation of transgenic mice 
Ackr3tm1Twb flox/+ mice were originally generated by Timothy W. Behrens, M.D.  
(University of Minnesota, MN, USA) 114. Mice were obtained from Mutant Mouse 
Resource and Research Centre (MMRRC) from a cryopreserved embryo stock.  
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Briefly, mice were generated with the help of a targeting vector designed to 
insert loxP sites, which are 34 base pair (bp) sequences that allow DNA to be 
modified in the presence of Cre recombinase, from either side of exon 2 of 
the Cxcr7 (Ackr3) locus (Figure 2-1). The targeting vector used for the generation 
of this transgenic line was created from PCR cloned 129/SvEv genomic DNA that 
has been inserted into the pK11-2xLox-MCS12.  
The linearized targeting vector was then electroporated into 129/SvEv embryonic 
stem (ES) cells. Correctly targeted, ES cells were injected into C57BL/6 mouse 
blastocysts. Chimeric offspring were crossed with C57BL/6J mice, and agouti 




Figure 2-1: Cre/Lox mechanism for transgenic mouse generation. A.) iCreERT2 (inducible 
Cre) transgene product expression is spatially regulated by the Pdgfb promoter. B.) Administration 
of tamoxifen causes a translocation of iCreERT2 protein into the nucleus. C.) In the nucleus, Cre 
induces recombination at loxP sites flanking exon 2, D.) resulting in excision of exon 2 and 
generation of endothelial-specific Cxcr7iΔEC mice. KO = Cxcr7iΔEC.  
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 Endothelial-specific gene ablation 
In order to examine the tissue-specific effects of Cxcr7 in adult mice, inducible 
iCreERT2 recombinase driven by the endothelial-specific platelet- derived growth 
factor B promoter (Pdgfb), referred to as Pdgfb-iCreERT2 was used.  
Since this form of Cre recombinase first needs to be induced by tamoxifen 
injection, it allowed us to not only spatially, but also temporally regulate the 
induction of Cre recombinase, and with it, Cxcr7 gene deletion. Temporal 
regulation of Cxcr7 deletion in vascular tissues is particularly important due to 
severe cardiovascular defects exhibited by embryos lacking Cxcr7 in the 
vasculature 119, 148. The iCreERT2 form of the Cre gene encodes a Cre sequence 
adjoined to a single human mutated ER (oestrogen receptor) binding domain, to 
which tamoxifen (oestrogen receptor modulator) binds to initiate nuclear 
translocation of iCreERT2 protein. Importantly, mutated ER receptor domain is not 
activated by endogenous ligand 17β-oestradiol to prevent unwarranted 
translocation of Cre protein 241. 
iCreERT2 has been previously reported as having lower background activity and 
higher efficacy than other Cre systems 242. C57BL/6JCre/+ mice expressing 
tamoxifen-inducible improved Cre recombinase driven by the platelet derived 
growth factor subunit B promoter (Pdgfb-iCreERT2), were obtained from Dr 
Marcus Fruttiger (UCL, London) and generated as described elsewhere 243. 
Pdgfb-iCreERT2 colony founders used to set up our colony also contained floxed 
Cxcr4 alleles. Cxcr4fl/fl animals were obtained from Dr Dan R. Littman (Columbia 
University, NY, USA) and generated using methods published elsewhere 244. 
 Colony maintenance 
Mice were bred as outlined in Figure 2-2 below. The iCreERT2 (henceforth called 
“Cre”) transgene was maintained as heterozygous for several reasons. Firstly, the 
exact insertion site of the Cre transgene is unknown due to random integration of 
the transgene construct and therefore it is difficult to distinguish homozygous and 
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heterozygous genotype, with heterozygous expression of Cre sufficient to induce 
recombination at the loxP sites 243, 245. Additionally, the very insertion of the Cre 
construct can cause disruption of the gene into which it inserts 246. Certain 
versions of Cre also have the ability to produce unanticipated effects when in 
homozygous form, such as myocardial dysfunction observed in myocyte-Cre 
overexpressing mice 247. Therefore, it is preferable to maintain mice as 
heterozygotes.  
Breeding pairs were made up of animals between 8 and 16 weeks of age, with 
females being allowed a maximum of 6 litters. Litters were weaned at 3 weeks of 
age after which ear biopsies were collected and genotypes determined by PCR. 
To describe the genetic status of transgenic animals, certain abbreviations are 
used throughout the text: wild type (WT, Cxcr7fl/fl Cre-, Cxcr7WT), floxed (FL, fl/fl, 








Figure 2-2: Transgenic mouse breeding scheme. A) Depicted are mouse breeding pairs 
used to breed experimental transgenic animals in our experiments. B.) Additional 
control mice that would need to be generated in order to investigate any potential 
effects of tamoxifen or Cre, since tamoxifen can exhibit various degrees of toxicity 
and certain Cre strains display detrimental effects on mouse tissues. 
 Mouse genotyping 
Mouse biopsies were collected by BSU staff shortly after weaning at 3 weeks of 
age. Total DNA was isolated from mouse ear biopsies, using Direct PCR lysis 
reagent (Viagen Biotech, CA, USA) and Proteinase K (Qiagen, Norway) in a ratio 
of 10:1 overnight at 55°C. Afterwards, samples were heated to 90°C for 45 min to 
terminate the lysis process and were subsequently stored at -20°C before 
analysis.  
PCR reactions were run using Taq PCR Master Mix Kit (Qiagen, 201443) with 
reagents outlined in Table 2-1 and 2-2 below.  Sequences of PCR primers used 




Reagent Volume per 
sample (µl) 
Final concentration 
10mM dNTPs 2.0 250µM of each dNTP 
10x PCR buffer 0.4 2x 
Forward primer 0.5 0.2 pmol/µL 
Reverse primer 0.5 0.2 pmol/µL 
Distilled water  15.4 - 
Taq DNA polymerase 0.2 - 
Template DNA  1.0 - 
Total volume per sample (µl) 20 





Reagent Volume per 
sample (µl) 
Final concentration 
10mM dNTPs 2.5 250µM of each dNTP 
10x PCR buffer 0.5 2x 
WT forward primer 0.5 0.2 pmol/µL 
FL forward primer 0.5 0.2 pmol/µL 
Common reverse primer 0.5 0.2 pmol/µL 
Distilled water  13.3 - 
DMSO 0.5 - 
Taq DNA polymerase 0.2 - 
Template DNA  1.5 - 
Total volume per sample (µl) 20 




Primer name Primer sequence (5’-3’) Tm (°C) 
Cxcr7 WT forward primer GCTGCAAACCCGTGAACAAGG  61.7 
Cxcr7 FL forward primer TCTATCGCCTTCTTGACGAGTTCTTC  60.1 
Cxcr7 Common reverse primer GGGCTCTCTGGCCGTTCTCTC  65.2 
Cxcr4 forward primer CCACCCAGGACAGTGTGACTCTAA 64.4 
Cxcr4 reverse primer GATGGGATTTCTGTATGAGGATTAGC 61.6 
Pdgfb-Cre forward primer CCAGCCGCCGTCGCAACT 62.8 
Pdgfb-Cre reverse primer GCCGCCGGGATCACTCTCG 65.3 
Table 2-3: PCR primer sequences and their melting temperatures. 
All PCR primers were purchased from Eurofins Genomics (Germany) and were 
dissolved in distilled MiliQ water at 100 pmol/µL, with the final working 
concentration of 10 pmol/µL. 
The PCR-cycling protocol outlined in Table 2-4 was used for Cxcr4 and Cre PCR 
reactions on a PTC-200 Peltier Thermal Cycler (MJ Research, Canada), including 
a heated lid setting. Samples were run using a “touch-down” cycling technique, 
where the annealing temperature is reduced from 65°C to 60°C by 1°C per cycle 
prior to standard cycling at 60°C annealing temperature. This allows for primers 
to achieve a highly specific binding at the first available temperature with further 
cycles utilizing incrementally lower annealing temperatures to achieve maximum 
efficiency of reaction. Subsequently, this also allows for reduction of non-specific 
binding at lower annealing temperatures providing a specific, sensitive and high-




PCR stage Temperature and duration Description 
5 cycles of: 
1. 94°C – 30 s  DNA denaturing 
2. 65°C – 30 s, decreasing 1°C per 
cycle until it reaches 60°C 
Primer annealing 
3. 72°C – 30 s DNA synthesis 
Then 40 cycles of: 
16. 94°C – 30 s DNA denaturing 
17. 60°C – 30 s Primer annealing 
18. 72°C – 1 min DNA synthesis 
Then 4°C until collection. 
Table 2-4: Cxcr4 and Cre PCR thermocycling protocol. 
Loading buffer was added to the samples and they were subsequently run on an 
agarose gel consisting of 2% agarose powder dissolved in 1x TAE buffer (Tris 40 
mM, acetic acid 20 mM and EDTA 1mM) at 118V in an Owl Easycast B2 Mini Gel 
Electrophoresis System (Thermo Fisher, MA, USA) electrophoresis chamber filled 
with TAE buffer. Migration distance was determined using the marker dyes added 
to the PCR loading buffer and electrophoresis of the gel was stopped once the 
leading front of the dye reached approximately 75% of the available gel distance, 
which occurred around the 40-minute time mark.  The Cxcr4 WT band presented 
at 481 bp and FLOXED band at 550 bp, whereas Pdgfb-Cre had a single band 
with a molecular weight of 440 bp. Primers utilized for detection of WT and FL 
bands are outlined in Figure 2-3 below.  
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Syto® 60 Red Fluorescent Nucleic Acid Stain (Thermo Fisher) was added to the 
gel before it solidified to allow for fluorescent detection of DNA bands. Images 
were obtained using a 700 nm laser via Odyssey® LI-COR imagining platform 
and software. 
To determine the sizes of DNA bands, each experiment was run alongside a 
BenchTop 1 Kb DNA Ladder (Promega, WI, USA). To detect any possible 
contamination each experiment was also run with an additional lane containing 
PCR master mix where DNA template was substituted with distilled water.  
 
Figure 2-3: Detection of wildtype (WT) and floxed (FL) gene sequences. A.) Combination of 
the WT forward primer (green arrow) and common reverse primer (orange arrow) produces a 212 
bp gene product, indicative of a WT genotype. B.) In mice with floxed Cxcr7 (FL) the sequence 
utilized by the WT forward primer is largely separated or obstructed, which renders the WT forward 
primer ineffective. Instead, floxed mice possess a neomycin resistance gene (neo) cassette insert, 
to which the FL forward primer (yellow arrow) binds and together with the common reverse primer 
forms a 709 bp gene product indicative of a FL genotype.  F = forward, R = reverse.  






Figure 2-4: Representative mouse PCR genotyping images. A.) Cxcr7 had a floxed (FL) band 
at 709 bp and wild type (WT) band at 212 bp, with B.) Cxcr4 presenting with a WT band at 481 bp 
and FL at 550 bp and finally, C.) the presence of Pdgfb-Cre was confirmed by a single 440 bp 
band, whereas WT animals displayed no visible bands. 






PCR stage Temperature and duration Description 
1.  94°C – 5 min Initiation/melting 
Then 40 cycles of: 
2. 94°C – 15 s  DNA denaturing 
3. 65°C – 30 s, decreasing 1°C per 
cycle until it reaches 55°C 
Primer annealing 
4. 72°C – 40 s DNA elongation 
Followed by    
5. 72°C – 5 min Amplification 
Then 4°C until collection. 
Table 2-5: Cxcr7 PCR thermocycling protocol. 
Once the thermocycling protocol has ended, the samples were run on a 1.5% 
agarose gel at 90 V for 90 min in 1 x TAE buffer, before visualisation on the 
Odyssey LI-COR system as described above. WT band (primer 1 and 2) was 
visible on the gel as 212 bp and FLOXED band (primer 2 and 3) at 709 bp. 
 Tamoxifen administration 
Since mice were generated using the inducible version of Cre recombinase, 
administration of tamoxifen or its active metabolite 4-hydroxytamoxifen was 
necessary to induce translocation of Cre product from the cytoplasm into the 
nucleus. In the absence of tamoxifen the iCreERT2 protein remains in the 
cytoplasm, where it is sequestered by heat shock protein 90 (HSP90) 243. 
Tamoxifen (T5648, Sigma-Aldrich) was adminstered via intraperitoneal (i.p.) 
injection, daily for three consecutive days with 100 µL of 15 mg/mL.  
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Tamoxifen was dissolved in 1:10 ratio of 100% ethanol to groundnut oil, by first 
introducing tamoxifen powder into 100% ethanol and agitating for ~20 min or until 
dissolution occurred, before adding the correct volume of groundnut oil and further 
agitating the mixture at 37°C until adequately mixed. Mice were injected between 
the ages of 6 – 14 weeks and left for 3 weeks after the date of the last injection to 
ensure the loss of protein, then used between the ages of 9 – 17 weeks. The age 
of experimental mice used did not surpass 16 weeks old due to susceptibility of 
the C57BL/6 strain to develop various age-related conditions (obesity, type 2 
diabetes, atherosclerosis) 249. Generated transgenic mouse lines produced litters 
with predicted robust expression of the recombinant enzyme throughout the 
microvascular endothelium of adult mice approximately 48 hours after 
administration of tamoxifen, as previously reported 243. After administration of 
tamoxifen, mice were monitored daily for any adverse effects. Tamoxifen-
associated mortality was <10%.  
2.3 Cell cultures 
Human umbilical vein endothelial cells (HUVEC, C2519A, Lonza, Switzerland) 
and immortalized mouse cardiac endothelial cells (MCEC, Cellutions Biosystems, 
Ontario, Canada), were both cultured as monolayers. HUVEC were cultured using 
Endothelial cell growth medium 2 kit (CC22111, PromoCell, Germany) or EGM-2 
bullet kit medium (CC-3162, Lonza) at 37°C and 5% CO2, while MCEC cells were 
cultured using DMEM media (11965092, Gibco, MA, USA) supplemented with 5% 
foetal bovine serum (FBS) and penicillin/streptomycin also at 37°C and 5% CO2. 
Both cell types were passaged when they reached 70- 80% confluence. 
Accutase solution or TrypLE Express Enzyme (12605028, Gibco) were used for 
the passaging of HUVEC and 0.25% Trypsin-EDTA (Thermo-Fisher Scientific) 
was used for passaging of MCEC cells. The media was changed every 2-3 days. 
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2.4 Mouse cardiac endothelial cell isolation 
 Preparation of anti-CD31 coated Dynabeads 
Dynabeads Sheep Anti-Rat IgG (11035, Invitrogen, MA, USA) were prepared by 
using 25 µl of Dynabeads solution (1 x 107 beads) in 1500 µl of wash buffer (0.1% 
bovine serum albumin/phosphate buffered saline), and subsequently washed four 
times with the wash buffer using the DynaMagTM magnetic separator (Thermo 
Fisher), before  resuspending in wash buffer and addition of anti-mouse CD31 
antibody (1:100, 553370, BD Biosciences, NJ, USA). Dynabeads were left to 
incubate on the rotator, overnight in the fridge at 4°C, before being washed and 
resuspended in the wash buffer, and stored at 4°C, for a maximum of 2 days, 
before use. 
 Cardiac endothelial cell isolation 
Two to four C57BL/6 mice were anesthetized via i.p. injection of pentobarbitone 
sodium (30mg/kg; Animalcare, UK) and heparin (30IU). Once the mice were 
under deep anaesthesia and no longer possessed a pedal reflex, hearts were 
rapidly excised and placed in cold DMEM media (Gibco). The hearts were then 
transferred to the sterile laminar flow hood, where they were washed with 
phosphate buffered saline (PBS, Oxoid, UK) twice to remove blood and minced 
into small pieces to increase cell yield. Afterwards, hearts were digested by 1 
mg/mL collagenase II (Worthington, NJ, USA) dissolved in DPBS with calcium 
and magnesium (Dulbecco’s Phosphate Buffered Saline, sterile, Gibco) and 
filtered using 0.2 µm cellulose acetate membrane filter, then placed on the shaker 
at 37°C, 150 revs/min for 1 hour, with occasional swirling to prevent 
sedimentation.  
After, the solution was triturated and passed through a 70 µm strainer (Falcon, 
Fisher Scientific, NH, USA), followed by the addition of 10 mL EGM-2 medium 
(CC-3162, Lonza). The suspension was centrifuged for 5 min at 2300 rpm, after 
which the pellet was resuspended in anti-CD31-enriched Dynabeads and 
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incubated for 40 min on the rotator at 30 revs/min and 4°C to reduce phagocytic 
activity. After incubation, the cell suspension was repeatedly washed with the 
wash buffer on the DynaMagTM magnetic separator and finally resuspended in 
EGM-2 medium (Lonza) and plated in a 12-well plate. Cells were incubated in the 
incubator at 37°C, 5%CO2 and media was changed every 3 days. After 10-12 
days in culture, when cells reached approximately 70% confluence, cells were 
harvested for experiments. 
2.5 Western blotting 
 Tissue collection 
Mice were anaesthetized as described in section 2.4.2. Tissues were harvested 
and immediately homogenized using cold lysis buffer (Tris 100 mM pH 6.8, NaCl 
300 Mm, NP40 0.5%) with the volume topped up to 100 mL with distilled water 
and pH adjusted to 7.4. Whole mouse hearts were first mounted on the 21G 
cannula via the aorta and flushed with cold PBS buffer, before undergoing 
homogenization. Lysis buffer was further supplemented with Halt™ Phosphatase 
Inhibitor Cocktail 100X (final conc. 1X, Thermo Fisher) and Halt™ Protease 
Inhibitor Cocktail 100X (final conc. 1X, Thermo Fisher) before use. A total of 100 
µL of lysis buffer was used per 10 mg of tissue to achieve satisfactory protein 
extraction. For cell samples, a confluent T75 flask was scrapped using a Corning® 
cell scraper, with 150 µL of supplemented lysis buffer used per flask.  After manual 
homogenization or cell scrapping, samples were left for 10 min on ice, before 
centrifugation at 10,000 rpm for 10 min. Subsequently, the supernatant was 
placed in a fresh Eppendorf tube and stored at -80°C until use.  
 BCA protein quantification 
Total protein content of samples was calculated using bicinchoninic acid (BCA)-
copper (II) sulphate (CuSO4) colorimetric assay as described below. Protein 
content is measured by reduction of Cu2+ to Cu+ by protein present in the sample 
and subsequent chelation of two BCA molecules to each Cu+ ion.  
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This reaction causes the solution to change from green to purple colour, with the 
intensity of the colour proportional to the concentration of protein in the sample. 
After protein extraction samples were further diluted 1:5 in lysis buffer and a total 
of 5 μL of the mix was placed into a 96-well plate in duplicates, along with pre-
diluted bovine serum albumin (BSA) standards from Pierce (Thermo Fisher, 
23208). This was topped up to 200 μL with a 1:50 mix of copper sulphate (Thermo 
Fisher) and BCA (Pierce). The plate was placed in the 37°C incubator for 30 mins 
and then absorbance at 562 nm measured on a FLUOstar Omega plate reader 
(BMG Labtech). The protein concentrations were calculated by interpolation from 
the standard curve obtained from the abovementioned BSA standards. 
Once the total protein concentration was known, samples were diluted to the 
same volume and concentration needed to load 20 μg of protein. Finally, loading 
buffer consisting of Laemmli buffer (Bio-Rad, CA, USA) and β-mercaptoethanol 
in ratio 20:1 were added to the samples, before they were boiled for 10 min at 
100°C in order to ensure denaturation of proteins. Samples were then used 
straight away or stored at -20°C until needed. 
 Experimental protocol 
A total of 20 μg of protein was loaded on to a 10% Invitrogen Nuvex NuPAGE 
MOPS SDS gel (Invitrogen) or TGX Tris-Glycine 10% gel (Bio-Rad), subjected to 
electrophoresis in an XCell Sure Lock Mini Cell chamber (Invitrogen) or Mini 
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad), respectively. NuPAGE™ 
MOPS SDS Running Buffer (20X, Invitrogen) was used for Invitrogen gels and 
10x Tris/Glycine Buffer (Bio-Rad) was used for Bio-Rad gels. 
Voltage and duration were set as suggested by the manufacturer for a given gel. 
After electrophoresis, proteins were transferred onto an Amersham Protran 
nitrocellulose membrane (GE Healthcare, IL, USA) in a Bio-Rad Mini Protean 
chamber (Bio-Rad) using freshly-made transfer buffer (Tris-base 25 mM, glycine 
200 mM, 20% methanol, pH 8.3) at 100 V, 0.3 mA for 1 h on ice. 
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Successful transfer was confirmed with 0.1% Ponceau S staining of the 
membrane. Once the transfer was complete the membranes were blocked with 
5% bovine serum albumin (BSA) in PBS for 1 hour at RT and subsequently 
incubated with relevant antibodies in 5% BSA in 0.1% PBS-Tween. Following 
incubation with primary antibodies, membranes were washed three times in PBS-
Tween (PBS-T), and subsequently incubated with goat anti-rabbit or goat anti-
mouse secondary fluorescent antibodies (both 1:10,000, LICOR) in Odyssey® 
blocking buffer (LI-COR, Bad Homburg, Germany) and PBS 1:1, for 1 h at room 
temperature, before being washed six times for 10 min in PBS. Precision Plus 
Protein™ Dual Color Standard (Bio-Rad) was used to determine protein band 
size. Blots were visualized and quantified using Odyssey Infrared Imaging System 
(LI-COR).  
 WES western blotting 
Murine cardiac endothelial cells were isolated as described in section 2.4. 
Following 10-12 days of incubation in PromoCell endothelial growth medium 
(CC22111, PromoCell) supplemented with 10% penicillin/streptomycin (Gibco), 
cells were lysed using a total of 60 µL of lysis buffer (Tris 100 mM pH 6.8, NaCl 
300 Mm, NP40 0.5%). A total of 1 µg of protein sample was loaded into the 13 – 
230 kDa protein cartridge (ProteinSimple, CA, USA) with each capillary already 
containing protein standards, and run according to the manufacturer’s 
instructions.  All reagents were purchased from ProteinSimple. WES western 
blotting (ProteinSimple) is system with automated protein separation and 
detection using capillary-based cartridges.  
It allows for use of very small protein quantities and is gel-free, since the entire 
western blotting process for an individual sample takes place within a single 
capillary. Western blotting analysis was performed using Compass software for 
Simple Western (ProteinSimple). 
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2.6 Ac-LDL uptake assay 
The identity of endothelial cells can be confirmed via an acetylated low-density 
lipoprotein (Ac-LDL) uptake assay. Scavenger pathway present in endothelial 
cells and macrophages allows for 7-15 times higher uptake of fluorescently-
labelled Ac-LDL, when compared to fibroblasts and smooth muscle cells, and 
provides a simple, yet effective way to confirm endothelial cell identity 250. Isolated 
murine cardiac EC were obtained as described in section 2.4. They were plated 
on Nunc™ Glass Bottom Dishes (Thermo Fisher) and cultured in EGMTM-2 
Endothelial Cell Growth Medium-2 BulletKitTM (Lonza, Switzerland) for 10 days. 
Afterwards, cells were incubated with 10 µg/mL Alexa Fluor™ 488 AcLDL 
(L23380, Thermo Fisher) for 2 hours at 37°C and the nuclei stained with Hoechst 
33342 Solution (1:200, 62249, Thermo Fisher). After staining cells were washed 
with DPBS and images obtained using a 40x objective on a Leica confocal 
microscope, with excitation wavelength at 488 nm, and collecting the 500-550 nm 
emitted light. 
2.7 Flow cytometry 
MCEC, HUVEC or isolated murine endothelial cells were detached using either 
0.25% Trypsin (Thermo Fisher) for MCEC or Accutase for HUVEC and isolated 
mouse endothelial cells. All cells were counted using a haemocytometer 
(Marienfeld, Germany) and centrifuged at 1,200 rpm for 5 min. Cells were then 
resuspended in 1 mL DBPS (Thermo Fisher) and fixed using 1% 
paraformaldehyde for 10 min on ice. Afterwards, cells were washed with 0.1% 




Cell samples that underwent permeabilization were resuspended in 0.1% Triton 
X-100 for 3 min at room temperature prior to washing with the isolation buffer. 
Cells were then re-suspended in isolation buffer and incubated with either anti-
CXCR7 rabbit monoclonal primary antibody (1:100, ab138509, Abcam, UK), anti-
CXCR4-PE mouse antibody (1:20, FAB21651P, R&D systems, MN, USA), rat 
IgG2B PE-conjugated isotype control (R&D Systems, IC013P, 1:50) or Isolectin 
GS-IB4 Alexa 647 (IB4, 1:50, I32450, Thermo Fisher). Goat anti-rabbit Alexa-488 
conjugated antibody (1:1000, A11008, Thermo Fisher) was used as a CXCR7 
secondary antibody in flow cytometry experiments. 
Samples were then analysed using a BD Accuri™ C6 flow cytometer (BD 
Biosciences) with 10,000 live cells (as determined by forward scatter/side scatter 
gating) counted for each sample. Positive Alexa-488 fluorescence (CXCR7) was 
determined on the FL-1H channel (488 nm laser, 585/30 nm filter; H-height). 
Positive CXCR4-PE and IgG2B PE-conjugated isotype fluorescence was 
measured on the FL-2H channel (488 nm laser, 585/40 nm filter) and positive GS-
IB4 Alexa 647 fluorescence was measured using the FL-4H channel (640 nm 
laser, 675/25 nm filter). The number of positively labelled (+ve) cells was 
determined using FlowJo (Tree Star, OR, USA) analysis software via a gating 
method described in section 3.3.1.  
2.8 RNAscope in situ hybridization 
Mice were anaesthetized as previously described in section 2.4.2 and hearts 
quickly excised. The aorta was cannulated using a 21G cannula and the heart 
was manually flushed through with ~5 mL PBS to remove the remaining blood, 
then flushed with 10% formalin solution for fixation. Hearts were left immersed in 
10% formalin overnight before being sent to UCL IQPath histology services (UCL, 
UK), where they were paraffin-embedded and cut longitudinally into equally thick 
slices (<7 µm), ready for staining. RNAscope® technology (Advanced Cell 
Diagnostics, CA, USA), was used to detect mRNA expression, according to the 
instructions published on the manufacturer’s website (Figure 2-5).  
79 
 
Briefly, Cxcr7-specific probe manufactured by Advanced Cell Diagnostics was 
used to probe for mRNA expression and amplified by TSA® Plus fluorophore 
Cyanin 3 (1:500, Perkin Elmer, MS, USA). Following this, slices were also stained 
with Isolectin GS-B4 - Alexa 647 (1:50, I32450, Thermo Fisher) for 2 h, before 
washing with PBS, counter-staining the nuclei with DAPI (Advanced Cell 
Diagnostics) for 30 s and finally mounting on to a glass slide with Prolong Gold 
Antifade Mountant (P36930, Life Technologies). After leaving the slides to dry 
overnight, the fluorescent signal was scanned using a Leica confocal microscope. 
Confocal images were obtained using a 40x objective and at 1024 x 1024 pixel 
resolution. Cxcr7 probe was detected using excitation wavelength 488 ± 20 nm 
and emission wavelength 510 ± 20 nm. For Isolectin GS-B4 Alexa 647 an 
excitation wavelength of 650 ± 10 nm and emission wavelength of 670 ± 10 nm 
was used. 
 
Figure 2-5: RNAscope in situ hybridization workflow. Cells or tissue are first permeabilized 
before undergoing hybridization of target-specific oligo probes to target RNA. After, signal 
generated by the hybridized probes is amplified and subsequently detected  
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2.9 Langendorff perfusion  
Sprague Dawley rats were provided from a colony established and maintained by 
the BSU facility (UCL, UK).  Male rats weighing 250-350 g were anaesthetized by 
i.p. injection of pentobarbitone (170 mg/kg) and heparin (160 IU/kg). The onset of 
surgical level of anaesthesia was determined by the absence of pedal and corneal 
reflexes prior to cardiac excision and exsanguination. Following this, hearts were 
excised and immediately arrested in ice-cold Krebs control solution, containing: 
NaCl 118 mM, CaCl2 1.84 mM, glucose 11 mM, NaHCO3 25 mM, MgSO4 1.22 
mM, KH2PO4 1.21 mM and KCl 4.7 mM. The aorta was cannulated, and the hearts 
were mounted on a Langendorff apparatus, with continuous perfusion performed 
through the aorta with gassed Krebs control solution (95% O2: 5% CO2, pH 7.3-
7.4). Solutions were circulated through the perfusion apparatus at 37°C and at a 
constant pressure of approximately 80 mmHg (generated by the height of the 
perfusion columns). Special care was taken to avoid any bubbles in the perfusion 
apparatus that might impede the flow of solution. A silk suture (3-0, Ethicon, UK) 
was placed under the left anterior descending artery, mid-distance to the apex 
and subsequently tightened during the period of ischaemia, to produce regional 
ischaemia distal to the placement of the suture. The left atrium was removed, and 
an intraventricular balloon made of polyvinyl chloride cling film and connected to 
the pressure transducer was passed through the left atrium into the left ventricle 
and filled with distilled water to provide the systolic and diastolic pressure 
measurements. A unipolar electrocardiogram (ECG) recording was used to 
assess cardiac rhythm: two ECG leads were attached to the cannula (earth and 
negative electrodes), and a wire electrode was inserted into the left ventricular 
wall at the apex of the heart. A representative image of rat heart mounted on the 




Figure 2-6: Cannulated heart on the Langendorff perfusion apparatus. A.) Silk suture 
underlying the LAD that when tightened results in an area of regional ischaemia downstream of 
LAD (added yellow shading), B.) Temperature probe in the right atrium, C.) ECG earth and 
negative leads, D.) ECG positive lead. 
 Experimental protocol 
The term “ischaemic preconditioning (IPC)” describes several short cycles of 
global ischaemia and reperfusion that are applied to the heart before the onset of 
index ischaemia, and induce a potent cardioprotection in all mammalian species 
tested 251. Therefore, IPC was used as a positive control for cardioprotection in a 
Langendorff perfusion model. The drug to be tested, CXCR7 agonist VUF11207 
fumarate (Tocris, UK) was administered via the perfusate beginning 5 min before 
reperfusion until the end of reperfusion. Rats were randomized to one of three 
groups, with researchers blind to the treatment, however due to the nature of IPC, 






Figure 2-7: Langendorff perfusion experimental protocol. Rats were randomly allocated to 
three different groups. A.) 10 min stabilization period, three 5 min cycles of IPC, 35 min LAD 
ischaemia, 2 h reperfusion; B.) 40 min stabilization, 35 min LAD ischaemia, 2 h reperfusion with a 
perfusion switch from Krebs to vehicle (Krebs) 5 min before onset of reperfusion; C.) 40 min 
stabilization, 35 min LAD ischaemia, 2 h reperfusion with a perfusion switch from Krebs to 
VUF11207 (1µM) 5 min before onset of reperfusion. LDH samples were collected at times as 
indicted by blue arrows. Figure not to scale.  
 Exclusion criteria 
Pre-defined exclusion criteria were set according to recommendations of Botker 
et al. before the experiment to ensure consistency as seen in Table 2-6 below 252. 
Heart rate, coronary flow, temperature, perfusion pressure (mmHg), systolic, 
diastolic and developed pressure (mmHg) were collected every 5 min to ensure 
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Baseline exclusion criteria (prior to any intervention, e.g. IPC) 
Parameter Rat Heart 
Time to perfusion > 3 min 
Coronary flow < 10 or > 28 mL/min 
Arrhythmias 
> 10 ectopic beats 
Ventricular tachycardia or fibrillation should not occur 
HR < 200 or > 400 bpm 
LV diastolic pressure < 5 or > 10 mmHg 
LV developed pressure < 70 or > 130 mmHg 
Temperature 37 ± 0.5°C (< 36 or > 38°C for > 1 min) 
Reperfusion exclusion criteria 
Parameter Rat Heart 
Coronary flow ≤ ischaemic flow 
Arrhythmia duration (VT or VF) 
> 2 min 
(intervene immediately – flicking, KCl or cold buffer) 
HR < 150 bpm 
Infarct criteria 
Parameter Rat Heart 
AAR < 35 or > 70% of ventricular tissue 
Table 2-6: Pre-set exclusion criteria for ex vivo Langendorff experiments.  
 Endpoint 1: Infarct size assessment 
The primary endpoint of ex vivo experiment was infarct size (IS) after IR. This was 
expressed as a percentage of area at risk (IS/AAR), which is the area of 
myocardial tissue, that was susceptible to ischaemic damage during the period of 




After the conclusion of the experimental protocol, the heart was taken off the 
perfusion rig, the silk-suture underlying the LAD was re-tightened and the heart 
was injected with approx. 0.5 mL of 0.25% Evans Blue dye to delineate the AAR, 
which was set as percentage of whole heart area (AAR/whole heart area) as seen 
in Figure 2-8 below. 
 
Figure 2-8: Quantifying AAR via planimetry. A.) Scanned transverse section of the heart 
showing staining with Evans blue; B.) The background was removed, and the colour channels 
separated to obtain only the red channel image; C.) The pixel intensity threshold was set to 
encompass the entire heart slice to obtain whole heart area for AAR calculation; D.) The threshold 
was set to encompass only the portion of the heart slice not stained by Evans blue (white area) to 
delineate AAR. AAR was calculated as percentage of whole heart area by measuring threshold 
area (pixels) in ImageJ.   
At the end of perfusion, the heart was removed from the cannula, weighed and 
placed into the -20°C freezer for 1 hour. Subsequently, the heart distal to the site 
of LAD occlusion was sliced into 5-8 sections and stained with 1% 2,3,5-
Triphenyltetrazolium chloride (TTC) dissolved in 5 mL of phosphate buffer (2 parts 
100 mM monobasic sodium phosphate and 8 parts 100 mM dibasic sodium 
phosphate). TTC staining was used to differentiate metabolically active versus 
inactive tissue. It is a white compound that is enzymatically reduced to red 1,3,5-
triphenylformazan (TPF) in metabolically active tissues due to activity of various 
dehydrogenases. However, in metabolically inactive (dead) tissues the enzymes 
are washed out and white 253.  
A B C D
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Following incubation in TTC for 20 min in the dark at 37°C, heart slices were fixed 
in 10% formalin at RT and incubated in formalin for further 15 min before scanning 
with a Canon scanner (LiDE 210, Canon, Japan) and analysed with Image J 
(version 1.52a, National Institute of Health, MD, USA), using planimetry as 
depicted in Figure 2-9. Analysis was performed blinded to the treatment group by 
both researchers separately, after which the results were averaged between the 
two observers. If the obtained values differed more than 10% between the 
observers, the heart slices were re-analysed by both. 
 
Figure 2-9: Quantifying IS via planimetry. A.) Scanned transverse section of the heart; B.) The 
background section was removed, and channels separated to obtain only green channel image; 
C.) The threshold was set to encompass only the portion of the heart that was metabolically 
inactive as determined by TTC (red area). IS was calculated as percentage of AAR by measuring 
threshold area (pixels) in ImageJ.   
 Endpoint 2: LDH release 
To provide an alternate endpoint to IS assessment, coronary effluent samples 
were collected for lactate dehydrogenase (LDH) measurement at defined 
timepoints in the protocol as outlined in Figure 2-7 above. LDH is an intracellular 
enzyme present throughout most cells and normally located in the cytosol. 
Following damage to the sarcolemma it is released into the circulation, where it 
has historically served as a surrogate marker of cardiac injury in clinical practice 




The first sample for LDH measurement was collected immediately after heart was 
mounted on the cannula, followed by collection at 9 min into stabilization/prior IPC 
intervention, then 39 min into stabilization just prior to ischaemia, then at 31 and 
34 min into ischaemia, before and after switching to vehicle/drug, respectively. 
Finally, the last and most important LDH sample was collected 15 min into 
reperfusion, which was the point of maximum LDH release, as determined from 
previous experiments in our laboratory 255.  
LDH content was measured with a commercially available LDH kit, Pierce™ LDH 
Cytotoxicity Assay Kit (88953, Thermo Fisher) in a 96-well plate according to the 
manufacturer’s instructions. The prepared plate was subsequently measured 
using a FLUOstar Omega microplate reader (BMG Labtech, UK) at 490 nm and 
680 nm wavelengths, whereby subtracting the 680 nm from the 490 nm 
wavelength ensured the elimination of background signal from the samples. The 
LDH measurements were adjusted to the flow rate (mL/min) and weight (g) of 
each individual rat heart to ensure consistency. The final LDH measurement was 
therefore calculated as amount of LDH product in a coronary effluent 
concentration (pg x mL-1) x coronary flow divided by the weight of the rat heart 
(mL x min-1 x g-1), and finally expressed as pg x g-1 x min-1. 
2.10  Cell migration 
HUVEC were cultured as described in section 2.3. At passage 4-8 they were 
detached from the surface of the flask using TrypLE Express (Gibco) reagent and 
counted using a haemocytometer (Marienfeld,). 450,000 cells were centrifuged at 
1,300 rpm for 5 min and resuspended in Endothelial Cell Serum-free Defined 
Medium (Cell Applications Inc., CA, USA), supplemented with 5% 
penicillin/streptomycin (Gibco). Drug treatments were prepared in DPBS and 
included FBS, SDF-1α (Miltenyi Biotec, Germany), TC14012 (Tocris, UK), 
VUF11207 fumarate (Cayman Chemical, MI, USA). 
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Before the start of the experiment, a 12-well chemotaxis chamber (Neuro Probe, 
MD, USA) was disassembled (see Figure 2-10 for chamber diagram) and 150 µL 
DPBS containing drug treatments was pipetted into the wells in the lower portion 
of the chamber. A polycarbonate filter membrane with 8 µm pores was placed on 
top of the lower chamber (PFB8, Neuro Probe), followed by a rubber gasket and 
the top portion of the chamber. Finally, a cell mixture containing 150,000 HUVEC 
suspended in 100 µL of Endothelial Cell Serum-free Defined Medium was 
carefully pipetted into the top wells of each chemotaxis chamber. The cellular 
migration was allowed to proceed for 3 hours in a cell incubator at 37°C and 5% 
CO2.  Afterwards, the membrane was carefully removed from the chamber, dipped 
in PBS and the bottom-part of the membrane was wiped free of residual non-
migrated cells three times before being placed in ice-cold methanol for 5 mins. 
After fixation, the membrane was air dried and stained with 0.5% crystal violet dye 
in PBS for 5 min, before air-drying and scanning with a Canon scanner (LiDE 210, 
Canon, Japan).  
 
 
Figure 2-10: Technical diagram of a representative chemotaxis chamber. DBPS containing 
drug treatments is shaded blue and HUVEC cell mixture is coloured red, with the filter membrane 
(purple line) placed in between. Cellular migration proceeds in a downward direction (from red to 
blue), and cells remain attached to the underside of the filter membrane, after migrating through 
membrane filter pores. Adapted image courtesy of Neuro Probe. 
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2.11 RNA isolation and quantitative real-time PCR  
 RNA extraction 
Mice were anaesthetized as described in section 2.4.2. An incision made just 
below the sternum of the mouse was extended diagonally and distally, and a 
section of ribcage was removed to expose the heart. Lungs and oesophagus were 
removed and distal end of thoracic aorta exposed. The aortas was blunt dissected 
along their length and separated from the underlying spinal tissue. The aortas 
were cut at the distal thoracic end and at the level of descending aorta and fatty 
tissue removed. Harvested aortas were stored in 300 µL of RNAlater® solution 
until needed. Total RNA was isolated using a RNeasy kit (Qiagen, Germany) at 
RT with RNase-free DNase I (Qiagen) used for removal of trace amounts of DNA, 
as per the manufacturer’s instruction, as briefly outlined in Table 2-7 below. Prior 
to RNA extraction, aortas (30 mg total) were homogenized using 23G needle, 
vortexing and sonication (10 s, 130W, 20 kHz, Vibra-Cell, CT, USA) in 600 µL of 
RLT buffer (RNeasy kit, Qiagen) with 1% β-mercaptoethanol (β-ME), which 
reduced RNases and disrupted protein sulphide bonds, respectively. Lysate was 
then centrifuged at 20,000 g and 1 volume of 70% of ethanol was added to the 
supernatant before transferring the solution to a RNeasy spin column containing 
a silica-based membrane, which bound the RNA, before elution with RNA-free 
water. RNA was quantified using an LVIS plate in a FLUOstar Omega plate reader 
(BMG Labtech, Germany), with 1 unit of absorbance (260 nm) corresponding to 
44 µg/mL of RNA. Extracted RNA was either stored at -20°C or used immediately 




Step Buffer Centrifugation (speed, duration) 
1. RLT + 1% β-ME/ethanol 700 µL 10,000 rpm for 15 s, discard flow-through 
2. RW1 500 µL  10,000 rpm for 15 s, discard flow-through 
3. 10 μL DNase I solution + 70 µL 
RDD 
Incubate for 15 min at RT 
4. RW1 500 µL 10,000 rpm for 15 s, discard flow-through 
5. RPE 500 µL 10,000 rpm for 15 s, discard flow-through 
6. RPE 500 µL 10,000 rpm for 2 min, discard flow-through 
 Change collection tube 
7. RNase-free water 50 µL 10,000 rpm for 1 min, keep flow-through 
(RNA-rich) 
Table 2-7: RNA extraction was performed using RNeasy kit (Qiagen), as per the 
manufacturer’s suggestion. 
Initially, RLT buffer supplemented with 1% β-ME was added to the homogenized tissue sample 
in the supplied RNeasy spin column (step 1), centrifuged and flow-through from the collection 
tube discarded. Subsequently, different buffers were added to the sample and either incubated 
or immediately centrifuged (steps 2-6). Finally, a fresh collection tube was used to elute the 
RNA-rich flow-through (step 7) with RNase-free water.  
 Reverse transcriptase polymerase chain reaction protocol (RT-qPCR) 
A two-step RT-qPCR reaction was used, firstly reverse transcribing extracted 
RNA to cDNA and secondly, utilizing a qPCR step to obtain quantifiable levels of 




cDNA was generated using 100 ng of RNA with the AffinityScript cDNA Synthesis 
Kit (Agilent, CA, USA), using 20 µL RNase-free distilled H2O, 10 µL first strand 
master mix, 3 µL Oligo(uT) primer, 1µL Affinity Script reverse transcriptase and 
100ng of RNA per reaction, as described in Table 2-8. 
Reagent Volume per sample (µL) 
RNase-free water 20 
cDNA master mix (2X) 10 
Oligo(dT) primers 3 
AffinityScript reverse transcriptase 1 
Template RNA Variable 
Total volume per sample (µL) 34 + template RNA volume 
Table 2-8: Reagents and volumes used to perform reverse transcription step, to obtain 
cDNA from RNA.  
The thermocycling protocol (Table 2-9) was used to reverse transcribe extracted 
RNA into cDNA, using PTC 200 Thermal Cycler, MJ Research).  
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Table 2-9: RNA reverse transcription thermocycling protocol used for obtaining cDNA from 
RNA. 
The cDNA was then used immediately in a quantitative polymerase chain reaction 
(qPCR) or stored at 4°C for a maximum period of 5 days. 
By utilizing a dye that fluoresces when bound specifically to the minor groove of 
double stranded DNA (dsDNA), qPCR allows for real-time quantification of DNA 
in the sample. During the annealing phase, PCR primers bind to the target 
sequence and elongate to produce complementary dsDNA, to which SYBR ® 
green dye binds and fluoresces. As the amount of PCR product increases over 
the successive cycles, so does the signal intensity of the fluorescent tag, providing 
a way to detect and quantify the amount of RNA in the sample. 
The qPCR step was performed using 2X Brilliant SYBR® green (Agilent), 
according to the manufacturer’s instructions, with the full list of reagents and 
quantities used set out in the Table 2-10 and the qPCR thermocycling protocol 





PCR stage Temperature and duration Description 
1.  25°C for 5 minutes Primer annealing 
2. 42°C for 25 minutes cDNA synthesis 
3. 95°C for 5 minutes Termination of reaction 
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Reagent Volume (µL) 
2X Brilliant SYBR® green 12.5 
Nuclease-free water 5.5 
Forward primer (2 pmol/L) 1 
Reverse primer (2 pmol/L) 1 
Template cDNA 5 
Total volume (µL)  25 
Table 2-10:  Quantitative PCR reaction reagents and volumes. 
 
PCR stage Temperature and duration Description 
1. 95°C for 5 min Hot start 
2. 95°C for 30 s DNA denaturing 
3. 60°C for 30 s Primer annealing 
4. 72°C for 30 s DNA synthesis 
Repeat steps 2-4 for 39 cycles 
5. 65°C to 95°C, increment 1°C for 
5 s 
Melt curve generation 
Table 2-11:  Quantitative PCR thermocycling protocol. 
All primers were maintained in a stock solution of 100 pmol/µL in autoclaved 
distilled water with a working concentration of 2 pmol/µL.  
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Gapdh and Hprt are constitutively expressed genes that were used as controls in 
the qPCR experiments. Primers for qPCR were purchased from Sigma-Aldrich 
(Cxcr7) or Eurofins (Gapdh, Hprt). Primer sequences are described in Table 2-
12. 
Table 2-12: RT-qPCR primer sequences 
After loading the samples into a 96-well PCR plate (Thermo Fisher), the plate was 
placed on a shaker for 30 s and briefly centrifuged, before being placed in a CFX 
Connect™ Real time PCR Detection System (Bio-Rad) and run as outlined in 
Table 2-11 above. 
Primer name Primer sequence (5’-3’) 
Gapdh forward   AGGTCGGTGTGAACGGATTTG 
Gapdh reverse TGTAGACCATGTAGTTGAGGTCA 
Hprt forward TCAGTCAACGGGGGACATAAA 
Hprt reverse GGGGCTGTACTGCTTAACCAG 
Cxcr7 forward AAAAACATTTGAGTTCAGGGG 




Figure 2-11: Representative plot of fluorescence during qPCR amplification. Fluorescence 
intensity (arbitrary units) is shown on y-axis and cycle number on x-axis. The representative 
amplification curve crosses the detection threshold line (Cq value) at approx. cycle 21, whereas a 
curve for a sample without template cDNA would not rise above the threshold line, unless 
contaminated. Image courtesy of Bio-Rad. 
Typical data obtained from a qPCR is shown in Figure 2-11. The fluorescence 
intensity (y-axis) is detected by the spectrofluorometric thermal cycler and it 
increases proportionately with the amount of detected PCR product. There are 
two distinct amplification phases, the exponential phase, where the amount of 
PCR product doubles with each subsequent cycle (x-axis) and the non-
exponential phase in which the reaction gradually uses up the reaction 
components and eventually plateaus. The most important point during the 
amplification reaction is the quantification cycle (Cq/Ct) value, which signifies the 
cycle number at which intensity of fluorescence rises above background levels 
and can be successfully detected. A lower Cq value represents a higher level of 
target template present in the sample and can therefore be detected sooner. 
Higher Cq values represent lower amount of target template, with higher number 
of cycles needed for successful fluorescent detection.  
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Double Delta Ct analysis (2-∆∆Ct) was used to calculate the relative differences 
between our chosen samples and expressed as a fold-difference, with target gene 
values (Cxcr7 ∆Ct) averaged to Gapdh and Hprt housekeeping genes in 
representative graphs. Ct values for all genes were obtained in triplicates. Cxcr7 
∆Ct = Ct (average of Cxcr7) – (average of Ct Gapdh + Ct Hprt), ∆∆Ct = ∆Ct 
(Cxcr7WT) – ∆Ct (Cxcr7iΔEC), fold gene expression = 2-∆∆Ct. 
 
Figure 2-12: Representative melt curve. The melt curves of several samples. All curves in this 
example are single-peak curves, denoting a homogenous melting point and therefore a relatively 
pure sample. Reaction temperature is plotted on the x-axis, with y-axis showing the rate of change 
of the relative fluorescence units (RFU) versus time (T), with the peak at the melting temperature 
(Tm). Image courtesy of Bio-Rad. 
In addition to amplification plots, a melt (dissociation) curve was also generated 
for each sample with representative image (Figure 2-12). The premise of a melt 
curve is the detection of dissociation of cDNA, which should provide a single, 
defined peak for pure samples and allows us to detect the signal produced by 
template cDNA accumulation, as opposed to non-specific dsDNA presence. 
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2.12 Statistical analysis and power calculations 
In estimating the total number of repeats required per experiment, calculations of 
statistical power were made using an online tool from the 
powerandsamplesize.com website. Statistical analysis was performed using 
GraphPad PRISM version 5.0 for Windows (GraphPad Software, Inc., CA, USA). 
Data is expressed as mean ± SEM, and p < 0.05 was accepted as statistically 
significant with the specific statistical test reported with each result. 
Sample size: Sample size calculations were used to estimate the minimum 
number of repeats for each experiment, based on pilot data. For all power 
calculations Gaussian distribution was assumed with a significance level of 5% 
(α=0.05) and 80% power (β=0.2). Sample size is reported with each result 
separately.  
Normality: Sample-size permitting, a normality test was performed to determine 
whether the data come from a Gaussian (parametric test) or non-Gaussian (non-
parametric test) population. Due to small sample sizes the most relevant test used 
was the Shapiro-Wilk normality test. If a sample size was too low to run a normality 
test, a Gaussian distribution was assumed. Since non-parametric tests exhibit 
lower power and require substantially higher sample sizes, if sample size was too 




3 Investigation of CXCR7 expression in cardiovascular cell 
types 
3.1 Background 
Since the discovery of CXCR7 receptor ligands, SDF-1α and I-TAC, over a 
decade ago, the presence of CXCR7 has been confirmed in many tissues, 
including in endocardial cells where it aids early cardiac development, and 
germline deletion of the receptor results in perinatal lethality 114. Less is known 
about the presence of the receptor in adult cardiovascular tissues, (e.g. 
endothelial cells), and its expression and function in various cell types has yet to 
be elucidated. Previously published literature also suggests that CXCR7 is 
expressed in juvenile mouse cardiomyocytes up to at least P5, but additional 
evidence of expression in cardiomyocytes from adult mice is not available. 
therefore, we also wanted to observe whether CXCR7 expression can also be 
detected in the adult cardiomyocytes 148. 
Therefore, we aimed to determine the expression profile of endothelial CXCR7 in 
the mouse heart, while we also wanted to observe whether CXCR7 expression 
can be detected in the adult cardiomyocytes 148, 115. CXCR7 expression in mouse 
vascular endothelium was visualized by using in situ hybridization while in cardiac 
endothelial cells western blot analysis was used 115, 119. Moreover, since 
successful isolation of endothelial cells can present a challenge, HUVEC, as well 
as the immortalized mouse cardiac endothelial MCEC cell line were utilized to 
examine the expression of CXCR7 and CXCR4 .  
3.2 Research aims and objectives 
Investigate expression of CXCR7 in cardiovascular cell types: 
- Confirm expression of CXCR7 in mouse cardiovascular tissues. 
- Confirm expression of CXCR7 in endothelial cells of cardiac origin. 
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- Investigate localization of CXCR7 receptor in endothelial cells and identify 
an appropriate cell line for use in in vitro experiments. 
3.3 Methods 
In addition to the general methods described in Chapter 2, the following specific 
methods were used in the experiments described in this chapter. 
 Flow cytometry  
First, cultured cells were trypsinized and fixed as described in section 2.7, before 
being run through the Accuri C6 flow cytometer. To identify the live population of 
cells in fixed-cell samples, a gating protocol was established based on forward 
(FSC) and side scatter (SSC) parameters, as well as propidium iodide (PI) 
staining. Forward scatter plotted against side scatter in a density plot reveals the 
size of cells and their granularity, respectively, which allows for exclusion of very 
small and granular cells, likely to be cell debris 256, 257.  
However, this method only enriches for live cells but does not have the power to 
completely eliminate non-viable cells from the analysis. Therefore, PI, a 
fluorescent nucleic acid stain able to discern viable cells from non-viable ones, 
was used. PI intercalates into the nuclear DNA of dead cells which have a 
disrupted plasma membrane, without any sequence preference, binding to every 
fourth or fifth base pair in the sequence.  
This allows detection of dead cells by the emission of red fluorescence, when 
excited with a laser of an appropriate wavelength 258. Experiments in which <5% 
of cells were positive for PI staining, were accepted. To determine the percentage 
of PI-labelled cells, manual gating was used with gates placed at the intersection 
of peaks from negative control sample and target sample in a histogram overlay. 
A total of 10,000 cells were counted per sample. 
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 Western blotting antibodies 
Western blotting was performed according to the protocol described in section 2.5 
with anti-CXCR7 (RDC1) rabbit monoclonal antibody (1:1000, ab138509, 
Abcam). Anti-GAPDH mouse monoclonal antibody (1:2000, ab8245, Abcam) or 
anti-α-Tubulin mouse monoclonal antibody (1:2000, ab7291, Abcam) were used 
to quantify loading controls. IRDye® 800CW goat anti-rabbit IgG (1:10,000, Li-
COR), or IRDye® 680RD Goat anti-mouse IgG (1:10,000, LI-COR) secondary 
fluorescent antibodies were used for detection. 
3.4 Results 
To confirm the presence of CXCR7 mRNA in mouse cardiac tissue, RNAscope in 
situ-hybridization was performed on paraffin-embedded whole-heart mouse 
slices. Initially, the tissue samples underwent antigen retrieval and protease 
treatment to ensure target mRNA availability. After, an RNA-specific 
oligonucleotide probe was added and allowed to bind to the target mRNA and was 
subsequently hybridized to a series of signal amplification molecules. Finally, the 
addition of TSA® Plus Cyanine 5 fluorophore enabled visualization of the target 
mRNA using a confocal microscope. Since the main objective was to identify the 
presence of CXCR7 in endothelial cells, the tissues were also co-stained with 
isolectin B4-Alexa 647 conjugate (IB4) to delineate the endothelial cells present 
in the myocardium (Figure 3-1).  
Co-staining with IB4 allowed confirmation of CXCR7 mRNA detection in 
endothelial cells and autofluorescence emitted by myocardial tissues confirmed 
the presence of CXCR7 mRNA in cardiomyocytes. Autofluorescence emitted by 
cardiac tissues, specifically cardiomyocytes, is thought to arise from mitochondrial 
dehydrogenases, containing flavin adenine dinucleotide (FAD) undergoing 
oxidation and detectable with a green laser (488 nm) excitation  used in confocal 
microscopy 259. This enabled the typical morphology of cardiomyocytes to be 
observed even in the absence of cardiomyocyte-specific markers.  
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To confirm that the CXCR7 mRNA signal was not caused due to autofluorescence 
or non-specific signals, positive and negative species-specific RNAscope control 
mRNA probes, obtained as part of the RNAscope kit were used. The positive 
control probe targeted the gene Ppib, which gives rise to Peptidyl-prolyl cis-trans 
isomerase B enzyme, otherwise known as Cyclophilin B, a cyclosporine-binding 
protein involved in protein folding and variety of immune responses, and which is 
known to be present in the heart 260-263. The Ppib positive control probe gave rise 
to easily identifiable, specific Ppib mRNA dots that were present in moderate 
numbers throughout mouse myocardium, as expected (Figure 3-2, B). The 
negative control probe is specific to the Escherichia coli dihydrodipicolinate 




Figure 3-1: CXCR7 mRNA expression in murine vascular endothelium. CXCR7 mRNA (green 
dots) is present in endothelial cells (white arrows) and cardiomyocytes (yellow arrows) of adult 
mouse hearts as detected by RNAscope in situ hybridization. IB4 (red) was used to label 
endothelial cells and DAPI (blue) depicts cellular nuclei. Autofluorescence on the green (488 nm) 
channel allows visualization of cardiomyocytes. 
Since DapB is not known to be present in animal or human tissues, no specific 
signal was expected. The probe only produced a few faint dots, lacking the 
intensity of dots produced by application of the positive control probe, as would 
be expected from a successful RNAscope experiment (Figure 3-2, A). 
 
Figure 3-2: Positive and negative control mRNA probe RNAscope experiment. A.) The 
negative control probe targeted to bacterial DapB (green dots) shows only a faint signal, while B.) 
positive control probe against Ppib mRNA (green dots) gives rise to strong fluorescent signals on 
the green (488 nm) channel. Nuclei are stained with DAPI (blue) and endothelial cells are labelled 
with IB4 (red).  
Expression of mRNA in the tissue does not always correlate with protein 
expression, therefore CXCR7 protein expression was investigated using a 
western blot analysis. CXCR7 protein expression was examined in whole mouse 
heart and mouse aorta tissue homogenates, as well as cell homogenates 
obtained from MCEC and HUVEC cell cultures. Further, cardiac endothelial cells 
(EC) were isolated from wild type mouse hearts using a CD31-Dynabeads 
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complex and were also included in the western blot analysis. Isolation of EC is 
known to be challenging due to their fragility, and cell cultures often contain cells 
of non-endothelial origin. Hence, several assays were deployed to validate the 
population of cells obtained as endothelial cells. 
 
Figure 3-3: Ac-LDL uptake assay on cardiac endothelial cell culture. Cardiac endothelial cells 
were isolated using CD31-Dynabeads complex. Addition of ac-LDL-Alexa Fluor 488 to a live 
endothelial cell culture results in the uptake of ac-LDL by endothelial cells, and detection of a 
strong signal when excited with the green (488 nm) confocal laser (top panel).  Addition of Hoechst 
nuclear stain (blue) on its own, does not produce a detectable signal on the 488 nm channel 
(bottom panel). 
One method of identifying endothelial cells is to incubate them with a fluorescent 
modified acetylated LDL (ac-LDL), which they readily take up. When submitted 
to an ac-LDL uptake assay EC displayed positive uptake, with >90% EC 
becoming fluorescent after 2 h (Figure 3-3, top row). There was little background 
fluorescence present after the addition of ac-LDL, nor was there any observable 
fluorescent signal on the 488 nm channel when Hoechst nuclear stain was 
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added to the cell culture in the absence of ac-LDL; indicating the validity of 
detected signal (Figure 3-3, bottom row).  
To further determine the percentage of endothelial cells in the isolated cell 
culture, EC were fixed, labelled with IB4 and analysed by flow cytometry. 
 
Figure 3-4: Flow cytometry gating for a viable cell population on cardiac EC culture. A.) A 
representative density plot depicting a gated “live” subpopulation of cells based on forward and 
side scatter parameters, with 62.7% of counted cells determined as viable. B.) Histogram overlay 
with non-stained (grey) and PI stained (red) cells already gated for live population (as shown in A) 
on the FL-3H channel (>670 nm emission), depicting only a single defined peak, which overlays 
the non-stained sample almost completely with only 1.29% of cells identified as positively labelled 
with PI, and therefore determined to be non-viable.  
Flow cytometry samples were first gated to separate intact cells from debris. This 
was achieved by displaying the cells population on a FSC and SSC density plot, 
with a gate placed manually around the region containing the cells (Figure 3-4, 
A). The percentage of non-viable cells in the population was then determined by 
counting the percentage of PI+ve cells in the FL-3H fluorescent channel (Figure 3-






Figure 3-5: Flow cytometry IB4 endothelial labelling of cardiac EC culture. A.) Representative 
histogram overlay of IB4 labelling, with IB4-Alexa 647 (pink) and unlabelled cells (grey) on the FL-
4H channel (675/25 nm emission), with 91.2% of cells IB4+ve. B.) The percentage of isolated EC 
that were determined to be IB4+ve in 5 individual isolations. 
When labelled with endothelial cell marker IB4, the major peak of endothelial cells 
is shifted to the right, denoting greater fluorescence on the FL-4H channel, and 
confirming the majority of cells to be endothelial (Figure 3-5, A). These preliminary 
experiments revealed that ~90% of the cells isolated from mouse heart using this 
procedure were endothelial cells, as they were positively identified using the 






Figure 3-6: CXCR7 western blotting of murine cardiovascular tissues, cardiac EC and 
commercially available cells. Western blot analysis of murine heart and aortic tissues A.), 
MCECs and HUVEC B.), as well as murine isolated cardiac endothelial cells C.). All tissues and 
cell types display CXCR7 protein band at approximately 41 kDa. GAPDH and α-Tubulin were used 
as loading controls, both displayed bands approx. 36 kDa in size. Red arrows signify the molecular 
weight markers. 
Once satisfied that the isolated cardiac cultures contained mainly cells of 
endothelial origin, the focus was shifted to the investigation of CXCR7 protein 
expression in various tissues. CXCR7 expression was examined by western blot 
analysis in whole mouse heart and aorta tissue homogenates (Figure 3-5, A), 
commercially available human umbilical vein endothelial cells (HUVEC) and 
immortalized mouse cardiac endothelial cells (MCEC, Figure 3-5, B), as well as 
EC (Figure 3-5, C). A 41 kDa band was detected in all tissues and cell types 
tested, which is the size expected for CXCR7. This suggests that CXCR7 is 
expressed in the adult mouse heart, aorta and likely in cardiac endothelial cells. 
Since CXCR7 is readily internalized and yet must be present on the plasma 
membrane in order to be capable of binding its ligand and activating signalling 




Figure 3-7: Membrane-bound and intracellular expression of CXCR4 and CXCR7 in MCEC. 
Representative flow cytometry histograms of cells labelled with CXCR4 (red), CXCR7 (green) and 
isotype-labelled or labelled with the secondary antibody alone (grey). Cell count is represented on 
the y-axis, plotted against fluorescence intensity on the x-axis. Left panels depict membrane-
bound (i.e.: non-permeabilized) CXCR4/CXCR7 labelling, and right panels depict intracellular (i.e.: 
after permeabilization) signal. The percentage of labelled cells is indicated. NON-PERM = non-
permeabilized, PERM = permeabilized. 
Due to the low number of endothelial cells that could be isolated from the mouse 
heart, it was not feasible to evaluate CXCR4 and CXCR7 expression in these 
cells. Instead, intracellular and cell-surface expression of CXCR4 in the MCEC 
and HUVEC cell lines was examined.  
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However, since the utilized CXCR7 antibody recognized the C-terminus of the 
protein it cannot be used to determine intracellular vs cell-surface expression 
profile of CXCR7. Instead, this experiment can be used as a gauge of antibody 
specificity where non-permeabilized or “membrane-bound” labelling corresponds 
to non-specific binding and permeabilized or “intracellular” labelling to specific 
binding of the monoclonal CXCR7 antibody (ab138509). 
 
Figure 3-8: Membrane-bound and intracellular expression of CXCR4 and CXCR7 in HUVEC. 
Representative flow cytometry histograms of cells labelled with CXCR4 (red), CXCR7 (green) and 
isotype-labelled or labelled with the secondary antibody alone (grey). Cell count is represented on 
the y-axis, plotted against fluorescence intensity on the x-axis. Left panels depict membrane-
bound (i.e.: non-permeabilized) CXCR4/CXCR7 labelling, and right panels depict intracellular (i.e.: 
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after permeabilization) signal. The percentage of labelled cells is indicated. NON-PERM = non-
permeabilized, PERM = permeabilized. 
 
Figure 3-9: Intracellular and membrane-bound expression of CXCR4/CXCR7 in MCEC and 
HUVEC. The percentage of cells exhibiting cell-surface (NON-PERM) and internal (PERM) 
CXCR4/CXCR7 labelling in MCEC and HUVEC cell lines. Green bars depict CXCR7 labelling and 
red bars indicate CXCR4. Permeabilized (intracellular, PERM) samples displayed significantly 
increased percentages compared to their non-permeabilized (membrane-bound, NON-PERM) 
counterparts for both receptors, CXCR4/7 and both cell lines, MCEC and HUVEC, indicating that 
the majority cells express receptor intracellularly. ** p < 0.01, *** p < 0.001, Student’s t-test, n = 
an individual flow cytometry experiment. 
Cells were either permeabilized, to allow the antibody to reach the intracellular, 
internalized population of CXCR4 receptor, or non-permeabilized to investigate 
surface, membrane-bound expression, with representative histogram overlays for 




Only a small proportion of MCEC were found to possess detectable surface 
CXCR4 labelling (Figure 3-9, A; non-perm vs perm = 2.1 ± 0.3% vs 93.5 ± 1.7%, 
n=6; p < 0.001). In HUVEC, the proportion of cells with surface CXCR4 labelling 
was slightly higher (Figure 3-9, B; non-perm vs perm = 16.2 ± 5.0% vs 62.8 ± 
6.6%; p < 0.01). When either cell type was permeabilized, the majority of cells 
displayed CXCR4 labelling, indicative of intracellular pool of receptors capable of 
binding the utilized anti-CXCR4 antibody. Overall, the percentage of cells with 
membrane-bound CXCR4 was quite low, which denotes that only a small 
proportion of MCEC and HUVEC express detectable levels of active receptors on 
the cell surface.  
Interestingly, when non-permeabilized MCEC or HUVEC were labelled with 
CXCR7 antibody there were detectable levels of staining on both cell types 
(Figure 3-9, bottom row; MCEC vs HUVEC = 17.1 ± 8.8% vs 25.7% ± 3.5%), 
suggesting that the specificity of this particular antibody was lower than expected.  
3.5 Discussion 
Despite being revealed as an SDF-1α receptor over a decade ago, the expression 
of CXCR7 in the heart, and specifically in the heart endothelium has not received 
as much attention as in other tissue types. Additionally, some published results 
have been obtained using antibodies with questionable specificity for CXCR7 and 
are therefore not particularly informative 266. Therefore, the expression of CXCR7 
mRNA and protein in the heart endothelium needed to be confirmed.  
RNAscope in situ hybridization confirmed the presence of CXCR7 mRNA in 
endothelial and cardiomyocyte cells found in the adult mouse myocardium. 
Furthermore, using western blot analysis CXCR7 protein was detected in whole 
mouse heart and aortic tissue, as well as commercially available endothelial cell 
lines and freshly isolated cardiac EC.  
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These results are consistent with published data reporting CXCR7 expression in 
cells of endothelial origins as described in detail in section 1.3.3 110-113. Most 
previous studies focused on non-cardiac tissues and none have shown the 
expression of CXCR7 on isolated cardiac endothelial cells specifically. Due to the 
limited numbers of cells that could be isolated from the mouse heart, in this study 
western blot analysis was only performed on a single EC sample. However, 
western blot analysis coupled with RNAscope in situ hybridization is enough to 
confirm the presence of CXCR7 in endothelial cells of cardiac origin.  
Additionally, RNAscope in situ hybridization revealed positive CXCR7 mRNA 
staining on cardiomyocytes, which were identified based on their observed 
morphological features. In general, not much is known about expression of 
CXCR7 in non-endothelial cardiovascular cell types, including cardiomyocytes, 
with only a handful of papers addressing the expression of CXCR7 receptors in 
those cells 123, 265, 267.  This is perhaps not surprising given the fact that recent 
studies point specifically to endothelial CXCR7 as capable of pro-regenerative 
and anti-fibrotic effects in multiple tissue types 234, 235. Furthermore, the presence 
of CXCR7 mRNA might not correlate with actual tissue protein expression and 
further experiments are needed to confirm CXCR7 expression in adult mouse 
cardiomyocytes. Cardiac EC served as a valuable tool to show the expression of 
CXCR7 protein, however, isolation and culture of cells has proven challenging. 
Using a Dynabeads-CD31 complex, a semi-pure population of EC was obtained, 
but at a cost of reduced cell numbers. This meant that using EC for experiments 
where a high volume of cells is needed to achieve valid results was not deemed 
feasible. Therefore, commercially available cell lines were utilized to provide cells 





When probed with anti-CXCR7 antibodies MCEC and HUVEC cell lines displayed 
a strong CXCR7 band using a western blot method. However, western blotting 
analysis does not distinguish between membrane-bound and intracellular (and 
therefore inactive) CXCR7. Therefore, further examination of the intracellular vs 
membrane-bound expression profile of CXCR7 was needed.  
Flow cytometry revealed that for both cell types studied, only a small proportion 
of cells contain detectable membrane-bound CXCR4 receptor. A higher 
proportion of cells with of CXCR4 membrane-bound labelling was detected in 
HUVEC compared to MCEC. Despite being of cardiac origin, MCECs are an 
immortalized cell-line, and therefore resemble their endogenous counterparts 
less. Primary cells, like HUVEC, more closely resemble healthy cells found in their 
tissue of origin, especially during early passages, as they have not yet 
accumulated mutations due to tumorigenesis or continuous cell culture 268.  
Immortalized cell lines are produced by overcoming the replicative senescence, 
which occurs in non-immortalized cells and is characterized by biochemical, 
morphological and functional changes, such as gradual shortening of telomeres 
269, 270. This can affect cell signalling and as a result, some immortalized cell lines 
display altered cell signalling pathways compared to non-immortalized cells 268, 
271. However, the published literature suggests that immortalized EC can retain 
their angiogenic potential in vivo and are deemed a valuable in vitro model, 
despite being less comparable to cells that one might find in vivo. 272, 273. 
Interestingly, permeabilization of MCEC and HUVEC revealed intracellular 
CXCR4 labelling of a much greater proportion of cells. There are multiple 
published studies noting the presence of intracellular pools of CXCR4 and CXCR7 
receptors in various cell types. Intracellular expression of CXCR4 receptor has 
been confirmed in hematopoietic progenitor cells, foetal mesenchymal cells and 




Early research suggests that after binding to SDF-1α, CXCR4 is rapidly 
endocytosed to regulate CXCR4 plasma membrane expression, playing a vital 
role in modulation of migratory clues 274.   
Meanwhile, intracellular pools of CXCR7 receptors have been detected in several 
cells of the immune system, including B and T cells, as well as tumour cells 143, 
144, 214, 277. Intracellular pool of CXCR7 receptor is thought to aid the scavenger 
function of CXCR7, by providing a way to quickly clear excess SDF-1α from 
circulation 133. However, the solely scavenging function of CXCR7 has been 
questioned by studies suggesting an active signalling role of CXCR7 through β-
arrestins 123. One theory would be that an intracellular pool of CXCR7 can recycle 
back to the membrane as either a scavenger of SDF-1α or as a receptor capable 
of active signalling, a capacity that will be discussed further in section 5.5. 
However, since we did not examine the intracellular vs membrane-bound labelling 
of CXCR7 receptor in our experiments, we cannot compare the percentage of 
cells expressing membrane-bound vs intracellular CXCR7 labelling in HUVEC 
and MCEC. Nevertheless, the existence of intracellular pool of not only CXCR4 
but also CXCR7 in endothelial cells is highly likely, although future research with 
a reliable and flow cytometry-compatible antibody is needed to confirm it.  
However, we have observed that the CXCR7 antibody utilized for flow cytometry 
(ab138509) might have lower specificity than desired. As it recognizes an 
intracellular epitope on the C-terminus section of the CXCR7 protein, non-
permeabilized cells should not display labelling with this particular antibody. 
However, ~17% MCEC and ~26% HUVEC displayed labelling with CXCR7 
antibody in their non-permeabilized state. Despite the antibody not being 
advertised as flow cytometry-compatible it raises questions regarding it’s 
specificity. Antibodies advertised as specific, which also recognize additional 
epitopes, can be hugely detrimental to scientific research, since the results 
obtained with such antibodies are not reliable.  
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Research into CXCR7 has garnered a lot of interest in the past years and 
specificity, or lack thereof, of antibodies represents a major hurdle for the scientific 
community, a topic previously addressed by Berahovich et al. 266 
 
 Summary 
The expression of CXCR7 was demonstrated in mouse cardiovascular tissues, 
endothelial cell lines and endothelial cells of cardiac origin. CXCR7 mRNA was 
also detected in cardiovascular cells of non-endothelial origin, namely 
cardiomyocytes. Additionally, CXCR7 receptor was detected in both, MCEC and 
HUVEC cells, however due to its primary cell origins HUVEC were chosen as the 
most suitable cell type for further in vitro experiments.  
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4 The effect of CXCR7 agonist VUF11207 fumarate in the 
Langendorff ex vivo heart perfusion model 
This chapter contains a project that was carried out in collaboration with Dr 
Catherine Wilder, who provided technical expertise necessary for the use of this 
experimental model. 
4.1 Background 
Previous studies have shown that administration of SDF-1α in various forms 
acts in a cardioprotective fashion, improving the state of myocardial tissue after 
I/R (e.g. infarct size reduction). Since CXCR7, an SDF-1α receptor has been 
shown to activate CXCR4-independent, β-arrestins-biased signalling it was 
postulated that it could exhibit cardioprotective effects in a wider range of 
cardiovascular disorders, including MI. More specifically, past research 
highlighted a cardioprotective role for β-arrestins signalling in mice with 
exaggerated catecholamine stimulation, such as heart failure 278, 279.  
In order to investigate the role of CXCR7 in acute MI setting, a rat ex vivo 
Langendorff I/R perfusion model was utilized. To allow for distinction between 
the effects of CXCR4 and CXCR7 receptor, VUF11207 a CXCR7-specific 
receptor agonist, was used immediately prior to reperfusion, as outlined in 
Figure 2-7. 
4.2 Research aims and objectives 
Investigate whether CXCR7 agonist VUF11207 exhibits cardioprotective effects 
in a rat ex vivo perfusion model: 
- Investigate if the administration of VUF11207 prior to reperfusion has an 
effect on the final infarct size in MI. 
- Investigate if the administration of VUF11207 prior to reperfusion has an 




The methods used are described in section 2.9. Rat isolated perfused hearts were 
randomized to one of three experimental groups: 1.) vehicle perfused group, 
where 5 min prior to reperfusion the perfusion solution was switched from Krebs 
to vehicle; 2.) IPC group, which received 3 x 5 min cycles of regional ischaemia 
prior to index ischaemia and 3.) VUF11207 perfused group, where Krebs 
perfusion was switched to 1 µM VUF11207 5 min before the onset of reperfusion. 
Experimental protocol is further described in section 2.9.1. 
During each experiment, LDH samples were collected and analysed as described 
in section 2.9.4. Following the conclusion of each experiment, hearts were stained 





When using the Langendorff ex vivo perfusion model it is important to maintain 
the consistency of LAD suture placement between experimental groups. To 
ensure that, AAR was measured independently by two observers, with the 
average results reported in Figure 4-1, A. There was no significant difference 
observed between AAR of different groups, therefore the experimental 
consistency was deemed satisfactory.  
 
Figure 4-1: Area at risk and infarct size assessment in isolated rat hearts. A.) Area at risk as 
a percentage of total ventricular area did not differ between groups. B.) Infarct size as a percentage 
of area at risk was found to be significantly lower in the IPC group compared to the vehicle group. 
The VUF11207 group was found not to be significantly different from the vehicle group. Normality 
was confirmed with a Shapiro - Wilk test. n = 6 hearts per group, * p < 0.05, One-way ANOVA with 
Dunnett’s post-hoc test with all groups compared to vehicle. AAR = area at risk, IS = infarct size, 




Infarct size was also independently determined by two observers, with the 
average values for each heart reported as a percentage of area at risk, in Figure 
4-1, B. The infarct size analysis showed that the positive control group, which 
received IPC prior to index ischaemia, exhibited significantly lower average infarct 
size than the vehicle group (vehicle vs IPC = 25.6 ± 3.1 vs 12.3 ± 3.0; p < 0.05). 
The VUF11207 group was not significantly different than the vehicle group.  
 
 
Figure 4-2: LDH release during ex vivo isolated heart perfusion. A.) Graphical representation 
of time-dependent release of LDH (the amount of LDH in pg released per min per gram of 
ventricular weight). B.) Dot plot representing release of LDH 15 min after onset of reperfusion 
(R+15’). IPC group displayed a significantly lower LDH release than the vehicle group, * p < 0.05, 
One-way ANOVA with Dunnett’s post-hoc test with all groups compared to vehicle. The period of 
index ischaemia is shaded pink on the graph; n = 6 hearts per group. 
In order to confirm the infarct size measurements using a different analysis, some 
of the perfusate was collected for LDH analysis at various timepoints during the 
experiment, as shown in section 2.9.1. Timepoints for collection of LDH samples 
were derived from previously published literature 255. The time-course of LDH 
release from the perfused heart is shown in Figure 4-2, A.  
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Due to potentially confounding effect of IPC treatment at timepoint -39’ the area 
under the curve for this experiment was not examined and overall statistical 
analysis was not performed for all timepoints together. Instead, samples collected 
15 min after the onset of reperfusion were of special interest, since peak LDH 
release was previously shown to occur during the first 10-15 min of the reperfusion 
stage Figure 4-3, B 255. Corroborating the infarct size measurements, the IPC 
group exhibited significantly lower “peak” LDH release than the vehicle group 
(vehicle vs IPC = 6.7 ± 1.1 vs 2.0 ± 0.3; p < 0.05), but the VUF11207 group was 
unchanged from vehicle. 
Along with the infarct size and LDH release measurements, several functional 
parameters were also observed during the course of the experiment. Flow rate 
was measured in mL of perfusate per minute and was not significantly different 
between any of the groups (Figure 4-3, A). Flow rate gradually decreased as the 
experiment progressed, for all three groups. The lowest flow rate in the IPC group 
prior to index ischaemia occurred during the 3 x 5 min IPC cycles as expected. 
During the three IPC cycles, total flow was manually turned off and those 
timepoints were, therefore, not included in the statistical analysis. Heart rate was 
not significantly different between the vehicle and the IPC group for all observed 
timepoints (Figure 4-3, B). VUF11207 group displayed a gradual lowering of the 
heart rate, especially in the last couple of timepoints; however, this was not 






Figure 4-3: Flow rate and heart rate measured during the ex vivo isolated heart perfusion. 
A.) Time-course of flow rate measurements showed no significant differences between different 
experimental groups. B.) The time-course of heart rate measurements showed that for the last 
three timepoints at the end of the reperfusion stage, VUF11207 group displayed a significantly 
lower heart rate than the IPC group. The period of index ischaemia is shaded pink on the graph. 
One-way ANOVA with Dunnett’s post-hoc test with all groups compared to vehicle, all 




Figure 4-4: Left ventricular developed pressure during the ex vivo isolated heart perfusion. 
Left ventricular developed pressure was obtained by subtracting the end-diastolic pressure from 
the systolic pressure, both obtained via the intraventricular balloon. The time-course of developed 
pressure measurements showed no significant differences between the groups. One-way ANOVA 
with Dunnett’s post-hoc test with all groups compared to vehicle, all comparisons were non-
significant; n = 6 hearts per group. 
Another functional parameter that was observed during the course of the 
experiment was left ventricular developed pressure. The left ventricular developed 
pressure was obtained by subtracting the end diastolic pressure from the systolic 
pressure, which was measured via a balloon positioned inside of the left ventricle. 
The plotted time-course of the developed pressure showed no significant 
differences between the groups for the entire duration of the experiment (Figure 
4-4). Due to the lack of perfusion during the 3 x 5 min IPC cycles, the contractility 
of the heart was reduced. As a result, the developed pressure was lower in the 
IPC group than in other groups for the same timepoints. Therefore, those 





Figure 4-5: Perfusion pressure and heart temperature during the ex vivo isolated heart 
perfusion. Perfusion pressure was maintained at 70mmHg or above, during the experiment. 
There were no significant differences observed between the three groups. During the 3 x 5 min 
IPC cycles, perfusion was switched off, hence the pressure reading was 0 (below the y-axis limit). 
Temperature was maintained at 37 ± 0.5°C with some fluctuations observed between when 
switching between different stages of the experiment (stabilization, ischaemia, reperfusion). 
Statistical analysis showed no significant differences between the three experimental groups. 
One-way ANOVA with Dunnett’s post-hoc test with all groups compared to vehicle, all 
comparisons were non-significant; n = 6 hearts per group.  
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Further functional parameters that were observed during the course of the 
experiment were perfusion pressure and internal heart temperature. Perfusion 
pressure was maintained around 70mmHg and there were no significant 
differences in the perfusion pressure between the vehicle, IPC and VUF11207 
groups for the entire duration of the experiment (Figure 4-5, A). The slight dip in 
the perfusion pressure following the change from the regional ischaemia to the 
reperfusion stage of the experiment was mostly related to the switch between the 
perfusion columns on the Langendorff apparatus. Heart temperature was 
maintained at 37 ± 0.5°C and remained stable throughout the duration of the 
experiment, with no significant differences present, when either the IPC group or 
the VUF11207 were compared to vehicle (Figure 4-5, B). 
There were a total of 29 rats used in the ex vivo isolated heart experiment with 18 
included in the final analysis (Figure 4-6). Exclusions were made based on the 
exclusion criteria described in section 2.9.2. Most hearts (8) were excluded due 
to AAR being <35%, after staining with Evans blue dye. One heart was excluded 
due to tearing of the aorta mid-way through the experiment, which made further 
retrograde perfusion through the aorta impossible. A single heart was excluded 
due to a period of ventricular fibrillation, which lasted for more than 2 min and did 
not respond to ice-cold KCl treatment. Lastly, another heart was excluded for 
presenting with a heart rate that did not consistently stay above 200 bpm during 
the stabilization period. The total number of exclusions per group was very similar 
across the three groups. Three hearts were excluded from the VUF11207 group 
and 4 hearts excluded from each of the IPC and vehicle groups. There was no 





Figure 4-6: Experimental exclusions during ex vivo isolated rat heart perfusion 
experiments. 29 animals were used with 18 included in the analysis. Most animals (62%) were 
excluded due to their AAR falling outside of the inclusion criteria. Further exclusions occurred 
either because of low heart rate (3%, HR) and   being too low or long duration of ventricular 
fibrillation (3%, v-fib).  A single heart (4%) was also excluded due to a torn aorta. 
4.5  Discussion 
The Langendorff ex vivo perfusion model is a well-described model used to 
investigate cardiac function independently of other organ systems and can offer 
important insights into the ability of drugs to protect the heart from I/R injury. One 
of the most common endpoints of ex vivo isolated heart perfusion is infarct size 
assessment, normally performed using a combination of Evans blue dye and TTC 
staining. In vivo, larger infarct size has been shown to correlate with adverse 
cardiac remodelling and haemodynamic dysfunction; therefore, interventions that 
can limit the initial infarct size are expected to confer long-term cardioprotective 
benefit 280-282. Many cardioprotective interventions that are applied immediately 
prior to reperfusion aim to inhibit the opening of the mPTP, as this is associated 













Such interventions that target myocardial reperfusion are considered as having 
potential clinical relevance, since they can be delivered after the onset of the 
ischaemic insult and prior to the reperfusion intervention, such as PCI, in the clinic. 
In the Langendorff model, the position of the suture with regard to the LAD 
determines the volume of myocardium subjected to regional ischaemia. The most 
common way to analyse the size of the ischaemic area at risk (AAR), and thereby 
ensure experimental consistency, is by re-tightening the suture at the end of the 
experiment and perfusing the heart with Evans blue dye, staining the perfused 
(i.e. non-ischaemic) tissue blue 285. In this experiment, the size of the AAR was 
not found to be significantly different between the experimental groups; therefore, 
the consistency of suture placement was deemed acceptable. The functional 
parameters measured during the course of the study were also found to be 
consistent between the experimental groups.  
Coronary flow rate was unchanged between the experimental groups, with the 
values consistent with previously published results 286. During the period of 
ischaemia, coronary flow rate exhibited a marked decline, which is expected due 
to perfusion of a smaller region of the heart. After the period of ischaemia, 
coronary flow rate briefly recovered, but then continued to gradually decline due 
to the “dying preparation” nature of the experimental model 286. Heart rate was 
maintained consistently up until the reperfusion stage of the experiment, when the 
VUF11207 group exhibit lowered heart rate in the last three timepoints of the 
experiments. Nevertheless the reduction in heart rate was not statistically 
significant when compared to the vehicle.  
Left ventricular developed pressure (LVDP) was also monitored during the 
experiment. Developed pressure is used as a measure of cardiac function and 
exhibited a reduction for all three experimental groups (vehicle, IPC, VUF11207), 
during the period of ischaemia. The recorded fall in LVDP is a well-established 
consequence of regional ischaemia, and agrees with previously published values 
of ~30% reduction, across all experimental groups 285.  
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Additionally, the combined effect of the delivered ischaemic insult and the dying 
preparation nature of the isolated heart model caused a gradual decline in the 
LVDP until the conclusion of the experiment 286. Perfusion pressure, which was 
maintained at approx. 70 mmHg, remained stable throughout the experiment for 
all experimental groups, as it should in a so-called “constant pressure” model. 
This type of model is a preferred model in a setting of regional myocardial 
ischaemia as it enables autoregulation of coronary tone 252. 
Heart temperature is another important parameter that was closely monitored, 
since it can greatly affect the overall function of the heart 285. Failure to maintain 
the heart at a physiological temperature (37 ± 0.5°C) can  affect the susceptibility 
of the heart to I/R injury, haemodynamic performance, and response to drugs 287. 
Since temperature remained within specified parameters for the entire duration of 
the experiment for all three experimental groups, there is no reason to assume 
that it modified the susceptibility of the rat heart to VUF11207 administration in 
any way.  
From 11 rat hearts that were excluded due to pre-defined exclusion criteria, small 
size of AAR (<35%) was the most common reason for exclusion (n=8). This likely 
occurred due to improper placement of the ligature or insufficient tightening prior 
to the ischaemic insult, and is undesirable, since it is associated with smaller 
infarct sizes and hinders testing of potential cardioprotective interventions in an 
ex vivo isolated heart perfusion model 288. Other exclusions were also 
unremarkable, with no significant differences in the number of exclusions between 
the groups. They included a low baseline heart rate (<200 bpm, n=1) and an 
episode of ventricular fibrillation (n=1), which lasted longer than 2 min. Low 
baseline heart rate is not desirable since it suggests an impaired cardiac function, 
while after the episode of ventricular fibrillation normal sinus rhythm was not 
restored, which prevented the conclusion of the experiment. A single heart also 
displayed a torn aorta, which occurred due to operator error. 
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Final infarct-size assessment and LDH measurements at various timepoints 
during the ex vivo heart perfusion were used as experimental endpoints. Rat 
hearts that received 3 x 5 min cycles of IPC administered prior to index ischaemia, 
exhibited significantly reduced infarct size compared to the vehicle-perfused 
group, which did not receive IPC (Figure 4-1). There has been extensive research 
into the mechanism IPC. It has been shown to exert cardioprotective effects 
through Protein kinase C (PKC) signalling, which is also a common target of 
various cardioprotective pharmacological agents (e.g. opioids, bradykinin) 289, 290. 
Controversy exists surrounding the particular isoenzyme of PKC responsible for 
conferring cardioprotection in the IPC setting, with PKC-δ (delta) and PKC-ε 
(epsilon) emerging as the most likely contenders 291-293. Furthermore, IPC has 
been shown to require activation of PI3K/AKT and ERK1/2 signalling within IPC 
in the first few minutes of reperfusion. This discovery provided a paradigm shift 
from early thinking, which postulated that IPC exerts most of its beneficial effect 
during the period of ischaemia 191, 289. The IPC stimulus was also shown to be 
responsible for the inhibition of the opening of the mPTP during the reperfusion 
period 294. This is believed to be mediated by the PI3K/AKT pathway, thought the 
precise target of the kinase that decreases mPTP opening is not known. In the 
present study, IPC was used solely as a positive control, due to its well-
documented and highly reproducible cardioprotective effect when used in this 
setting 183, 295, 296. In contrast to IPC, administration of CXCR7 agonist VUF11207 
(1 µM), commencing 5 min prior to and continuing throughout reperfusion, did not 
reduce infarct size. Possible reasons for this are discussed below. 
To date, the only publication that directly addresses the role of CXCR7 in MI and 
its cardioprotective effects has been published by Hao et al. 115. They showed that 
using an adenovirus to induce over-expression of CXCR7 prior to inducing in vivo 
MI in mice significantly reduced the average infarct size by ~13%, when measured 
28 days after induction of MI; compared to hearts injected with a control 
adenovirus. Furthermore, Hao et al. administered a CXCR7-specific agonist 
TC14012 i.p., immediately post-MI and every 6 days thereafter for 24 days.  
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Final infarct size analysis 28 days post-MI showed a significant ~16% reduction 
in the average infarct size between the group that received TC14012 injection and 
the group that received saline 115. Additionally, Hao et al. utilized a conditional, 
endothelial CXCR7-knockout model, which exhibited higher infarct sizes than the 
wild type group, when measured 28 days post-MI 115. These mice also exhibited 
reduced survival, greater cumulative death and worse cardiac function within 28 
days post-MI. However, the deleterious effects of endothelial CXCR7 deletion 
only became obvious after the induction of MI, showing that the absence of 
endothelial CXCR7 is detrimental after the occurrence of MI, but not before. These 
data suggest that endothelial CXCR7 plays an important protective role after MI 
and ameliorates the damage sustained by the heart from the ischaemic insult in 
the longer term. On the other hand, Hao et al. did not examine the acute role of 
CXCR7 activation or deletion on MI. Furthermore, all of the infarct size 
measurements were made 28 days post in vivo MI, and after the use of permanent 
ligation, a model which differs substantially from one of ischaemia and 
reperfusion.  
In the permanent ligation experiment the coronary vessel, usually LAD, is 
permanently ligated, which does not allow for reperfusion to the ischaemic area 
to occur directly through the LAD but is achieved through any collateral circulation 
present in the area. This normally results in a larger infarct size, because the 
entire area at risk becomes infarcted 297. It is a model predominantly used to 
investigate longer-term effects, such as ventricular remodelling and cardiac 
contractility. Ex vivo isolated heart experiments on the other hand are more 
commonly used to investigate short-term consequences of MI. They are the 
preferred model when investigating the effects of pharmacological agents, 
especially those administered before or early during the reperfusion period. In 
summary, a permanent ligation model is performed in vivo and focuses on longer 
term ischaemic damage, while the isolated heart perfusion is an ex vivo model 
investigating the effects of acute I/R injury. 
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Both models have their strengths and weaknesses but are ultimately designed to 
examine different aspects of ischaemic damage on the heart post-MI, which might 
be the reason why Hao’s study showed a cardioprotective role of CXCR7, while 
in our experiments VUF11207 did not exhibit such cardioprotective effects. 
Another difference between our study and that of Hao et al. is that they used 
Masson trichrome staining instead of the TTC method for determination of the 
final infarct size, which could also contribute to contrasting results. TTC in 
combination with Evan’s blue dye is frequently used to assess final infarct size 
after an acute MI, since it has the ability to distinguish between metabolically 
active and inactive tissues in the first few hours after the ischaemic insult has 
occurred; as described in section 2.9.3 253. However, TTC staining also relies on 
adequate reperfusion occurring in the ischaemic area, to achieve a clear 
delineation of the infarcted zone. This is a crucial step prior to TTC staining, since 
washout of dehydrogenases upon which TTC acts and haem-containing proteins 
present in the heart is needed to avoid a mottled appearance of the infarcted area 
and underestimation of the infarct size 298. Measuring flow rate can help determine 
whether sufficient washout has occurred for TTC staining to be effective. In this 
study, flow rate was adequate for all experimental groups throughout the duration 
of the experiment. Additionally, flow recovery after the period of index ischaemia 
was satisfactory for all experimental groups and it is unlikely that insufficient 
washout prevented accurate assessment of infarct size  
There are additional factors that could have affected the response to VUF11207, 
among them the existence and extent of collateral coronary vasculature. For 
various mammalian species the extent of coronary collaterals that exist in the 
heart can be drastically different. For example, guinea pigs, dogs and cats exhibit 
much higher rates of collateral flow than rats and mice, which are more similar to 
young and/or healthy humans and display lower rates of collateralization in the 
heart 299-301. However, formation of collaterals in the human heart varies greatly 
between individuals and can be affected by age and disease 302.  
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Past studies also show that in mice, the strain of mice can influence the extent of 
collateral vasculature formation in different vascular beds 303-306. This is important 
because collaterals present in the heart can help ameliorate ischaemic injury by 
supplying blood flow to the ischaemic area, independent of the ligated coronary 
vessel 301. Ultimately, the extent of collateral circulation in the heart could also 
affect the extent of delivery of a pharmacological agent, such as VUF11207, to 
the ischaemic region. Since VUF11207 was administered shortly before 
reperfusion this might not be as relevant as if it were administered prior to, or 
during ischaemia. However, it is still important to note that the varying extent of 
coronary collateralization could also represents a differing number of CXCR7 
receptors present in endothelial cells, which can in turn have an impact on the 
strength of the response to a CXCR7 agonist. There is limited information on the 
presence and importance of coronary collaterals in murine species, it is difficult to 
determine whether collateralization played a significant part in the differences 
observed in results obtained by Hao’s study and ours. 
The time between the administration of CXCR7 agonist and the onset of MI might 
also be an important factor in determining the cardioprotective effects of said 
agonist. In the study performed by Hao et al. the time between the MI and final 
infarct size analysis was 4 weeks, which might mean that CXCR7 or its agonists 
need a longer period or several administrations before exerting beneficial effects 
on the heart. Studies performed on other tissue types by Ding and colleagues 234, 
235, 240 and described earlier in section 1.3.3 would support the theory that CXCR7 
might act in the longer term, with a more regenerative, anti-fibrotic mode of action, 
which could be the reason why VUF11207 did not exhibit cardioprotective effects 
in our study. 
A further explanation for the lack of cardioprotection seen in our study might also 
be the choice of CXCR7 agonist, VUF11207. Most studies examining the effects 
of CXCR7 signalling use the agonist TC14012.  
130 
 
However, due to the long duration of the experiment, and consequently large 
volumes (litres) of perfusion buffer needed, the use of TC14012 was not deemed 
financially feasible. T140 compounds, precursor compounds to TC14012, were 
first synthesized and published two decades ago 150, 152, 307. Consequently, 
TC14012 has been commercially available for longer than VUF11207. TC14012 
has also been used in more published articles than VUF11207, and its mode of 
activation and binding properties have been fairly well described, which might also 
explain why this agonist is more popular than others 151, 308. In contrast, VUF11207 
was only synthesized in 2012, and there is only a single published paper using 
VUF11207 153, 309. Additionally, the two agonists have a different chemical 
structure; T14012 is a peptidomimetic agonist and VUF11207 is a small molecule 
agonist. A peptidomimetic compound mimics the properties of a natural peptide 
or protein (in this case SDF-1α) and is able to interact with the same biological 
target and elicit the same biological effect. Often, peptidomimetics also display 
improved bioavailability and duration of activity, compared to natural peptides, 
which makes them an attractive investigative tool for many researchers 310.  
On the contrary, small molecule drugs are low molecular weight compounds, with 
relatively short half-lives that can typically pass through cell membranes with 
ease, due to their small size 311. There are advantages and disadvantages to 
using either small molecule drugs, such as VUF11207 or peptidomimetic 
compounds, like TC14012 with both displaying markedly different 
pharmacokinetics and pharmacodynamics. Perhaps the preferential use of 
TC14012 to VUF11207 is simply due to the fact that it has been around longer 
and is therefore considered a tried and tested approach. 
Based on the reported EC50 of 1.6 nM for VUF11207 in the β-arrestin2 recruitment 
assay in CXCR7-expressing HEK293 cell, it was expected that the concentration 
of 1 µM would be sufficient to exert any beneficial effects 153. Nevertheless, it is 
possible that a greater or smaller concentration might yield different results, and 
time permitting, a concentration-response curve would be the next sensible step. 
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Furthermore, it would be preferable to have a biological readout confirming 
stimulation of CXCR7 receptor, such as a measure of β-arrestin activity, which is 
currently not feasible in an ex vivo model. Another measure that could have been 
taken to ensure that the utilized VUF11207 compound displays functional activity, 
especially after aliquoting and freezing, would be to test its functionality. Such a 
test would be best performed on a cell type where CXCR7-dependent SDF-1α 
signalling has already been shown, e.g. ERK1/2 signalling in Jurkat T cells, and 
with the same drug concentration as intended for isolated rat heart perfusion 
experiments 220. This would help to confirm whether our chosen, commercially 
available CXCR7 agonist VUF11207 has the ability to elicit the same response in 
Jurkat T cells and inform us whether it would make an effective CXCR7 agonist. 
The second endpoint of the ex vivo perfusion experiment was the analysis of LDH 
release at set timepoints throughout the experiment. LDH has been used as a 
surrogate marker of myocardial injury in the clinic, since high circulating values 
are associated with greater myocardial damage and subsequently worse 
prognosis after MI 312, 313. Nowadays, it is still used as a marker of myocardial 
injury in basic research, although it is slowly being replaced by highly sensitive 
and specific cardiac troponin assays, as they become more cost efficient 314.  
The timepoint selected for LDH analysis was 15 min (R+15’) after the start of the 
reperfusion period, since Rossello et al. showed a pronounced peak of LDH 
release between 10 - 15 min of reperfusion and a steady decline thereafter 255. 
IPC significantly reduced LDH release at R+15’ compared to vehicle, whereas 
VUF11207 did not have an effect on LDH release at the same timepoint.  
In general, previously published research has found LDH release to be a relatively 
inconsistent measure of the cardioprotective potential of IPC compared to TTC 
staining 254, 255, 315, 316. Furthermore, peak LDH release does not appear to directly 
correlate to infarct size, whereas it does show correlation with the ischaemia 
length 255. For these reasons, we considered LDH levels as being of secondary 
importance to TTC measurement.  
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It is possible that VUF11207 might have been found to alter LDH levels at 
timepoints other than R+15 min, but to determine this, a prolonged time-course of 
LDH measurements would be needed. Interestingly, Povlsen et al. showed two 
peaks of LDH release following ischaemia instead of one. The first peak occurred 
at 2 - 20 min and the second at 30 - 120 min, after the start of the reperfusion 
period, which is in contrast to the single peak reported by Rossello et al. 254, 255.  
Povlsen et al. also make an interesting observation regarding the correlation 
between the second peak of the LDH release and cardioprotective interventions 
applied past the period of ischaemia 254. They postulate that the first LDH peak in 
the rat heart occurs as a result of ischaemic and early reperfusion damage and 
the second LDH peak as a result of late reperfusion damage, with both peaks 
being amenable to cardioprotective interventions. This would fall in line with IPC, 
which is known to attenuate ischaemic and reperfusion damage, having the ability 
to reduce the level of LDH release during the first peak (R+15’). It is important to 
note that Rossello et al. performed the study on mice, whereas Povlsen et al. used 
rats, which could explain the inconsistent reporting of the existence of the second 
peak. Since our study only collected perfusate for LDH analysis up to R+15’, 
neither the existence of the second peak, nor the effect of VUF11207 on said peak 
could be determined.  
In brief, Hao et al. showed that increased expression of CXCR7 or administration 
of its agonist TC14012 is cardioprotective, while the lack of CXCR7 is deleterious. 
However, they investigated the impact of MI on the heart several weeks thereafter, 
when cardiac remodelling, angiogenesis, fibrosis and scar formation has already 
occurred. Consequently, all of these processes represent possible targets of 
CXCR7 and its agonist TC14012, with prior research already pointing to the 
importance of CXCR7 in ameliorating fibrosis in various tissues; as described in 
section 1.3.3. However, their choice of experimental model and staining preclude 
from investigating the effects of CXCR7 on the initial infarct formation, which 
according to our study are unremarkable. 
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Overall, in our hands the administration of VUF11207 just prior to reperfusion in 
an ischaemia/reperfusion model of a rat heart did not reduce either final infarct 
size or LDH release at our chosen investigated timepoint R+15’. As already 
discussed above, there are several limitations to this study which could preclude 
us from observing the hypothesized effects of VUF11207.  
However, it could be that VUF11207,  or potentially any CXCR7 agonist, lacks the 
ability to exert beneficial effects in an acute setting of MI. As previously published 
by Ding and colleagues, as well as others, most beneficial actions of CXCR7 were 
seen in a chronic setting, either as an anti-fibrotic or a pro-angiogenic effector 234, 
235, 240. This could mean that 2 h for which the VUF11207 is active during the 
reperfusion period is not long enough either to exert its beneficial effects or for the 
ischaemic myocardium to benefit from those effects in a way that we could 
observe in our experiment (i.e. infarct size, LDH release). Additionally, the study 
published by Hao et al., where administration of another CXCR7 agonist, 
TC14012, did demonstrate cardioprotective effects in a chronic MI setting, the 
lack of acute (within hours of the ischaemic insult) cardioprotective  response 
further indicates this as the most likely scenario 115. Therefore, it would be prudent 
to direct further investigation into the beneficial effects of CXCR7 agonist 
administration in an ischaemia/reperfusion setting towards the more chronic anti-






IPC decreased final infarct size and reduced LDH release at R+15’. This positive 
control demonstrates that the experiment was successful, and detection of 
significant cardioprotection was technically feasible. However, CXCR7 agonist 
VUF11207 (1 µM) did not affect either the final infarct size, or the LDH release at 
set timepoints throughout the experiment. This suggests that this dose of 
VUF11207 administered at reperfusion does not exhibit cardioprotective effects 




5 The effect of CXCR7 agonists VUF11207 and TC14012 on the 
RISK pathway 
5.1 Background 
As discussed previously in section 1.4.2. there is compelling evidence that 
activation of effectors downstream of CXCR7 is cell type-specific and 
encompasses processes such as, chemotaxis, cell migration and cell survival 123, 
219, 220. However, since our research focuses on the role of CXCR7 in endothelial 
cells, we wanted to investigate the effects of CXCR7 activation on the RISK 
pathway specifically in cells of endothelial origin and its possible links to 
cardioprotection. There is currently little evidence linking RISK pathway activation 
through CXCR7 signalling with a cardioprotective benefit to the heart. However, 
identifying whether CXCR7 is capable of signalling through the RISK pathway is 
an important step towards determining whether there is a role for CXCR7-
dependent acute cardioprotection. 
To investigate RISK pathway activation, CXCR7 agonists VUF11207 and 
TC14102 were used to examine phosphorylation of ERK1/2 and AKT downstream 
of CXCR7 receptor activation. The CXCR7 agonists used in below experiments 
are described in detail in section 1.3.3. 
5.2 Research aims and objectives 
Investigate whether administration of CXCR7 agonists is able to induce AKT 
and/or ERK1/2 phosphorylation, in order to examine RISK pathway signalling: 
- Examine the effect of VUF11207 and SDF-1α on AKT, ERK1/2 
phosphorylation status in HUVEC. 
 
- Examine the effect of TC14012 and SDF-1α on AKT, ERK1/2 





In addition to the general methods described in Chapter 2, the following specific 
methods were used in the experiments described in this chapter. 
 Western blotting antibodies 
RISK pathway signalling was investigated in HUVEC, using western blotting 
methods described in section 2.5. Membranes were incubated with anti-phospho 
AKT rabbit monoclonal (1:1000, #9271, Cell signalling), anti-pan AKT mouse 
monoclonal (1:1000, #2920, Cell Signalling), anti-p44/42 MAPK mouse 
monoclonal (1:1000, #9107, Cell Signalling) or anti-phospho p44/42 MAPK rabbit 
polyclonal (1:1000, #4370, Cell Signalling) primary antibodies. 
IRDye® 800CW goat anti-rabbit IgG (1:10,000, Li-COR), or IRDye® 680RD Goat 
anti-mouse IgG (1:10,000, LI-COR) secondary fluorescent antibodies were used 
for detection. 
 Cell treatments 
Prior to western blotting, HUVEC were cultured as described in section 2.3. 
HUVEC were serum-starved for 3 h with DMEM medium (Gibco) supplemented 
with penicillin/streptomycin (Gibco), prior to the administration of the following cell 
treatments prepared in 200 µL of PBS: insulin (100 nM, Sigma-Aldrich), SDF-1α 
(250 nM, Miltenyi Biotec), VUF11207 (100 nM/250 nM, Tocris), Bradykinin (1 µM, 
Sigma-Aldrich) or TC14012 (30 µM, Cayman Chemical). In western blotting 
experiments involving VUF11207, the control cell sample only received 200 µL of 
PBS. For experimental sets containing TC14012, vehicle contained DMSO (final 




 Normalization of western blotting results 
In order to be able to directly compare western blotting results obtained from 
different experimental repeats, individual blots were normalized using an 
additional sample (internal control sample). The internal control sample was used 
solely to ensure a correct analysis of western blots and is therefore not shown in 
the results section. 
5.4 Results  
In order to investigate the effects of CXCR7 agonists VUF11207 and TC14012 on 
phosphorylation of ERK1/2 and AKT, western blotting was used. The selected 
times for HUVEC cell incubation with the relevant drugs were based on previously 
published research described in section 1.4.2, which suggests that incubation of 
5 - 15 min is needed to elicit maximal ERK1/2 and AKT phosphorylation. Insulin 
was used as a positive control for AKT phosphorylation, since its ability to induce 
AKT phosphorylation status in various cell types is well established 317, 318. 
Similarly, SDF-1α has previously been shown to be able to induce 
phosphorylation of ERK1/2 in endothelial cells and was, therefore used as a 





Figure 5-1: The effect of VUF11207 (100 nM) on phosphorylation of AKT in HUVEC. 
Administration of insulin (100 nM) 10 min prior to cell lysis induced a significant increase in AKT 
phosphorylation. Administration of SDF-1α (250 nM) for 10 min or VUF11207 (100 nM) for 5 – 30 
min before cell lysis did not significantly affect AKT phosphorylation. Total AKT was used as a 
loading control. *** p < 0.001 insulin vs control, Repeated Measures ANOVA with Bonferroni post-
hoc test comparing all groups to control; n = 6 independent experiments per group. 
Western blotting for phospho-AKT in HUVEC revealed that 10 min treatment with 
insulin (100 nM), induced significant phosphorylation of AKT, with an approx. 4-
fold increase, compared to control (Figure 5-1). The administration of SDF-1α for 
10 min or VUF11207 for various lengths of time as indicated, did not significantly 
affect the phosphorylation status of AKT. 
When western blotting for ERK1/2, SDF-1α administered 10 min prior to cell lysis 
induced significant ERK1/2 phosphorylation, which was increased approx. 5-fold, 
when compared to control (Figure 5-2). Again, administration of VUF11207 for 
various lengths of time did not induce phosphorylation of ERK1/2 at any timepoint. 
139 
 
Additionally, insulin administration for 10 min did not induce phosphorylation of 
ERK1/2. 
 
Figure 5-2: The effect of VUF11207 (100 nM) on phosphorylation of ERK1/2 in HUVEC. The 
administration of SDF-1α (250 nM) 10 min prior to cell lysis induced significant phosphorylation of 
ERK1/2. Administration of insulin (100 nM) for 10 min or VUF11207 (100 nM) for 5 – 30 min did 
not induce changes in ERK1/2 phosphorylation status. Total ERK1/2 was used as a loading 
control. * p < 0.05 SDF-1α vs control, Repeated Measures ANOVA with Bonferroni post-hoc test 
comparing all groups to control; n = 5 independent experiments per group. 
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Since the concentration of VUF11207 (100 nM) used in the western blotting 
experiments was lower than that of SDF-1α (250 nM), the concentration of 
VUF11207 was increased to 250 nM in the subsequent experiment (Figure 5-3).  
In this experiment, bradykinin (1 µM) was used as an alternative positive control 
for ERK1/2 activation 321. A single incubation timepoint of 10 min was chosen for 
all experimental groups, on the basis of previously published research, where a 
10 min incubation was sufficient to successfully induce phosphorylation of ERK1/2 
220, 320.  
Bradykinin administration 10 min prior to cell lysis successfully induced 
phosphorylation of ERK1/2 in HUVEC cell, whereas VUF11207 (250 nM), 
administered for the same amount of time, did not induce phosphorylation.  
 
Figure 5-3: The effect of VUF11207 (250 nM) on phosphorylation of ERK1/2 in HUVEC. The 
administration of bradykinin (1 µM) 10 min prior to cell lysis significantly increased induction of 
ERK1/2 phosphorylation. Administration of VUF11207 (250 nM) 10 min prior to cell lysis did not 
have an effect on ERK1/2 phosphorylation levels. Total ERK1/2 was used as a loading control.     
* p < 0.05 bradykinin vs control, Repeated Measures ANOVA with Bonferroni post-hoc test 





Figure 5-4: The effect of TC14012 on phosphorylation of AKT in HUVEC. The administration 
of insulin (100 nM) 10 min prior to cell lysis induced significant phosphorylation of AKT. 
Administration of SDF-1α (250 nM) for 10 min or TC14012 (30 µM) for 10 – 60 min did not induce 
changes in the AKT phosphorylation status. Total AKT was used as a loading control. * p < 0.05 
insulin vs control, Repeated Measures ANOVA with Bonferroni post-hoc test comparing all groups 
to control; n = 3 independent experiments per group. 
Since VUF11207 did not induce phosphorylation using western blotting, an 
alternative CXCR7 agonist, TC14012 was also investigated. In these 
experiments, administration of insulin (100 nM) 10 min prior to cell lysis induced 
AKT phosphorylation, which was approx. 2-fold greater than the vehicle control 
(Figure 5-4). Administration of TC14012 (30 µM) for 10, 30 or 60 min, or incubation 
with SDF-1α 10 min prior to cell lysis did not affect the phosphorylation status of 
AKT (Figure 5-4). When western blotting for phospho-ERK1/2, administration of 
neither TC14012, SDF-1α or insulin induced statistically significant 





Figure 5-5: Effect of TC14012 on phosphorylation of ERK1/2 in HUVEC. There was no change 
in ERK1/2 phosphorylation levels with administration of either insulin (100 nM), SDF-α (250 nM) 
or TC14012 (30 µM) in HUVEC. n = 3 independent experiments per group. Total AKT was used 
as a loading control. * p < 0.05 insulin vs control, Repeated Measures ANOVA with Bonferroni 




Figure 5-6: Effect of insulin and SDF-1α on AKT phosphorylation in HUVEC – pooled data. 
Administration of either SDF-1α (250 nM) or insulin (100 nM) significantly increased AKT 
phosphorylation response compared to control in HUVEC. Data were pooled from experiments 
in Figure 5-1 and Figure 5-4. Total AKT was used as a loading control. * p < 0.05 insulin vs 
control and SDF-1α vs control, Repeated Measures ANOVA with Dunnett’s post-hoc test 
comparing all groups to control; n = 9 independent experiments per group. 
In order to gain a clearer picture of the effects of insulin and SDF-1α on AKT 
phosphorylation, data concerning control, insulin and SDF-1α from western 
blotting experiments with VUF11207 and TC14012 from Figure 5-1 and Figure 5-
4 were pooled together and presented in Figure 5-6. Statistical analysis revealed 
that administration of either insulin (100 nM) or SDF-1α (250 nM) 10 min before 
cell lysis significantly increased AKT phosphorylation compared to control. There 
was an approx. 3-fold increase in mean AKT phosphorylation response after 
administration of insulin and 1.5-fold increase after administration of SDF-1α, 




Figure 5-7: Effect of insulin and SDF-1α on ERK1/2 phosphorylation in HUVEC – pooled 
data. Administration of either SDF-1α (250 nM) or insulin (100 nM) significantly increased the 
ERK1/2 phosphorylation response compared to control in HUVEC. Data were pooled from 
experiments in Figure 5-2 and Figure 5-5. Total ERK1/2 was used as a loading control. * p < 
0.05 insulin vs control and SDF-1α vs control, Repeated Measures ANOVA with Dunnett’s post-
hoc test comparing all groups to control; n = 8 independent experiments per group. 
As in Figure 5-6, data in Figure 5-7 were also pooled from previous experiments 
already outlined in Figure 5-2 and Figure 5-5. Administration of insulin (100 nM) 
for 10 min prior to cell lysis significantly increased ERK1/2 phosphorylation 
response, which translated into a 2-fold increase compared to control. Similarly, 
administration of SDF-1α 10 min prior to cell lysis also induced a statistically 
significant increase in mean phosphorylation response of ERK1/2, which was 
approx. 4-fold greater when compared to control, although it exhibited a wide 
spread of data points and consequently a large standard error of the mean. Both, 
insulin and SDF-1α were able to induce a statistically significant induction of either 
AKT or ERK1/2 phosphorylation when values from all relevant experiments were 




The RISK pathway is an important pro-survival pathway, utilized by many 
mechanical and pharmacological cardioprotective interventions 190, 194-196. The 
parallel signalling cascades of PI3K/AKT and MEK1/ERK1/2 form the cornerstone 
of RISK pathway signalling. Consequently, measurement of the phosphorylation 
of these kinases can offer insight into whether or not a drug is able to induce RISK 
pathway signalling. To investigate the CXCR7-dependent activation of the RISK 
signalling pathway, CXCR7 agonists, VUF11207 and TC14012 were used in 
western blotting experiments in HUVEC. Positive controls, insulin and bradykinin 
significantly induced phosphorylation of AKT and ERK1/2, respectively. SDF-1α 
induced phosphorylation of ERK1/2, but not AKT, whereas VUF11207 and 
TC14012 did not induce phosphorylation of AKT or ERK1/2 at any timepoint 
tested.  
SDF-1α-induced phosphorylation of ERK1/2 was examined in both, VUF11207 
and TC14012 experimental sets. In both cases, the same experimental conditions 
were used; however, the obtained results differ between the two sets. There was 
a notable SDF-1α-dependent ERK1/2 phosphorylation, when SDF-1α (250 nM) 
was administered 10 min before cell lysis, in the set of western blotting 
experiments using VUF11207 (Figure 5-2), but not in the experimental set using 
TC14012 (Figure 5-5). In both cases, there was a large standard error present in 
the SDF-1α data set, showing a large degree of variability in the cell response. 
Statistical power of the TC14012 experimental set was adequate (97.5%) and 
should enable statistical detection of ERK1/2 phosphorylation changes. Having 
an adequately powered experiment reduces the probability of Type II error, and 
since sample size was lower in the TC14012 vs VUF11207 data set (n=3 vs n=5), 




Furthermore, since HUVEC are primary cells, the reproducibility of results can 
vary from donor to donor. Even though commercially available HUVEC from 
pooled donors were used in our western blotting experiments, the inherent 
variability of HUVEC cannot be excluded as a possible reason for observed 
differences in obtained results. For that reason we have pooled data from control, 
insulin and SDF-1α from experimental sets including both, TC14012 and 
VUF11207 (Figure 5-7). Pooled data revealed that administration of insulin 
significantly increased induction of ERK1/2 phosphorylation. Since administration 
of insulin in our individual experiments displayed a relatively small effect size, 
pooling the data provided us with more statistical power and; therefore, enabled 
us to observe this effect, which would have likely gone unnoticed. Insulin-induced 
ERK1/2 phosphorylation observed in our pooled data has been described before 
as part of the MAPK arm of insulin signalling response with broad physiological 
implications 324, 325. While an interesting observation, the role of insulin in RISK 
signalling, and more broadly, cardioprotection, goes beyond the scope of this 
thesis, where the primary role of using insulin was as a positive control for 
induction of AKT phosphorylation.   
Pooled data also revealed significantly increased induction of ERK1/2 
phosphorylation after administration of SDF-1α. Individual values obtained for 
SDF-1α-induced phosphorylation of ERK1/2 exhibited a wide spread of data 
points. This was in part counteracted by increasing the sample size by pooling 
data from separate VUF11207 and TC14012 experiments, which allowed us to 
show that administration of SDF-1α (250 nM) does induce ERK1/2 
phosphorylation, which was statistically significant.  
Our results agree with work published by others, showing that SDF-1α induces 
ERK1/2 phosphorylation in various cell types. Chen et al. showed ERK1/2 
phosphorylation in cardiac stem cells stimulated with SDF-1α (100 ng/mL ~ 12.5 
nM), which peaked after a 30 min incubation period 219.  
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Similarly, Laakko et al. showed that Jurkat T cells incubated with SDF-1α (20 
ng/mL ~ 2.5 nM) for 5 min exhibit increased phosphorylation of ERK1/2 326. 
Additionally, a study by Zhuo et al. showed that SDF-1α (100 ng/mL ~ 12.5 nM) 
induces phosphorylation of ERK1/2 in lymphatic endothelial cells, which peaks 30 
min after administration. This supports our findings that SDF-1α induces ERK1/2 
phosphorylation, although altering the time of incubation might be crucial in 
achieving a maximum phosphorylation response, since both Chen’s and Zhuo’s 
group found peak phosphorylation response to occur 30 min after beginning of 
the incubation period. In our experiment, SDF-1α was administered in the 
absence of CXCR7 or CXCR4 inhibitors and activate RISK pathway signalling in 
endothelial cells. Therefore, ERK1/2 phosphorylation could have occurred as a 
consequence of either CXCR4 or CXCR7 activation. We have shown that SDF-
1α is capable of eliciting a response through ERK1/2, but not AKT on endothelial 
cells, both important players in many  signalling pathways. However, they also 
form a crucial part of the RISK cardioprotection signalling pathway, shared by 
many cardioprotective interventions.  
In contrast, administration of SDF-1α (250 nM) did not induce phosphorylation of 
AKT in the experimental set using neither VUF11207 nor TC14012. Pooling the 
data from both experimental sets allowed us to increase the sample size, although 
it was clear that administration of SDF-1α did not induce phosphorylation of AKT. 
On the other hand, positive control insulin (100 nM) performed as expected and 
induced a significant AKT phosphorylation response showing that HUVEC have 
respond to stimuli as expected.  
Our results do not agree with previously published work, where SDF-1α has been 
shown to induce phosphorylation of AKT in various cell types. Possible reasons 




There are two key phosphorylation sites on AKT, namely Thr308  (Threonine 308) 
and Ser473 (Serine 473) with our research focused on Ser473, which can be found 
on the C-terminal hydrophobic motif of the AKT kinase 197, 327. Chen et al. also 
examined phosphorylation of Ser473 on AKT kinase and found that SDF-1α (100 
ng/mL ~ 12.5 nM) administration induced phosphorylation of AKT on cardiac stem 
cells, which peaked after 30 min of incubation 219. Similarly, Shao et al. showed 
that administration of SDF-1α (100 ng/mL ~ 12.5 nM) for 5 min before cell lysis  
on bone marrow-derived cells induced phosphorylation of AKT; however the exact 
phosphorylation site investigated was not reported 328. The investigated site of 
AKT phosphorylation, which is not always reported, could contribute to different 
results observed in AKT phosphorylation studies. Importantly, neither of the above 
studies used endothelial cells. The choice of cell type might be especially relevant 
in the case of cardiac stem cells, which are not terminally differentiated and 
display hugely different characteristics to differentiated cells, including a different 
transcriptomic profile and signalling ability 329. The same is true for differences 
between our obtained results and those obtained by other in regards to ERK1/2 
phosphorylation, with the exception of the site of phosphorylation. Site of 
phosphorylation is not an issue with ERK1/2 as the antibodies for phospho-
ERK1/2 target the same two phosphorylation sites at Tyr204/187 (Tyrosine 
204/187) and Thr202/185 (Threonine 202/185) 330  
When examining the activation of phospho-AKT in endothelial cells, Zhang et al. 
previously reported that SDF-1α (100 ng/mL ~ 12.5 nM) induced phosphorylation 
of AKT specifically in HUVEC cells 222. However, they do not report the time of 
incubation or the phosphorylation site examined, which hinders any direct 
comparison with our study. Meanwhile, Zhuo et al. showed that SDF-1α (100 
ng/mL ~ 12.5 nM) induced AKT phosphorylation in lymphatic endothelial cells with 
peak phosphorylation response present between 10 and 30 min post-
administration 331. They also do not report exactly which phosphorylation site they 
examined; however, their use of cells of endothelial origin seems to suggest that 
cell type is not the reason for the different results obtained by other groups and 
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ours. However, endothelial cells exhibit different phenotypes depending on their 
site of origin. While HUVEC are venous endothelial cells, it is arterial and capillary 
endothelial cells that might represent a more relevant cell type in the myocardium 
332, 333. There are not many commercially available cardiac endothelial cell lines 
and a specific subtype (e.g. arterial) of endothelial cells can be difficult to isolate. 
That is why HUVEC are a popular endothelial cell model; however, it is important 
to remember that their venous origins might not accurately reflect the in vivo state.    
Additional reasons for varying results obtained by us and others, could also 
include the duration of cell starvation without serum, which is intended to reduce 
the basal signalling activity but is often not well reported in published literature 334. 
In our study, the cells were starved for 3 h, whereas most other groups do not 
report whether the cells were starved or not 222, 331. This could mean that the basal 
level of phosphorylation was different between various studies, making increases 
in phosphorylation response more or less difficult to identify.  
Since our interests lay primarily in the CXCR7-dependent activation of RISK 
pathway, CXCR7 agonists VUF11207 and TC14012 were utilized to induce 
CXCR7 signalling in HUVEC. Administration of neither VUF11207 (100 nM and 
250 nM) or TC14012 (30 µM) was able to induce phosphorylation of ERK1/2 or 
AKT in HUVEC.  This disagrees with some of the already published data, 
previously discussed in section 1.4.2 and briefly outlined below.  
SDF-1α incubation in the presence of CXCR4-blocking antibody has been shown 
to elicit maximal phosphorylation of ERK1/2 10 min post-administration on Jurkat 
T cells 220. Additionally, Rajagopal et al. showed that HEK293 cells transfected 
with CXCR7 and stimulated with SDF-1α exhibited sustained ERK1/2 activation 
30 min post administration123. This is in contrast with our results, where direct 
stimulation of CXCR7 via either VUF11207 or TC14012 did not induce 
phosphorylation of ERK1/2, despite the use of similar incubation time points.  
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Similarly, Kumar et al. showed that administration of SDF-1α on Jurkat T cells 
pre-treated with CXCR4-blocking antibody induced maximal phosphorylation of 
AKT 15 min after administration 220. Additionally, Zhang et al. showed that 
activation of CXCR7 via administration of TC14012 (30 µM) in HUVEC induces 
phosphorylation of PI3K, but no time of incubation was discussed 222. We did not 
observe an increase in AKT phosphorylation as a result of CXCR7 stimulation (via 
VUF11207 and TC141012). However, we have found that administration of SDF-
1α alone was already incapable of eliciting an induction of AKT phosphorylation, 
which means that perhaps HUVEC used in this experimental setting are not 
capable of a response in  the form of AKT phosphorylation. Due to that fact, it was 
not surprising that the two utilized CXCR7 agonists also did not elicit an induction 
of AKT phosphorylation.  
Hao et al. decided on a slightly different approach to investigating the involvement 
of CXCR7 in signalling through PI3K/AKT and ERK1/2. They did not induce 
CXCR7 signalling directly, but instead they pre-incubated aortic endothelial cells 
with IL-1β, which increased CXCR7 mRNA levels. Incubation with IL-1β  also 
mimics what happens after myocardial infarction in vivo, when IL-1β signalling is 
known to be active 335. After, they used CXCR7-specific inhibitors to show that 
lack of CXCR7 signalling reduces phosphorylation of ERK1/2 and AKT. Since 
their study differs greatly from the one we performed, we cannot directly compare 
to our results; however, they show that CXCR7-dependent signalling through 
RISK pathway in endothelial cells does occur, at least in the presence of IL-1β. 
The length of incubation with CXCR7 agonists, might also be important, since it 
is possible that a longer duration of receptor stimulation is needed to achieve β-
arrestin-dependent signalling through CXCR7. Such intricacies of CXCR7 
signalling are not well explored and based on available studies we cannot form a 
complete picture of what happens when a CXCR7 agonist binds to its receptor, 
or the exact impact that signal duration or concentration might exert on the 
CXCR4 and CXCR7 receptor signalling.  
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Recently, Gutkind and Kostenis, published an interesting short paper proposing 
that β-arrestins act as rheostats, modulating G protein-dependent signalling, but 
requiring G proteins for signalling through ERK1/2 336. In a classical model of G 
protein signalling, G proteins and β-arrestins compete for binding to the receptor, 
with G proteins initiating signalling and β-arrestins desensitizing the receptor by 
outcompeting the G proteins through steric hindrance. Gutkind and Kostenis 
present a plausible alternative hypothesis, which could help explain why CXCR7 
stimulation is able to induce ERK1/2 signalling in some cases but not others 336. 
They note that β-arrestins  can be recruited to receptors without any detectable G 
protein activity, although this does not lead to successful ERK1/2 phosphorylation 
336. Perhaps something similar occurs with CXCR7-specific agonists, which are 
only able to signal through β-arrestin-biased CXCR7 receptor but fail to activate 
the G protein coupled CXCR4 receptors. To date, no studies explored the 
possibility of a similar connection between G proteins and arrestin-biased ligands 
in PI3K/AKT signalling; therefore, we cannot comment on the possibility of similar 
action occurring during AKT phosphorylation. 
There is not a lot of published research investigating SDF-1α-dependent RISK 
pathway activation specifically in endothelial cells. However, RISK pathway, 
which includes activation of ERK1/2 MAPK kinase or PI3K/AKT pathway 
underpins many known acute cardioprotective interventions. Therefore, 
identifying whether CXCR7 agonists can elicit signalling through the RISK 
pathway can provide the first step towards identifying any acute cardioprotective 
effects the agonists might exhibit. We confirmed that SDF-1α is capable of 
inducing ERK1/2 phosphorylation response in endothelial cells; however, it was 
not able to elicit the same response in terms of AKT phosphorylation. Most 
importantly, neither CXCR7 agonist was able to induce phosphorylation of either 
ERK1/2 or AKT. This means that the ERK1/2 phosphorylation response seen with 
SDF-1α administration is more likely to come from interaction of SDF-1α and 
CXCR4, rather than SDF-1α and CXCR7 receptor. Based on work done by Hao 
et al. it seems that an initial stimuli, such as pro-inflammatory IL-1β, might need 
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to preclude CXCR7 signalling in order to initiate ERK1/2 and/or AKT 
phosphorylation. This might mean that basal state HUVEC, or indeed other 
endothelial cells, are not capable of RISK signalling response, which would need 
to be considered in further experimental approaches. Further work could therefore 
examine RISK signalling in endothelial cells that have undergone I/R injury, such 
as those, which could potentially be harvested from hearts undergoing a murine 
ex vivo heart perfusion experiment.  
 Summary 
Positive controls insulin and bradykinin were able to successfully induce 
phosphorylation of AKT and ERK1/2 in HUVEC, respectively. While the increase 
in ERK1/2 phosphorylation in response to SDF-1α treatment was significant only 
in one of two experimental sets, it was again confirmed in the experimental set 
using pooled data from both sets of experiments. SDF-1α did not induce 
phosphorylation of AKT in either VUF11207 or TC14012 experimental set, nor 
when both data sets were pooled. Administration of CXCR7 agonists VUF11207 
and TC14012 for various lengths of time also did not affect the phosphorylation 
status of either AKT or ERK1/2. All in all, VUF11207 and TC14012 were not able 
to initiate CXCR7-dependent RISK pathway signalling in HUVEC, under chosen 
experimental conditions. Further investigation is needed to confirm whether this 
occurred because CXCR7 does not signal through the RISK signalling pathway, 
or whether an adjustment of experimental conditions is needed to confirm 




6 Unsuccessful endothelial-specific inducible Cxcr7 gene 
deletion with Pdgfb-CreERT2 in adult mice 
6.1 Background 
The ability to manipulate DNA sequence of an organism is an extremely valuable 
investigative tool in the arsenal of a scientist. Arguably the most famous 
mechanism for precision gene manipulation is the Cre-lox system, using a 
topoisomerase enzyme, Cre recombinase, which enables assessment of the 
importance of a specific gene by using in vivo genetic manipulation 337. The 
Fruttiger group generated a Pdgfb-Cre construct, which is widely used by 
researchers and reportedly exhibits activity in aortic and capillary endothelial cells, 
with some non-endothelial cell activity recorded in keratinocytes and 
megakaryocytes 243, 338. Platelet-derived growth factor beta (Pdgfb) plays an 
essential role in migration and proliferation of vascular smooth muscle cells, 
promotes differentiation of endothelial cells and participates in wound healing 
through recruitment of various cell types to the site of injury 339-341.  
Fruttiger’s group  utilized the Pdgfb promoter in tandem with iCreERT2, which is 
the improved, second generation CreER, efficient in initiating Cre recombination, 
and is currently the most successful version of Cre available 342. Pdgfb-Cre line 
provided by the Fruttiger group has been previously successfully utilized to 
generate adult transgenic mice with endothelial-specific labelling of enhanced 
yellow fluorescent protein (EYFP), and was therefore deemed an appropriate line 
to use for our experiments 343.  
In order to generate endothelial-specific transgenic mice we used Pdgfb-CreERT2 
construct obtained from the Fruttiger group and Ackr3tm1Twb flox/+ obtained from the 




6.2 Research aims and objectives 
Generate mice with inducible, endothelial-specific CXCR7 deletion: 
- Characterize the mouse model by investigating endothelial CXCR7 RNA 
and protein content. 
 
- Examine whether the mice exhibit the loss of endothelial CXCR7 protein. 
6.3 Methods 
In addition to the general methods described in Chapter 2, the following specific 
methods were used in the experiments described in this chapter. 
 Transgenic animals 
Cxcr7iΔEC = Cxcr7flox/flox Cre +/- injected with Tamoxifen 
Cxcr7WT = Cxcr7flox/flox Cre+/+ 
Transgenic mice were generated as described in section 2.2. Experiments with 
Cxcr7iΔEC mice, were performed 3 weeks after the last tamoxifen injection. 
Cxcr7WT mice did not receive any injections.  
 Western blotting 
The expression of CXCR7 was investigated in HUVEC, using western blotting 
methods described in section 2.5. Membranes were incubated with anti-CXCR7 
rabbit monoclonal antibody (1:1000, ab138509, Abcam). Anti-GAPDH mouse 
monoclonal antibody (1:2000, ab8245, Abcam) was used as a loading control.  
IRDye® 800CW goat anti-rabbit IgG (1:10,000, Li-COR), or IRDye® 680RD Goat 




 WES western blotting 
The expression of CXCR7 was investigated on isolated mouse cardiac endothelial 
cells using WES western blotting method as described in section 2.5.4. Anti-
CXCR7 rabbit monoclonal primary antibody (1:20, ab138509, Abcam) and anti-
VDAC1 rabbit monoclonal antibody (1:50, ab154856, Abcam) were used in 
conjunction with rabbit antibody detection kit (ProteinSimple). 
 RNAscope in situ hybridization 
RNAscope in situ hybridization experiment on whole mouse heart slices was 
performed as described in section 2.8. Cxcr7iΔEC mice used for RNAscope in situ 
hybridization were injected with 100 µL of 15 mg/mL tamoxifen for 3 consecutive 
days as described in section 2.2.5. Images of background staining for this 
experiment can be seen in Figure 3-2.  
 Quantitative real-time PCR  
RNA extraction and quantitative real-time PCR were performed on aortas from 
male and female mice aged 8-12 weeks, as described in section 2.12.  
6.4 Results 
To examine whether endothelial-specific deletion of CXCR7 in mice was 
successful, several different experimental procedures were utilized. Firstly, 
western blotting was used to compare CXCR7 protein levels in whole mouse 
hearts between Cxcr7WT mice and genetically modified, tamoxifen injected 
Cxcr7iΔEC mice.  
Tamoxifen administration was performed over 2 consecutive days, starting with 
100 µL of 15 mg/mL of tamoxifen (2 mg/animal total) for 2 consecutive days, which 
did not affect CXCR7 protein levels in whole mouse hearts (Figure 6-1). Since the 
initial dose of tamoxifen was relatively low, the dose was increased for the 





Figure 6-1: CXCR7 western blotting on Cxcr7WT and Cxcr7iΔEC whole mouse hearts. Cxcr7iΔEC 
mice were injected with 100 µL of 15 mg/mL tamoxifen for 2 days (2 mg/animal total) to produce 
knockout mice. Wild type (Cxcr7WT) mice received no injections. There was no significant 
difference between the CXCR7 protein levels of Cxcr7iΔEC and Cxcr7WT mice. GAPDH was used 
as a loading control. Student’s t-test, n = an individual mouse heart. KO = Cxcr7iΔEC, WT = Cxcr7WT, 




Figure 6-2: CXCR7 western blotting on Cxcr7WT and Cxcr7iΔEC whole mouse hearts. Cxcr7iΔEC 
mice were injected with 100 µL of 15 mg/ml tamoxifen for 3 days (4.5 mg/animal total) to produce 
knockout mice. Wild type (Cxcr7WT) mice received no injections. There was no significant 
difference between the CXCR7 protein levels of Cxcr7iΔEC and Cxcr7WT mice. GAPDH was used 
as a loading control. Student’s t-test, n = an individual mouse heart. KO = Cxcr7iΔEC, WT = Cxcr7WT, 
ns = non-significant. 
Administration of 100 µL of 15 mg/mL tamoxifen (4.5 mg/animal total) for 3 
consecutive days did not have a significant effect on CXCR7 protein levels in the 
whole mouse heart (Figure 6-2). The dose of tamoxifen was again increased to 
100 µL of 20 mg/mL (6mg/animal total) and injected for 3 consecutive days. 
Following western blotting, CXCR7 levels in the whole mouse hearts were 
observed to be unchanged between the Cxcr7WT and Cxcr7iΔEC mice (Figure 6-3). 
The bulk of the protein in whole mouse heart lysates comes from cardiomyocytes, 
which are large cells, in addition to vascular smooth muscle cells, fibroblasts and 
endothelial cells etc. It is possible that all of those cell types express CXCR7, 





Figure 6-3: CXCR7 western blotting on Cxcr7WT and Cxcr7iΔEC whole mouse hearts. Cxcr7iΔEC 
mice were injected with 100 µL of 20 mg/ml tamoxifen for 3 days (6 mg/animal total) to produce 
knockout mice. Wild type (Cxcr7WT) mice received no injections. There was no significant 
difference between the CXCR7 protein levels of Cxcr7iΔEC and Cxcr7WT mice. GAPDH was used 
as a loading control. Student’s t-test, n = an individual mouse heart. KO = Cxcr7iΔEC, WT = Cxcr7WT, 
ns = non-significant. 
Because it is challenging to isolate sufficient quantities of endothelial cells for 
standard western blotting, the WES automated western blotting system was used. 
In this system the samples are run and probed on small capillaries, allowing 
detection of bands using very small (~1 µg) quantities of protein. To determine 
whether CXCR7 protein was absent in mouse endothelial cells, WES automated 
blotting system was performed on isolated cardiac mouse endothelial cells, as 
previously described in section 2.5.4. This revealed no significant differences 
between the CXCR7 protein levels of Cxcr7WT and Cxcr7iΔEC groups (Figure 6-4).  
It was still challenging to obtain enough endothelial cells for robust analysis of 
CXCR7. CXCR7 should be deleted in all endothelial cells, not just in the heart; 
therefore, thoracic aortas were used to further examine whether endothelial 
CXCR7 deletion was successful.   
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Aortic tissue contains a higher ratio of endothelial cells to other cell types present 
in the tissue and should therefore provide a clearer picture of CXCR7 presence 
in endothelial cells 344. Since investigation of CXCR7 protein levels revealed no 
differences between Cxcr7WT and Cxcr7iΔEC animals, CXCR7 RNA levels were 
also examined. 
RT-qPCR for CXCR7 on Cxcr7WT and Cxcr7iΔEC mouse thoracic aortas did not 
reveal significant differences between the two groups based on their ΔCt values, 
where the smaller ΔCt denotes a higher CXCR7 RNA content (Figure 6-5). This 
translated into the 0.77-fold difference, which was not significant.  
Aortas contain cells other than those of endothelial origin, which can impede the 
investigation of endothelial-specific CXCR7 gene deletion 344. Therefore, 
RNAscope in situ hybridization was used to specifically and directly investigate 
endothelial-specific expression of CXCR7 RNA in whole mouse heart slices. 
Cxcr7WT tissues stained with CXCR7 RNA probe revealed CXCR7 RNA dots 
(white arrows) in IB4-delinated endothelial cells (Figure 6-6, upper panel). 
Interestingly, CXCR7 expression was mainly observed in endothelial cells, with 
lower levels of expression also present in other cell types (e.g. cardiomyocytes). 
Unfortunately, Cxcr7iΔEC tissues also revealed the presence of CXCR7 RNA dots 
in endothelial cells (yellow arrows), pointing to incomplete or unsuccessful 




Figure 6-4: WES western blotting for CXCR7 on isolated mouse cardiac endothelial cells. 
Cxcr7iΔEC animals were injected with 100 µL of 15 mg/mL tamoxifen (4.5 mg/animal total) for 3 
consecutive days to produce knockout animals. Despite some variability, there was no significant 
difference between the CXCR7 protein levels of Cxcr7iΔEC and Cxcr7WT mice. VDAC1 was used 
as a loading control. Note that in the WES automated blotting system, the protein samples run on 
individual capillaries, thus the position of the band can vary between “lanes”. Student’s t-test, n = 





Figure 6-5: Quantitative real-time PCR for CXCR7 in mouse aortic tissue.  Cxcr7iΔEC animals 
were injected with 100 µL of 15 mg/mL of tamoxifen for 3 consecutive days (4.5 mg total) to 
produce knockout animals. There was no significant difference detected in CXCR7 RNA content 
between the Cxcr7WT and Cxcr7iΔEC mice. Gapdh and Hprt were used as housekeeping controls. 





Figure 6-6: CXCR7 mRNA expression in Cxcr7WT and Cxcr7iΔEC mouse whole heart slices. 
Cxcr7iΔEC animals were injected with 100 µL of 15 mg/mL tamoxifen (4.5 mg/animal total) for 3 
consecutive days to produce knockout mice (Cxcr7iΔEC). CXCR7 mRNA (green dots) is present in 
endothelial cells in wildtype (Cxcr7WT, white arrows) and knockout (yellow arrows) adult mouse 
hearts as detected by RNAscope in situ hybridization. IB4 (red) was used to label endothelial cells 
and DAPI (blue) depicts cellular nuclei. Left and right panels show alternative regions of the same 




The overall strategy behind the Cre-lox system is to employ site-specific 
recombination, which allows for genetic deletion of the target gene or sequence. 
It is a robust system, and successful recombination depends on both the Cre 
recombinase and the loxP sites performing their intended function. However, if 
the function of either element is impaired, it will result in incomplete or 
unsuccessful manipulation of the target gene.  
After breeding several generations of CXCR7iΔEC mice, we did not observe 
endothelial-specific CXCR7 deletion using several different techniques. Western 
blotting examination revealed unchanged levels of CXCR7 protein when 
comparing Cxcr7WT and Cxcr7iΔEC animals. Similarly, RT-qPCR and RNAscope in 
situ hybridization showed that CXCR7 mRNA was still present in endothelial cells 
of Cxcr7iΔEC animals.  
Western blotting of whole mouse heart tissue showed no changes between 
CXCR7 protein expression in Cxcr7WT and Cxcr7iΔEC mice. The initial dose of 
tamoxifen was set at 2 mg per animal total, as it is desirable to use the lowest 
dose of tamoxifen possible, due to its potential toxic side effects at higher doses 
345. Since this comparatively low dose of tamoxifen could have been the reason 
why CXCR7 protein levels persisted unchanged, tamoxifen dose was 
subsequently increased to 4.5 mg per animal total. Since this dose of tamoxifen 
also had no effect on the CXCR7 protein levels it was again raised to 6 mg of 
tamoxifen total. However, this also had no effect on the CXCR7 protein levels, 
which were not significantly different between Cxcr7WT and Cxcr7iΔEC animals. 
The dose of tamoxifen required for a successful initiation of Cre-mediated gene 
deletion via i.p. injection was derived from previously conducted experiments in 
our own lab and from published literature using the same strain of Pdgfb-CreERT2 
mice in which the target gene had been successfully deleted 343, 346.  
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Therefore, it is unlikely that a low concentration of tamoxifen is the reason for 
unsuccessful Cre recombination, and subsequently reduction of endothelial 
CXCR7 protein levels. Additionally, the i.p. route of tamoxifen dosing is a well-
established and commonly used route and is unlikely that choosing this particular 
method over a different administration technique (e.g. oral gavage) played a part 
in the failure to achieve endothelial CXCR7 protein deletion. 
Despite being a great tool to initiate Cre recombination, tamoxifen can be toxic, 
especially with repeat administration or in high doses. The toxicity exhibited by 
tamoxifen is seen in both sexes, and with both, oral and i.p. administration. We 
observed an approx. 10% mortality rate, which was not affected by the number of 
days of tamoxifen injections, although the highest tamoxifen dose of 20 mg/mL (6 
mg per animal total) did exhibit a larger mortality rate of approx. 15% and was 
therefore not utilized beyond the initial experiments.  
Huh et al. showed that tamoxifen toxicity (5 mg tamoxifen/ 20 mg body weight, 3 
consecutive days) can be abolished by proton pump inhibition with omeprazole, 
which points at modulated acid secretion as the likely contributor to tamoxifen-
associated toxicity 347. Jahn et al. reports tamoxifen-associated mortality as 3.7% 
for 3 consecutive days of injection; however, the skill of the handler is also known 
to affect the mortality rate 345. Furthermore, mortality rate of tamoxifen, although 
known, is often not reported which precludes us from making a more informed 
observation on whether our mortality rate was abnormal compared to that seen 
by others. There is a small possibility that tamoxifen at sufficiently high dose to 
activate Cre recombinase (6 mg/animal total) killed the mice, while in surviving 
mice and those with lower level of injected tamoxifen Cre was not induced and 
therefore CXCR7 loss could not be detected. Similarly, if endothelial CXCR7 
deletion in adults is lethal, then the surviving mice would not exhibit detectable 
CXCR7 loss. However, both of these possibilities are unlikely to have occurred in 
our transgenic model.  
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It is also important to note that whole mouse heart tissue contains cells of non-
endothelial origin that express CXCR7, which could hinder detection of CXCR7 
protein changes on the endothelial level. For example, CXCR7 mRNA was found 
to be expressed in human fibroblasts, and CXCR7 protein and mRNA were 
detected in rat vascular smooth muscle cells 123, 267. Further, CXCR7 mRNA was 
also shown to be expressed in mouse cardiomyocytes, as previously shown by 
us in section 3.4. and elsewhere 148. The cumulative CXCR7 protein content of 
these non-endothelial cells could have obstructed detection of endothelial-specific 
CXCR7 changes, which means that it might be difficult to detect deletion of 
endothelial CXCR7 on the level of whole mouse heart.    
For that reason, CXCR7 protein content was also assessed in isolated endothelial 
cells via WES western blotting method, which enables detection of protein level 
changes even in small protein samples. WES did not reveal any significant 
differences between the CXCR7 protein levels of Cxcr7WT and Cxcr7iΔEC mice. 
Despite a low sample size of Cxcr7iΔEC cells (n=2) , the observed standard error 
in both, Cxcr7WT and Cxcr7iΔEC mice, were such that altering the n number would 
perhaps have an effect on the statistical outcome of the experiment; however, we 
chose to examine endothelial CXCR7 expression with other methods (e.g. qPCR). 
Combined, western blotting experiments in whole mouse heart tissue and isolated 
endothelial cells point to unsuccessful deletion of endothelial CXCR7 gene. 
Since protein content in endothelial cells persisted unchanged despite increasing 
the concentrations of tamoxifen, I examined more directly if CXCR7 mRNA was 
still present after tamoxifen administration. Ideally, isolated endothelial cells would 
have been used for this experiment; however, obtaining samples of isolated cells 
that were suitable for a successful qPCR experiment was challenging. Instead, 
thoracic aorta tissue was used to assess cellular mRNA levels.  
Again, there was no difference observed between Cxcr7WT and Cxcr7iΔEC animals. 
However, like whole mouse heart tissue, aortic tissue also contains non-
endothelial cell types, which could obstruct determination of endothelial-specific 
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CXCR7 deletion. For example, vascular smooth muscle cells that make up a large 
portion of aortic vessel wall, and fibroblasts, which can be found in the outer layer 
of the aortic vessel wall, both express CXCR7 123, 267. RNAscope in situ 
hybridization in combination with IB4 labelling was used to determine the 
presence of CXCR7 mRNA specifically in endothelial cells. Unsurprisingly, there 
was no difference between the Cxcr7WT and Cxcr7iΔEC mice, with both displaying 
CXCR7 mRNA dots in endothelial cells positively labelled with IB4. Interestingly, 
expression was mostly localized within EC suggesting that previous western 
blotting experiments should have been able to detect any reduction in CXCR7 
expression if it had been decreased.  
Cxcr7WT and Cxcr7iΔEC animals consistently displayed comparable levels of 
CXCR7 on protein and mRNA level, an indication of an unsuccessful CXCR7 
gene excision/deletion. In summary, a combination of experiments investigating 
endothelial CXCR7 protein and mRNA changes showed that target gene deletion 
had not occurred, and endothelial cells continued to express CXCR7 protein. This 
could have occurred due to a variety of reasons. For example, the parent-of-origin 
effect, whereby the sex of the parent with a specific allele can have an effect on 
the expression of that gene, is known to occur in certain Cre driver lines 348, 349.  
Additionally, Gallardo et al. and Hayashi et al. reported maternal Cre excision 
patterns that were different than those inherited paternally, for their respective Cre 
driver lines 350, 351. Seeing as a functioning Cre recombinase is crucial for target 
gene deletion, any modification in expression of Cre recombinase could result in 
unsuccessful deletion of endothelial CXCR7 in our mouse model. This could have 
been verified by experiments to measure expression levels of Cre. 
 
Other recombination anomalies, such as mosaic or inconsistent gene deletion and 
deletion in off-target tissues are also known to occur 352-354. Additionally, Cre gene 
expression inconsistency between littermates is also possible, and variability in 
Cre expression has been shown in certain endothelial and haematopoietic Cre 
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driver lines 349, 355. These gene expression anomalies can be difficult to detect, 
and such knowledge can become anecdotally known in specific labs, but it is 
rarely followed by a detailed characterization of a Cre driver line and is not 
commonly disseminated to a wider audience.  
Cre protein is expressed and present in the cell cytoplasm until after the injection 
of tamoxifen, when it translocates into the nucleus and initiates Cre recombination 
at the loxP sites 342. This attribute of Cre recombinase would enable us to check 
whether endothelial cells are the ones expressing Cre by using an anti-Cre 
antibody via a technique such as western blotting or immunohistochemistry. 
However, we know from personal correspondence with Kirsty Naylor and Prof. 
Christiana Ruhrberg (University College London, UK) that this particular Cre is 
indeed expressed in endothelial cells obtained from Cre transgenic mice. 
Furthermore, the Cre construct used in our experiments contains an EGFP 
element, which can also be used to assess the expression of Cre in target tissues. 
If EGFP can be detected in endothelial tissue of Cre-positive mice, then Cre 
recombinase is expressed in those tissues. Furthermore, to determine whether 
successful Cre recombination has taken place in target tissues, mice can be 
injected with tamoxifen and their target tissue genotyped for the presence of the 
recombined allele.  
Experiments described above would inform us on whether Cre was successfully 
expressed in target tissues and the ability of said Cre recombinase to initiate loxP 
site recombination in those tissues. Additionally, we could have also utilized 
primers to distinguish a recombined (knockout) vs floxed allele, which would 
reveal directly whether Cxcr7 has been successfully excised in target tissues.  
We would achieve that by designing primers that bind upstream and downstream 
of respective loxP sites surrounding exon 2 of the Cxcr7 gene. This would mean 
that when running a PCR, a floxed allele would produce a larger product and a 
recombined allele a shorter product, since the exon 2 of Cxcr7 would no longer 
be present in the target tissue of the mouse with a successfully recombined allele, 
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providing us with a clear-cut way to investigate whether our target sequence was 
successfully excised. 
Mouse lines that were inbred for a significant number of generations over a long 
period of time can also accumulate mutations, leading to genetic drift 356.  Genetic 
drift refers to spontaneous changes occurring in genomic DNA, and can have an 
effect on the mouse phenotype 356.  The mice used in our experiments were not 
an inbred strain, which decreased the probability of genetic drift. Inbred mice are 
brother-sister mated for more than 20 generations and a small, spontaneous DNA 
mutation can have a significant impact on their genetic makeup, due to their 
genetic uniformity 356. Mice that are not inbred or are regularly backcrossed  to a 
relevant genetic background accumulate genetic changes at a slower rate and 
are not as susceptible to the occurrence of spontaneous DNA mutations 357. 
Nevertheless, there is still a possibility that a critical mutation could have occurred 
in this time period. For example, in the event that the mutation was at or near a 
loxP site, the ability to excise the CXCR7 exon flanked by loxP sites could be lost. 
It could have been interesting to perform genomic sequencing on genetic material 
obtained from colony founders and later generations of mice to investigate if such 
mutations have indeed occurred.  
Moreover, the distance between loxP sites can also have an impact on the 
success rate of Cre recombination, since the longer the distance the more difficult 
the DNA sequence can be to recombine 358. However, the loxP sites in our mice 
were <1000 bp apart (as confirmed by PCR), which is far shorter than the >20,000 
bp sequences that have previously been reported as challenging to recombine 
359.   
Most papers report favorable recombination efficiency with a comparable distance 
between loxP sites and it seems unlikely for this to be the reason why endothelial 
CXCR7 gene expression persisted in our transgenic mouse model 360. 
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Ultimately, the most likely reason for unsuccessful deletion of CXCR7 gene in 
endothelial cells rests with the actual Pdgfb-Cre driver line itself. Pdgfb is known 
to exhibit the highest level of expression in the endothelial tip cells, which lead 
sprouting vessels during development, while stalk cells, which form most of the 
trunk of the sprouting vessel, are known to express less 361. Consequently, using 
the Pdgfb-Cre driver will result in different subpopulations of endothelial cells (e.g. 
stalk cells) exhibiting varying levels of Cre recombinase activity.  
Furthermore, Claxton et al. report that in these mice certain large vessels such as 
the dorsal aorta do not exhibit Cre recombinase activity at P1 243. Since dorsal 
aorta later develops into parts of descending aorta, it is possible that this lack of 
Cre activity affects a large portion of mouse aorta (used in our characterization 
experiments), which would prevent CXCR7 gene deletion in the vessel from 
occurring 243. It is also important to note that most of their model characterization 
was performed on pups with the majority of focused placed on endothelial cells 
found within developing vessels. Additionally, when Cre recombination was 
induced in the retinal plexus of an adult animal as opposed to a pup, 
recombination was seen to occur only in a small subpopulation of cells 243. It is 
possible that this extends beyond the retina to other vascular beds, which would 
make Pdgfb unsuitable as an endothelial Cre driver line in adult mice and more 
suitable for investigating endothelial cells during blood vessel development. 
However, in my experiments, expression of Cre was not investigated, and 
therefore it is not known whether Cre was actively expressed in target tissues. 
The hypothesis that Pdgfb-Cre is more suitable to use in pups could have been 
tested by investigating CXCR7 endothelial-cell deletion in adults and pups 
injected with tamoxifen.  
If pups injected with tamoxifen displayed successful deletion of CXCR7 in a large 
population of endothelial cells, but not adult mice, then it is likely that age of mouse 
at tamoxifen injection is important for successful deletion of CXCR7 in endothelial 
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cells. Further work is needed to validate these hypotheses, and asses the 
suitability of Pdgfb-Cre in adult inducible transgenic mouse models.  
Therefore, for researchers hoping to use an endothelial-specific Cre driver line for 
generating adult transgenic mice, I would recommend one of the well-researched 
vascular cadherin 5 (Chd5) Cre driver lines, since Chd5 is expressed in all 
endothelial cells, and its Cre constructs exhibit good rates of recombination 338. 
 Summary 
Western blotting, qPCR and RNAscope in situ hybridization revealed that CXCR7 
protein and mRNA levels continued to be detected in endothelial cells of the heart 
and aorta of Cxcr7iΔEC animals. Expression of CXCR7 mRNA and protein in 
Cxcr7iΔEC cells was quite robust and comparable to the levels observed in Cxcr7WT 
mice. It is therefore possible that endothelial-specific CXCR7 gene deletion was 
unsuccessful. Based on the paper by Claxton et al., the Cre recombination activity 
of Pdgfb-Cre line is far superior in neonatal mice, while Cre recombination activity, 
when induced in adult mice is poor and limited to a small subpopulation of cells 
243. Therefore, an alternative Cre driver line (e.g. Chd5) should be considered for 
future transgenic models with endothelial-specific inducible CXCR7 deletion in 




7 Examining the effect of VUF11207 and TC14012 on 
endothelial cell migration 
This chapter contains work that was carried out in collaboration with Kaloyan 
Takov, who provided two experimental repeats for Figure 7-4. 
7.1 Background 
Angiogenesis is a crucial physiological process, which enables formation of new 
vessels from pre-existing vasculature and is described in more detail in section 
1.2.2 362. Along with its role in vascular development, angiogenesis is also 
involved in many pathological processes, such as diabetic retinopathy and wound 
healing 363, 364. It consists of different stages of vessel formation, one of which is 
cell migration. However, angiogenesis as a whole, and specifically cell migration 
require a trigger, which can be either mechanical, chemical or in the form of an 
immobilized ligand 62-67.  
 
SDF-1α has previously been shown as a pro-angiogenic factor capable of 
stimulating endothelial cell migration 62, 365. However, there is limited data 
available regarding CXCR7-dependent cell migration since most studies either 
focused on the CXCR4 receptor or did not differentiate between the two 366, 367. 
Therefore, we wanted to examine the role of CXCR7 in endothelial cell migration 
in vitro, for which CXCR7 agonist TC14012 and VUF11207 were used in a 
multiwell Boyden chamber assay. CXCR7 agonists used for cell migration 
experiments were previously described in detail in section 1.3.3. 
 
7.2 Research aims and objectives 
Investigate the effects of CXCR7 agonists on HUVEC migration: 
- Examine the effects of CXCR7 agonists, VUF11207 and TC14012 on 




In addition to the general methods described in Chapter 2, the following specific 
methods were used in the experiments described in this chapter. 
 Cell culture 
HUVEC were cultured as previously described in section 2.3. Prior to the 
experiment, HUVEC were serum-starved for 3 h with DMEM medium (Gibco) 
supplemented with penicillin/streptomycin (Gibco). HUVEC were used in the 
experiment between passages 5-8. 
 Cell treatments with VUF11207 and TC14012 
HUVEC were cultured as described in section 2.10. At the beginning of the 
experiment VUF11207 (100 nM, 1 µM, 30 µM), SDF-1α (100 nM), TC14012 (1 
µM, 10 µM, 30 µM), TC14012 (1 µM) + SDF-1α (100 nM), PBS alone or 10% FBS 
diluted in PBS were added to the migration chamber for the duration of the 
experiment. For experimental sets containing TC14012, DMSO (<0.05% final 
conc.) was added to all treatments. All individual migration experiments were 
normalized to 10% FBS.  
 Cell migration analysis 
After the conclusion of the experiment, blots were stained with 0.5% crystal violet 
as described in section 2.10 and visualized with LiDE 210 Canon scanner. Each 






To investigate whether CXCR7 agonists, VUF11207 and TC14012 stimulate 
migration of HUVEC, a series of cell migration experiments were performed. As 
shown in Figure 7-1, administration of SDF-1α (100 nM) or VUF11207 at various 
concentrations did not significantly increase cell migration after a 6 h migration 
experiment in HUVEC.   
Based on previously published data and observed lower variation in cell response, 
the duration of cell migration was shortened to 3 h and the above experiment 
repeated 368, 369. As seen in Figure 7-2, SDF-1α (100 nM), but not VUF11207 (100 
nM – 30 µM), significantly increased HUVEC cell migration compared to control 
(SDF-1α vs ctrl = 79.1 ± 13.3 % vs 45.6 ± 7.6 %, p < 0.01). However, no effects 






Figure 7-1:  The effect of VUF11207 on 6 h cell migration in HUVEC. Cells were treated with 
SDF-1α or VUF11207 at the beginning of the experiment and allowed to undergo cell migration 
for 6 h. None of the treatments significantly increased cell migration compared to control. A.) 
Representative image of cell migration membrane stained with 0.5% crystal violet. VUF11207 is 
listed only as respective concentrations. B.) Quantification of cell migration. Results were 
normalized to 10% FBS. One-way ANOVA with Dunnet’s post-hoc test with all groups compared 






Figure 7-2: The effect of VUF11207 on 3 h cell migration in HUVEC. Cells were treated with 
SDF-1α or VUF11207 at the beginning of the experiment and allowed to undergo cell migration 
for 3 h. Administration of SDF-1α (100 nM) significantly increased cell migration compared to 
control. A.) Representative image of cell migration membrane stained with 0.5% crystal violet. 
VUF11207 is listed only as respective concentrations. B.) Quantification of cell migration. Results 
were normalized to 10% FBS. ** p < 0.01 SDF-1α 100 nM vs ctrl, One-way ANOVA with Dunnet’s 




Figure 7-3: The effect of TC14012 on cell migration in HUVEC. Cells were treated with SDF-
1α or TC14012 at the beginning of the experiment and allowed to undergo cell migration for 3 h. 
Administration of SDF-1α (100 nM) or TC141012 (1 µM) significantly increased cell migration 
compared to control. A.) Representative image of cell migration membrane stained with 0.5% 
crystal violet. TC14012 is listed only as respective concentrations. B.) Quantification of cell 
migration. Results were normalized to 10% FBS. * p < 0.05 SDF-1α 100 nM vs ctrl, TC14012 1 
µM vs ctrl, One-way ANOVA with Dunnet’s post-hoc test with all groups compared to control; n = 




In order to confirm the above experiments, an alternative CXCR7 agonist, 
TC14012, was tested in a new set of experiments using 3 h cell migration. Here, 
SDF-1α (100 nM) significantly increased HUVEC migration (Figure 7-3) compared 
to control, as expected (SDF-1α vs ctrl = 74.7 ± 14.9 % vs 36.3 ± 6.1 %, p < 0.05). 
Similarly, administration of TC14012 (1 µM) resulted in a significant increase in 
HUVEC migration, compared to control (TC14012 vs ctrl = 78.4 ± 17.0 % vs 36.3 
± 6.1 p < 0.05). Higher concentrations of TC14012 (10 µM and 30 µM) had no 
effect on HUVEC migration. 
Since both TC14012 and SDF-1α exhibited pro-migratory effects, we wanted to 
test whether a combination of both drugs would further increase HUVEC migration 
compared to each drug administered alone (Figure 7-4). Co-incubation of SDF-
1α (100 nM) and TC14012 (1 µM) significantly increased HUVEC migration 
compared to control (SDF-1α + TC14012 vs ctrl = 109.5 ± 12.7 % vs 41.0 ± 5.8 
%, p < 0.01). The additive cell migration effect was also significant when 
compared to TC14012 (1 µM) administered alone (SDF-1α + TC14012 vs 
TC14012 = 109.5 ± 12.7 % vs 69.5 ± 8.5 %, p < 0.05), but not when compared to 
SDF-1α (100 nM) administered alone. In contrast, incubation of either SDF-1α 
(100 nM) or TC14012 (1 µM) alone did not significantly increase HUVEC migration 






Figure 7-4: The effect of TC14012 + SDF-1α on cell migration in HUVEC. Cells were treated 
with SDF-1α, TC14012 or a combination of both at the beginning of the experiment and allowed 
to undergo cell migration for 3 h. Administration of SDF-1α (100 nM) + TC14012 (1 µM) 
significantly increased cell migration compared to control. SDF-1α (100 nM) or TC14012 (1 µM) 
administered on their own did not significantly increase HUVEC migration compared to control. 
A.) Representative image of cell migration membrane stained with 0.5 % crystal violet. B.) 
Quantification of cell migration. Results were normalized to 10% FBS. ** p < 0.01 SDF-1α + 
TC14012 vs ctrl, # p < 0.05 SDF-1α + TC14012 vs TC14012, One-way ANOVA with Tukey’s post-




Figure 7-5: The effect of TC14012 and SDF-1α on cell migration in HUVEC - pooled data. 
Cells were either treated with SDF-1α (100 nM) or TC14012 (1 µM) at the beginning of the 
experiment and allowed to undergo cell migration for 3 h. Administration of either SDF-1α or 
TC14012 significantly increased cell migration compared to control. Data were pooled from 
experiments presented in Figure 7-3 and Figure 7-4. Results were normalized to 10% FBS. ** p < 
0.01 SDF-1α vs ctrl and TC14012 vs ctrl, One-way ANOVA with Tukey’s post-hoc test comparing 
all groups to each other; n = 12 individual migration experiments. 
Administration of neither SDF-1α, nor TC14012 was able to consistently generate 
a significant increase in HUVEC cell migration in previous experiments. 
Therefore, we pooled data from two experiments utilizing comparable 
methodology (Figure 7-3 and 7-4), in order to increase the n numbers and show 
more definitively whether SDF-1α (100 nM) or TC14012 (1 µM) are capable of 
inducing cell migration. Separate administration of either SDF-1α or TC14012 
significantly increased mean HUVEC cell migration when compared to control 
(SDF-1α vs ctrl = 74.6 ± 8.7 % vs 38.6 ± 4.7 %, p < 0.01; TC14012 vs ctrl = 73.9 
± 9.2 % vs 38.6 ± 4.7 %, p < 0.01). Based on the pooled data, both SDF-1α and 




Following the discovery of CXCR7 as an alternative receptor for SDF-1α, it was 
postulated that, like CXCR4, it plays an important role in a variety of physiological 
processes. Since SDF-1α is a known chemotactic factor, which participates in 
vessel regeneration, tumour cell migration, and homing of HSC and other stem 
cell types, a clear hypothesis was that CXCR7 is also involved in some, if not all 
of these processes 370-373. With increased interest in the CXCR7 receptor, new 
agonists were developed, enabling investigation of the effects of CXCR7 separate 
from those of CXCR4 151, 153. Based on previous results indicating a role for 
CXCR7 in angiogenesis broadly, and cell migration specifically, we wanted to 
examine the role of CXCR7 in endothelial cell migration in an in vitro cell migration 
assay 366, 374.  
SDF-1α (100 nM) increased HUVEC migration after 3 h, but not after 6 h of 
incubation. CXCR7 agonist VUF11207 did not increase HUVEC migration at any 
concentration tested, while TC14012 significantly increased HUVEC migration at 
1 µM, but not at 10 or 30 µM. Pooling data from two separate experiments 
confirmed that both, SDF-1α and TC14012 increase HUVEC migration at 100 nM 
and 1 µM, respectively. As previously discussed in section 1.3.3.3 the 
concentration of both agonists used in the cell migration assay was based on their 
EC50 values and was expected to be sufficient to elicit a response.  
CXCR7 has been shown  to be involved in different aspects of angiogenesis of 
various types of endothelial cells and their progenitors 375. Deletion of CXCR7 in 
cardiac microvessels has been shown to impair the expression of pro-angiogenic 
growth factor HB-EGF (Heparin-binding EGF-like growth factor) 119, 222, 375. 
Furthermore,  Melo et al. described an essential role for CXCR7 in HSC cell 
migration after stimulation with SDF-1α and Essencay et al. reported pro-
migratory effects of SDF-1/CXCR7 axis in glioma cell migration 366, 367.  
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The majority of cell migration experiments were performed using a 3 h incubation 
protocol versus the 6 h migration protocol, due to the positive control (SDF-1α) 
exhibiting significantly increased cell migration only in the latter. One of the 
reasons for this might be unstable gradients in the cell migration chamber, created 
by fluid level imbalances 376. Such imbalances can be introduced into the 
experiment during the pipetting phase or during the placement of a liquid-porous 
membrane over the bottom half of the migration chamber. It is challenging to 
account for such errors due to difficulties with quantifying and controlling said 
gradients in a migrations chamber 376. Therefore, a 3 h incubation, which 
produced more reproducible and, therefore more reliable results was used for the 
remainder of cell migration experiments.  
Not all researchers agree that CXCR7 exhibits pro-migratory effects, Mazzinghi 
et al. reported that while CXCR7 is involved in  human renal EPC survival and 
adhesion to endothelium, it was CXCR4 that mediated cell migration 377. Similarly, 
Dai et al. reported that the migration of bone marrow-derived EPC was not 
affected by the administration of either CXCR4-blocking antibody or CXCR7 
inhibitor (CCX733) 374. Interestingly, of the two agonists tested, only TC14012 
significantly increased HUVEC migration in our study (Figure 7-3). This reflects 
the discrepancy observed in past studies, where there is little consensus over the 
existence of pro-migratory effects via CXCR7. The differences may also be 
related to the type of cell (EPC versus differentiated endothelial cell), and type of 
drug, (CXCR4 inhibitor vs CXCR7 agonist), that were seen to have an effect in 
the above experiments. After all, small molecules of different structures can have 
very different characteristics, including potential off-target effects. 
Past research indicates that VUF11207 and TC14012 exhibit high affinity to 
CXCR7 and/or strong β-arrestin recruitment abilities. 151, 153, 308. VUF11207 
displayed high affinity (pKi = 8.1) in a CXCR7 radioligand binding assay using 
radiolabelled SDF-1α 153. It also performed favourably in a β-arrestin2 recruitment 
assay, as discussed previously in section 1.3.3. 153. 
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TC14012, a CXCR4 inverse agonist, also exhibited good β-arrestin recruitment to 
CXCR7 using a BRET-based experimental system 151. The investigation of β-
arrestin recruitment to CXCR7 does not directly measure the specificity of 
VUF11207 and TC14012. Instead, it measures the ability of the agonist to initiate 
recruitment of β-arrestins, which is G-protein independent and limited to CXCR7. 
Additionally, measuring affinity does not directly measure specificity 378. However, 
it is often argued that high-affinity can be equaled to high-specificity, since 
selecting for high-affinity compounds should ensure highly specific binding 378. 
Therefore, selecting for high-affinity compounds based on functional binding 
assays coupled with sophisticated computer modelling experiments is considered 
a tried and tested approach of determining drug specificity 379. Nevertheless, there 
are very few studies and consequently limited data available on the affinity, 
specificity and potency of both drugs, especially in the case of VUF11207, which 
was not commercially available until recently 153.  
Levoye et al. reported that anti-CXCR7 antibody reduced SDF-1α-dependent 
migration at 30 nM, but not at 0.3 nM or 3 nM. They interpret these results as 
showing that CXCR7 acts as a modulator of migration by scavenging SDF-1α and 
thereby decreasing its activity on CXCR4 120. However, this interpretation does 
not agree with our results.  If that were the case then TC14012 would not be able 
to increase cell migration when administered alone, since it does not bind to or  
activate CXCR4. Therefore, it could be that CXCR7 acts as a modulator of 
CXCR4-dependent cell migration when both receptors are active, while also being 







We also wanted to examine the effect of both, SDF-1α and TC14012 combined 
on HUVEC migration. Co-administration of  SDF-1α (100 nM) and TC14012 (1 
µM) significantly increased cell migration of HUVEC, while in the same experiment 
either drug administered alone did not exhibit a significant increase in cell 
migration (Figure 7-4). Since SDF-1α and TC14012 were observed to significantly 
increase cell migration in previous experiments, increasing the number of repeats 
could increase the power of the experiment to detect a significant difference 
between the groups. Similarly, using an incubation time of more than 3 h might 
assist with analysis as the staining of migrated cell is clearer after a longer period 
of time; however, this can come at an expense of reproducibility/repeatability of 
results, as already discussed above. Interestingly, co-administration of SDF-1α 
and TC14012 also significantly increased cell migration, when compared to 
TC14012 (1 µM) alone.  
To overcome the inconsistent results obtained with SDF-1α (100 nM) and 
TC14012 (1 µM) data was pooled from two separate experiments with 
comparable experimental setup (Figure 7-5). Combining the two experiments 
provided a higher n number and therefore more statistical power. In turn, both 
compounds produced statistically significant increases in HUVEC migration when 
compared to control. Therefore, we confirmed that SDF-1α acts as a pro-
migratory molecule, as previously shown by others 222, 380, 381. Since we did not 
differentiate between the CXCR4 and CXCR7 receptor involvement we cannot 
comment on whether pro-migratory signalling in this instance proceeds through 
either one single receptor or perhaps through both. On the other hand, 
administration of CXCR7 agonist TC14012 also resulted in HUVEC migration 
increase in our pooled data. Since TC14012 is not reported to show any signalling 
through CXCR4 it can be presumed that this pro-migratory effect proceeds 
entirely via the CXCR7 receptor. This is particularly interesting since CXCR7 has 
not been shown previously as actively involved in cell migration in HUVEC.  
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Instead it has been presented as capable only of aiding in cell migration by 
scavenging excess SDF-1α entering the pro-migratory SDF-1α/CXCR4 signalling 
axis 141. However, our results show that TC14012 is capable of increasing 
endothelial cell migration through CXCR7, adding to the number of other pro-
angiogenic processes that the CXCR7 receptor has been shown to participate in 
112.  
Interestingly, co-administration of SDF-1α and TC14012 did not significantly 
increase cell migration when compared to SDF-1α alone. As described earlier, 
increasing the number of repeats and using a slightly longer incubation period 
could help solve this problem. Alternatively, the SDF-1α concentration used in 
HUVEC cell migration experiments might not elicit a maximal chemotactic 
response, which could help explain the low effect size observed. Nevertheless, 
the obtained results suggest that CXCR7 plays an active role in cell migration and 
there are two possible reasons how this occurs. 
In the event that SDF-1α at 100 nM does not elicit a maximal chemotactic 
response, be it through CXCR4 and/or CXCR7, addition of TC14012 further 
stimulates chemotactic signalling and consequently further increases the cell 
migration response. As previously stated, Jinquan et al. report that on CD4+ T 
lymphocytes they observed a bell-shaped SDF-1α dose response curve with the 
greatest chemotactic response observed at 100 ng/mL, which is equivalent to 
approx. 12.5 nM 382. Since we used 100 nM SDF-1α in our experiments, this 
concentration could have already surpassed the dose needed for a maximal 
response. The experiments by Jinquan et al. were performed on CD4+  T 
lymphocytes and the question remains whether their findings can be directly 
extrapolated to endothelial cells 382. This could be investigated by performing a 
dose-response curve for SDF-1α and TC14012 on HUVEC to determine which 




On the other hand, if 100 nM SDF-1α did already elicit a maximal response it 
could be that addition of TC14012 activates signalling through an alternative 
pathway to that utilized by SDF-1α. Past research suggests that SDF-1α/CXCR4-
dependent cell migration signals through PI3K/Akt 230, 383. We did not observe 
phosphorylation of Akt with TC14012 in our western blotting experiments (section 
5.4), which would suggest CXCR7 chemotactic signalling proceeds through a 
different signalling pathway. Again, this could be examined by combining SDF-1α 
at a concentration that elicits a maximal chemotactic response with TC14012 to 
observe whether incubation of both drugs together results in further increase in 
cell migration compared to incubation of these drugs alone. 
Additionally, TC14012 significantly increased cell migration only at 1 µM, but not 
at 10 or 30 µM. This might suggest a bell-shaped concentration-response curve, 
rather than a sigmoidal curve for involvement of TC14012 in cell migration. Bell-
shaped concentration response curves are often indicative of a complex biological 
relationship between the ligand and its target 217. Levoye et al. also suggest that 
the chemotactic curve of SDF-1α/CXCR7 interaction is bell-shaped, which 
translates into increased cell migration at lower concentrations. The existence of 
a bell-shaped chemotactic curve for SDF-1α is also shown by Jinquan et al. on 
CD4+ T lymphocytes and considering the intricate signalling interplay exhibited 
between CXCR4 and CXCR7 in other physiological and pathological processes 
lends this theory/hypothesis further credence  382, 384, 385.   
Overall, we have shown that along with SDF-1α, TC14012 is also able to induce 
endothelial cell migration. This is important since pro-migratory effects of SDF-1α 
have been previously contributed solely to the SDF-1α/CXCR4 signalling axis, 
while we have shown that CXCR7 exhibits pro-migratory effects in its own right, 
along with its other pro-angiogenic actions described previously (e.g. tubule 
formation) 386. In a broader setting this means that due to its various pro-
angiogenic effects CXCR7 might play an important role in long-term regeneration 
of heart muscle after MI.  
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We know that angiogenesis plays a crucial role in the myocardium post-MI, as 
rebuilding the vascular network and establishing sufficient collateral circulation 
helps to reperfuse the heart after MI. Therefore, there is potential for developing 
of pro-regenerative therapies based on the CXCR7 receptor that would aid in 
myocardial salvage and recovery after MI. Despite the existence of many pro-
angiogenic therapies, few have shown promise when taken into from bench to 
bedside. Therefore, any novel pro-angiogenic therapy represents an exciting 
target that could provide beneficial effects to patients who have suffered from a 
myocardial infarction and also prevent the occurrence of heart failure in these 
patients later in life.  
 Summary 
Administration of SDF-1α (100 nM) exhibited pro-migratory effects on HUVEC 
after 3 h, but not after 6 h. CXCR7 agonist VUF11207 did not increase HUVEC 
migration at any concentration tested, while TC14012 elicited a cell migration 
response at 1 µM; demonstrating a possible pro-migratory role of CXCR7. 
Combined treatment of SDF-1α and TC14012 significantly increased cell 
migration, although in the same experiment SDF-1α and TC14012 administered 
alone did not significantly increase cell migration. Pooling data from multiple 
experiments revealed that both, SDF-1α (100 nM) and TC14012 (1 µM) exhibit 
pro-migratory effects. In conclusion, not only CXCR4 but also CXCR7 looks to be 
involved in endothelial cell migration downstream of SDF-1α binding. However, 
each receptor might stimulate endothelial cell migration through different 
intracellular pathways and further research is needed to elucidate their respective 




8 General conclusions 
CXCR7 has only recently been discovered as an atypical chemokine receptor for 
the ligand SDF-1α, in addition to the already established CXCR4 receptor. Since 
the role of CXCR4 in cardioprotection and angiogenesis has been well 
documented, focus was expanded to CXCR7 and its role in these processes, 
which was aided by emergence of novel CXCR7 receptor modulators. 
To date, CXCR7 has been shown to be involved in anti-fibrotic and pro-
regenerative effects in various endothelial cell types and shown to exert 
cardioprotective effects in murine tissues. Past research also revealed the 
presence of CXCR7 receptor in non-endothelial cell types; however, it is the 
endothelial CXCR7 which has shown most therapeutic potential. The main aim of 
this thesis was to investigate the effects of CXCR7 agonist administration on acute 
MI, as well as determining the mechanism behind CXCR7 receptor activation on 
endothelial cells. Furthermore, we also wanted to examine the pro-regenerative 
potential of endothelial CXCR7, by probing its participation in endothelial cell 
migration, a crucial step in the process of angiogenesis. Each of these factors has 
been discussed in detail in previous chapters.  
After confirming the presence of CXCR7 on isolated endothelial cells and 
commercially available endothelial cell lines, our focus was shifted on to 
determining the cardioprotective potential of CXCR7 via the CXCR7 agonist 
VUF11207.  
Described as CXCR7-biased with no purported action on CXCR4, it represented 
a fine investigative tool to be used on rat isolated perfusion model ex vivo. 
Interestingly, administration of VUF11207 immediately prior to reperfusion 




However, as previously discussed in section 4.5., there are numerous reasons 
why this could have occurred and what the implications are. Based on the cell-
migration results presented in this thesis the culprit might be the agonist, 
VUF11207, which also failed to initiate endothelial cell migration, further described 
below. Therefore, this lack of observed cardioprotection does not necessarily 
signify the lack of CXCR7 cardioprotective potential immediately after MI. Further 
research would be needed to fully comprehend the role of CXCR7 in this setting 
by making use of reliable CXCR7 agonists to ensure the validity of obtained 
results. 
This thesis also examined the role of the RISK signalling pathway in endothelial 
CXCR7 receptor activation. Since RISK pathway, which includes signalling 
through PI3K/AKT and MAPK pathways, is known as the main effector of 
cardioprotection, which is initiated by binding of SDF-1α to CXCR4, it was 
expected that CXCR7 would exhibit similar signalling properties. Surprisingly, this 
was not the case for CXCR7. Administration of CXCR7 agonists VUF11207 or 
TC14012 failed to activate either PI3K/AKT or MEK/ERK arm of the RISK 
signalling pathway. Again, this does not eliminate a possible role for CXCR7 in 
cardioprotection, although it suggests that a different signalling axis is behind any 
cardioprotective effects exhibited by CXCR7. There is still a lot of uncertainty and 
contrasting results regarding the signalling abilities of the CXCR7 receptor, 
compounded by the fact that it does not signal via classical G protein signalling, 
but instead utilizes less well understood β-arrestin-biased signalling. Further work 
is needed to decode the exact signalling pathway downstream of CXCR7 receptor 
activation and investigate whether its activation is capable of affording 
cardioprotection. 
The aim of this thesis was also to generate an inducible transgenic mouse model 
of endothelial CXCR7 deletion, which could help shed light on the acute 
cardioprotective potential of endothelial CXCR7 receptor.  
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However, the desired transgenic model was not generated successfully, which 
somewhat hindered the plans for this thesis to be focused mainly on 
cardioprotection. In the light of the issues we faced with the transgenic mice, the 
focus was switched to another aspect of CXCR7 receptor function. As with 
CXCR4, there is evidence of CXCR7 involvement in various aspects of 
angiogenesis, including cell migration. In the scope of MI, angiogenesis is 
particularly important, since it has the ability to salvage ischaemic myocardium, 
impact ventricular remodelling and consequently prevent the transition to heart 
failure. Angiogenesis is also involved in tissue regeneration in the long term as 
opposed to acute cardioprotection, which affords beneficial effects immediately 
after MI. Therefore, CXCR7 participation in cell migration, and consequently 
angiogenesis, could present a potential pro-regenerative role of CXCR7.  
Interestingly, multiwell Boyden chemotaxis assay suggested a pro-angiogenic 
role for CXCR7 agonist TC14012, but not VUF11207, using a commercially 
available endothelial cell line. Any pro-angiogenic effects observed with 
administration of SDF-1α have previously been attributed to its signalling via the 
CXCR4 receptor, with CXCR7 portrayed mainly in a scavenging role, regulating 
circulating SDF-1α. However, the data presented in this thesis suggest a pro-
migratory role for CXCR7 in HUVEC, independent of the CXCR4 receptor, which 
represents a novel finding of this thesis. As discussed in Chapter 7 and elsewhere, 
the downstream effectors responsible for initiating cell migration might differ 
between the CXCR4 and CXCR7 receptors. This highlights a need for further 
research into the cell migration role of endothelial CXCR7, to elucidate the exact 
mechanism responsible for the observed effects and explain the difference in pro-
angiogenic potential of both CXCR7 agonists, which have been discussed in 





In conclusion, I believe there was merit in querying the involvement of CXCR7 in 
cardioprotection and angiogenesis, specifically cell migration. For clarification, my 
original aims focused more on the role of immediate vs longer-term 
cardioprotection examined through generation of CXCR7 transgenic animals and 
utilization of commercially-available CXCR7 agonists. However, half way through 
my PhD a study was published by Hao et al., which already explored many of the 
same ideas that I was also interested in, which meant that the scope for 
undertaking novel research in this area shrunk significantly. To retain an aspect 
of novelty in my thesis I then turned to less-explored immediate cardioprotection 
(observed <day after initial MI), as well as the cell-migration role of endothelial 
CXCR7 as the central theme of this thesis. As discussed throughout this thesis, 
investigation of acute cardioprotective effects of CXCR7 mere hours post-MI did 
not yield positive results. This is perhaps not surprising as most beneficial effects 
that CXCR7 has been shown to exert, occurred throughout a longer period of time 
(weeks) post-MI. Since angiogenesis in the heart post-MI also does not occur 
immediately, but represents a long-term process it is more likely that CXCR7 
exhibits its beneficial effects by affecting re-vascularization of the damaged 
myocardium. This would agree with the lack of acute cardioprotection seen in 
Chapter 4, as well as the lack of RISK pathway involvement seen in Chapter 5. 
Consequently, CXCR7 might represent an exciting target for pro-regenerative 
treatments, but its future as an acute cardioprotective effector seems uncertain. 
Hence, future work on this topic will be better suited to a research group that 
utilizes techniques, which are capable of successfully identifying and 
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